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ABBREVIATIONS 
4-AP  4-aminopyridine 
AC  adenylyl cyclase 
ACh  acetylcholine 
ADP  adenosine diphosphate 
AKAP  A-kinase-anchoring protein 
ANP  atrial natriuretic peptide 
ATP  adenosine triphosphate 
AT1R  angiotensin II receptor type 1  
AUC   area under the curve 
BKCa  large conductance calcium-activated potassium channels 
BSA  bovine serum albumin 
Ca2+  calcium ions 
[Ca2+]i  intracellular calcium concentration 
Ca2+/CaM  Ca2+-calmodulin complex 
CaD  caldesmon 
CaM  calmodulin 
CGRP  calcitonin gene-related peptide 
CO  cardiac output 
CO2  carbon dioxide 
cAMP  cyclic adenosine monophosphate 
cGMP  cyclic guanosine monophosphate 
CRR  concentration-response relationship 
DAG  diacylglycerol 
DMSO  dimethyl sulfoxide 
DPO-1  diphenyl phosphine oxide-1 
EC50  half maximal effective concentration 
EDTA  ethylenediaminetetraacetic acid 
EGTA  ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
EPAC  exchange protein directly activated by cAMP 
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eNOS  endothelial nitric oxide synthase 
GC  guanylyl cyclase 
GFR  glomerular filtration rate 
GPCR  G protein coupled receptor 
GTP  guanosine triphosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IBTX  iberiotoxin 
IC  internal circumference  
IC1  IC at which a maximum response to a vasoconstrictor is observed 
IC50  half maximal inhibitory concentration 
IC100  IC at which a transmural wall pressure of 100mmHg is observed 
iNOS  inducible nitric oxide synthase 
IP3   inositol 1,4,5-trispohosphate 
IP3R  inositol 1,4,5-trispohosphate receptor 
K+  potassium ions 
KATP  ATP-sensitive potassium channel 
Kir  inward rectifyier potassium channel 
Kv  voltage-gated potassium channel 
KCl  potassium chloride 
LCA  left coronary artery 
L-NNA  NG-Nitro-L-arginine-methyl ester 
LTCC   L-type calcium channel 
MLCK  myosin light chain kinase 
MLCP  myosin light chain phosphatase 
Mx  methoxamine hydrochloride 
MYPT1  myosin phosphatase target subunit 1 
NCX  Na+/Ca2+ exchanger 
Na+  sodium ions 
pD2  negative logarithm of the half maximal effective concentration (EC50) 
PAH  pulmonary arterial hypertension 
PCR  polymerase chain reaction 
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PKA  cAMP-dependent protein kinase 
PKC  protein kinase C 
PKG  cGMP-dependent protein kinase 
PLC  phospholipase C 
PMCA  plasma membrane Ca2+ ATPase 
PSS   physiological salt solution 
PVAT  perivascular adipose tissue 
qPCR  quantitative polymerase chain reaction 
RAAS  renin-angiotensin-aldosterone system 
RBC  red blood cell 
RBF  renal blood flow 
RPP  renal perfusion pressure 
ROCK  Rho-associated protein kinase 
RCA  right coronary artery 
RLC  regulatory light chain 
rpm  rounds per minute 
RyR  ryanodine receptor 
SEM  standard error of the mean 
SERCA  sarco/endoplasmic reticulum Ca2+-ATPase 
SHR  spontaneously hypertensive rat 
SOPF   specific and opportunistic pathogen free 
SPF   specific pathogen free  
STX  stromatoxin 
SVR  systemic vascular resistance 
TGF   tubuloglomerular feedback 
TRP  transient receptor potential 
V50  voltage at which half maximal activation is observed 
Vm  membrane potential 
VOCC  voltage-operated calcium channel 
VSMC  vascular smooth muscle cell 
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1 INTRODUCTION 
1.1 Function of the cardiovascular system 
The circulatory system serves to enable cell homeostasis in an organism that is too large to be supplied 
by diffusion. Through the mechanism of convection, it contributes to cell respiration and metabolism 
by providing oxygen, water and nutrients while removing carbon dioxide and wasteful metabolites. 
Simultaneously, it acts as a transport and communication system for distributing intermediary 
metabolites or even cells and for delivering hormones or autacoids. Complex mechanisms are 
necessary for regulation of blood distribution between and within organs to match cellular demand. 
Convection of blood happens along blood pressure gradients; blood pressure is the product of cardiac 
output (CO) and systemic vascular resistance (SVR), and vascular resistance is largely determined by 
the tone of small arteries and arterioles 1-3. Overall, the regulation of blood vessel tone is subject to 
involuntary systemic mechanisms. The three main players orchestrating vascular tone are the 
autonomic nervous system infiltrating the vessel wall, the autoregulatory mechanisms of the vessel 
itself, and the hormones, autacoids or other agents influencing the vessel from the luminal as well as 
from the abluminal side 4.  
1.2 Cardiovascular function and autoregulation of the kidney 
The kidney plays a central role in the circulatory system due to its excretory, hormonal and metabolic 
functions contributing to intravascular fluid maintenance and blood pressure control. Most prominent 
among these many mechanisms the kidney contributes to is the renin-angiotensin-aldosterone system 
(RAAS), which relies upon secretion of the hormone renin from renal juxtaglomerular cells into 
systemic circulation to first stimulate formation of angiotensin I and subsequent conversion into 
angiotensin II through the angiotensin-converting enzyme (ACE) 5. The RAAS is of central function in 
the regulation of blood pressure and is target of two main groups of antihypertensive drugs, ACE-
inhibitors and angiotensin receptor blockers. To fulfil its complex integrative task, the kidney itself 
vitally depends upon fine-tuned regulation of blood supply. Renal autoregulation maintains renal 
blood flow (RBF) and glomerular filtration rate (GFR) independent of renal perfusion pressure (RPP) in 
a manner distinguished from most other organs insofar as it is intrinsic to the kidney and thus largely 
independent of extrinsic nervous regulation or circulating hormones 6. Thus, the tone of renal 
resistance arteries is intrinsically determined by an interplay of two major mechanisms, the relatively 
quickly-acting renal myogenic response 7 and the more delayed macula densa tubuloglomerular 
feedback response 8, 9. 
1.3 Vascular microscopic anatomy 
Blood vessels generally consist of three distinct layers 10. The innermost tunica intima is made up of a 
single layer of endothelial cells mounted on a basal lamina, which besides regulating vascular tone are 
involved in immunological and inflammatory processes 11. Underneath it the three-dimensional tunica 
media is the thickest layer in arterial vessels and besides elastic fibers for structural support contains 
mostly the vascular smooth muscle cells (VSMC) responsible for active contraction and relaxation 12. 
The outermost tunica adventitia consists of fibroelastic connective tissue fixating the vessel in its 
environment and contains nervous plexus participating in the control of vessel tone 10.  
1.4 Mechanisms of vasocontraction 
VSMCs can be stimulated by a variety of mechanisms that eventually converge to the common end 
point of increasing actin-myosin interaction, resulting in ATP-powered myosin lever arm rotations that 
cause VSMC shortening and exertion of force 13. This may happen either through activation of the 
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motor protein myosin II via phosphorylation of its regulatory light chain (RLC) or through removal of 
actin filament inhibition 14. First, actin-myosin interaction as a prerequisite requires the exposure of 
the myosin-binding sites on the actin surface through phosphorylation of Caldesmon (CaD), which 
otherwise inhibits myosin ATPase activity 15. Second, the contractile state of VSMCs largely depends 
on the state of myosin RLC phosphorylation, which is increased by myosin light chain kinase (MLCK) 
and decreased by myosin light chain phosphatase (MLCP) 16. 
From a mechanistic-focused perspective, one can differentiate (i) VSMC activation through 
electromechanical or pharmacomechanical coupling 17 and (ii) Calcium (Ca2+)-dependent mechanisms 
from Ca2+ sensitization 16. From an organism-focused perspective, VSMC activation may be induced or 
supported by the autonomic nervous system, by vasoactive substances like hormones, autacoids and 
metabolites, or by transmural pressure 18. For the sake of structural comprehensiveness, these two 
perspectives will in the following be elaborated consecutively, first elucidating the mechanistic 
elements and then drawing the bigger picture of their implementation in the organism. 
1.4.1 Vasocontraction from a mechanistic-focused perspective 
VSMC activation can be systematized into electromechanical and pharmacomechanical coupling 17 or 
Ca2+-dependent and Ca2+-sensitizing mechanisms 16. 
Electromechanical coupling operates through membrane potential (Vm) changes that affect the 
cytoplasmatic Ca2+ level 17. A depolarizing stimulus, by shifting the negative resting Vm of VSMC (-40 to 
-70 mV) to more positive potentials, can open voltage-operated Ca2+ channels (VOCC) 19. 
Depolarization can be induced through action potentials in phasic (e.g. intestinal) smooth muscle or 
graded depolarization in tonic (e.g. vascular) smooth muscle 19. Among the multitude of membrane-
associated proteins involved in Vm regulation, ion channels like potassium (K+) channels are primarily 
important structures which when blocked contribute to VSMC depolarization 1. 
Pharmacomechanical coupling includes various cellular signaling mechanisms that show the common 
feature of changing VSMC force generation without requiring changes in Vm 17. Its major two 
mechanisms governing contraction are increasing cytosolic Ca2+ [Ca2+]i in a manner not dependent on 
VOCC but largely on inositol 1,4,5-trispohosphate (IP3) and increasing the Ca2+ sensitivity of the 
contractile apparatus 19.  
Ca2+-dependent mechanisms of contraction are of central importance, since an increase of [Ca2+]i is the 
primary stimulus for VSMC activation 20. Ca2+ binds to calmodulin, forming the Ca2+-calmodulin complex 
(Ca2+/CaM) that activates MLCK to phosphorylate the myosin RLC and thus enables contractile activity 
21. Elevation of [Ca2+]i may result from passive transmembrane movement along electrochemical 
gradients, either in form of extracellular Ca2+ influx through plasma membrane ion channels or via 
release from intracellular Ca2+ stores 20. In VSMCs, influx of extracellular Ca2+ is mediated primarily by 
voltage-gated L-type Ca2+ channels (LTCC), with contributions from T-type Ca2+ channels and Ca2+-
permeable ligand-gated or transient receptor potential (TRP) cation channels, whereas Ca2+ release 
from intracellular stores is mediated by sarcoplasmatic membrane ryanodine receptors (RyR) and IP3-
receptors (IP3R) 22. While the IP3R releases Ca2+ when activated by IP3 following activation of PLC, the 
RyR is activated by an increase in [Ca2+]i itself, which is referred to as Ca2+-induced Ca2+ release 23. 
Ca2+-sensitizing mechanisms of contraction have in common the ability to induce tonic contraction with 
only transient increases or differing magnitudes of [Ca2+]i, which has been labeled Ca2+ sensitization 14. 
Changes in Ca2+ sensitivity of the contractile apparatus may occur through increasing the ratio of 
activity of MLCK over MLCP, resulting in a higher degree of myosin RLC phosphorylation and thus 
myosin activity 16 or through increasing the activity of ERK, which by phosphorylating CaD results in a 
higher degree of actin availability 14, 15. The former and more well-studied mechanism involves 
inhibition if MLCP through two different G protein coupled receptor (GPCR)-mediated pathways. One 
pathway involves activation of the monomeric G protein RhoA and its effector Rho-associated protein 
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kinase (ROCK) that may directly inhibit MLCP, while another employs the MLCP inhibitor CPI-17, which 
can be activated via phosphorylation through either ROCK or protein kinase C (PKC), the latter resulting 
from Gq/11-mediated activation of phospholipase C (PLC) producing the PKC activator diacylglycerol 
(DAG) 16. 
1.4.2  Vasocontraction from an organism-focused perspective 
Putting things into perspective, in the organism it is an interplay of the above described fundamental 
mechanisms which in concert define the level of VSMC activation and vascular tone. 
One key principle is endocrine and paracrine regulation through circulating vasoconstrictors including 
hormones like noradrenaline, angiotensin II (AII) or vasopressin and autacoids like endothelin 1 
(ET-1) 24. After binding to their corresponding membrane receptor, they may through Gq/11-mediated 
activation of PLC induce both IP3 formation with consecutive IP3R-mediated Ca2+ release from 
intracellular stores and DAG formation with consecutive PKC-dependent phosphorylation of CPI-17 
inhibiting MLCP 25, thus combining Ca2+-dependent and Ca2+-sensitizing mechanisms of contraction. 
Additionally, PKC may activate VOCC indirectly through membrane depolarization by means of 
reducing K+ currents through inhibitory phosphorylation of voltage dependent K+ channels (Kv) 26, 27, 
large conductance Ca2+-activated K+ channels (BKCa) 28-33, inward rectifier K+ channels (Kir) 34-36 and ATP-
sensitive K+ channels (KATP) 36-41, thus also including both electromechanical and pharmacomechanical 
coupling in agonist-induced contraction. The autonomic nervous system releasing the 
neurotransmitter noradrenaline from nerve endings in the blood vessel wall to increase vascular 
tone 42 is another example involving a similar combination of mechanisms.  
Another major principle relevant to the maintenance of arteriolar blood flow is the myogenic response, 
which is the term describing the phenomenon that an increase in transmural pressure results in arterial 
constriction, while a decrease in pressure is followed by dilation 18, 43. Stimulated by a change in wall 
tension, a not yet clearly defined sensor, possibly stretch-activated cation channels from the TRP 
channel family, initiates cell membrane depolarization and activation of VOCCs and Ca2+ entry, while 
simultaneously mechano-transduction mechanisms independent of stretch-activated channels and/or 
signaling pathways including ROCK- or PKC-mediated Ca2+ sensitization appear to contribute 14, 43. The 
myogenic response accordingly is also orchestrated by both Ca2+-dependent and Ca2+-sensitizing 
mechanisms, but unlike agonist-induced vasoconstriction does not require pharmacomechanical 
coupling yet includes electromechanical coupling.  
1.5 Mechanisms of vasorelaxation 
Vascular relaxation may occur passively through a decrease of the contractile stimulus towards the 
VSMC or actively through specific vasodilatory agonists acting through the intracellular messengers 
cyclic guanosine monophosphate (cGMP) or cyclic adenosine monophosphate (cAMP) 44. Common end 
point is the decrease of actin-myosin interaction, resulting from a lower level of myosin RLC 
phosphorylation or from lower actin availability 14. 
1.5.1 Vasorelaxation from a mechanistic-focused perspective 
Analogously to vasoconstriction, vasodilation my involve antagonization of all mechanistic elements 
described above (see: Chapter 1.4.1).  
Counteracting electromechanical coupling may occur through VSMC hyperpolarization, which 
decreases the open probability of VOCC, reduces Ca2+ influx and lowers [Ca2+]i 19. Membrane 
hyperpolarization most importantly involves, but is not limited to, increased outward K+ currents 1. 
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Counteracting pharmacomechanical coupling may besides receptor antagonization of the contractile 
substance involve inhibition of IP3-dependent Ca2+ release or decreasing Ca2+ sensitivity of the 
contractile apparatus 19.  
Ca2+-dependent mechanisms of vasorelaxation reduce VSMC activity by lowering [Ca2+]i either through 
inhibition of Ca2+ influx and/or release from intracellular stores or by actively removing Ca2+ from the 
cytosol, both resulting in lowered CaM levels and decreased MLCK activity 20, 21. Outward transport of 
Ca2+ across membranes is against its electrochemical gradient and therefore happens energy-
dependently through active or secondary active transport via the plasma membrane Ca2+ ATPase 
(PMCA) and Na+/Ca2+ exchanger (NCX) or through the sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA) 22. Both PMCA and SERCA function can be enhanced by PKC activation 45.  
Ca2+-desensitizing mechanisms of vasorelaxation right-shift the relation between VSMC force 
production and [Ca2+]i and are determined by a reduction in myosin RLC phosphorylation 16. Aside from 
receptor antagonization of GPCR dependent vasoconstrictive agonists, these mechanisms may involve 
a vast array of interactions between intracellular signaling cascades, many of which target the myosin 
phosphatase target subunit 1 (MYPT1), a regulatory subunit of MLCP 16. The RhoA/ROCK pathway is 
most prominent among these cascades for its phosphorylation of MYPT1 inhibiting MLCP function 46 
and this specific inhibitory phosphorylation may be prevented by MYPT1 phosphorylation through 
protein kinase G (PKG) 47, 48, which is thus considered a Ca2+ desensitizing mechanism 14. Ca2+ 
desensitization via increased MLCP activity may also occur in form of MYPT1 dephosphorylation 
through protein kinase A (PKA) 49, 50. However, MYPT1 regulation is quite complex not only due to the 
vast number of kinases that may be involved, but also to its tissue-specificity 14.  
1.5.2 Vasorelaxation from an organism-focused perspective 
Like in vasoconstriction, it is mostly combinations of the above mechanisms that are observed in 
vasodilator actions in the organism. The two key players among the intracellular second messengers 
involved in VSM relaxation are the cyclic nucleotides cGMP and cAMP, which (i) are generated by 
nucleotide cyclases – guanylate cyclase (GC) resp. adenylate cylase (AC); (ii) exert their effect by 
activating cyclic nucleotide-driven kinases – cGMP-dependent kinase (PKG) resp. cAMP-dependent 
kinase (PKA), and (iii) are degraded by various phosphodiesterases (PDE) 51.  
1.5.2.1 cGMP/PKG 
cGMP in VSMCs can be generated by soluble cytosolic GCs activated by nitric oxide (NO) 52 or carbon 
monoxide 53 and by membrane-bound GCs activated by transmembrane receptors for the natriuretic 
peptide family 54. The main, though not exclusive, effector of cGMP is PKG 55. Either or both cGMP and 
PKG have been implemented in various anticontractile mechanisms. These involve (i) inhibition of Gq/11 
mediated signaling 56, 57, (ii) lowering of [Ca2+]i through activation of PMCA 58, 59, SERCA 60-62 or NCX 63, 64 
as well as inhibition of Ca2+ release through inhibition of IP3R 65-68 or of Ca2+ influx through VOCC 69; (iii) 
supporting Ca2+ desensitization through protective phosphorylation of MYPT1 to prevent inhibition by 
various kinases 47, 48, 70 or phosphorylation of RhoA to prevent activation of ROCK 71-73 and (iv) VSMC 
hyperpolarization through activation of outward K+ currents through Kv 74-77, KATP 78-81 or BKCa 76, 82-85.  
1.5.2.2 cAMP/PKA 
cAMP formation in VSM is most importantly controlled by GPCRs like the β2 adrenergic receptor which 
is coupled to the G protein Gs 86, but may also result from activation of corticotropin releasing factor 
(CRF)-receptors 87, both which are linked to ACs 86, 88. Cross-talk exists between cAMP and cGMP 
signaling insofar as both cyclic nucleotides can activate both kinases at 10 times higher concentrations, 
although this may occur only unidirectionally since plasma concentrations of cAMP are 10-fold higher 
than cGMP 55. This way, cAMP may also activate PKG, which has been observed in cAMP-induced PKG-
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mediated inhibition of IP3R 65, 66 or VOCC 69 as well as activation of BKCa 89. Otherwise, the specific 
implications for cAMP/PKA signaling are similar to those of cGMP/PKG and thus include (i) notably, 
phosphorylation of MLCK leading to decreased MLCK activity 90, 91, (ii) Ca2+ desensitization through 
protective phosphorylation of MYPT1 preventing MLCP inhibition by other kinases 47, 49 or through 
inhibition of Rhoa/ROCK 92, 93 and (iii) activation of hyperpolarizing K+ currents through Kv 94-104, BKCa 105-
109, KATP  1, 39, 99, 110-114 and also Kir 115, 116.  
1.6 Potassium channels in vascular reactivity 
As can be perceived from the above, K+ channels play a central role in regulating VSMC activity: with 
their significant influence on Vm  they contribute to electromechanical  and Ca2+-dependent 
mechanisms, and due to interaction with intracellular kinases, they also participate in 
pharmacomechanical and Ca2+-sensitizing mechanisms. Accordingly, K+ channels are involved in all 
vasoregulation through agonist-induced contraction, the myogenic response and cyclic nucleotide-
mediated dilation.  
Although the K+ equilibrium potential at physiological intra- and extracellular K+ concentrations 
according to the Nernst equation is -85 mV, Vm is in general more positive due to the presence of the 
other permeant ions and their respective channels 117. Vm in VSMCs from renal interlobar artery and 
afferent arterioles has been reported to be in the range of -40 mV 118 to -55 mV 119. The conductance 
for K+ exceeds that of the other ions in VSMCs; due to their high membrane resistance 120 only small 
numbers of K+ channels are necessary to influence Vm and therefore small changes in K+ conductance 
will have a rather large effect on Vm, which in turn has a steep relationship to arterial tone 1, 121. Thus, 
inhibition of relatively few K+ channels may considerably decrease K+ efflux, causing membrane 
depolarization which through increasing the open probability of VOCC leads to vasocontraction, 
whereas activation of K+ channels may enhance K+ conductance, resulting in membrane 
hyperpolarization and vasodilation 1, 120. 
Four classes of VSMC K+ channels that have been identified in the renal vasculature 121 and shown to 
affect baseline renal vascular resistance 122 are the inward rectifier Kir, the ATP-sensitive KATP, the large 
conductance Ca2+-activated BKCa and various voltage-gated Kv channels 1. A common structural theme 
shared by all of these are two transmembrane domains forming the ion-permeable pore which are 
linked by a pore-loop responsible for ion selectivity and pore regulation 123.  
1.6.1 Kir 
Inward rectifier K+ channels derive their name from their ability to conduct K+ ions into cells at Vm 
negative to the K+ equilibrium potential, which is limited at more positive Vm levels 124, 125. Nonetheless, 
at physiological Vm the electrochemical gradient will direct K+ currents through Kir outwards from the 
cell 1, while at elevated extracellular K+ concentrations, for example resulting from increased 
metabolism, Kir conduct increased hyperpolarizing currents resulting in vessel dilation 126. Currents 
through Kir channels contribute to resting Vm in isolated VSMCs and to resting tone in isolated 
resistance arteries from several vascular beds, while Kir expression and function appears to be inversely 
related to vessel diameter 123. 
Kir are predominantly expressed in small resistance arteries including renal afferent arterioles 127 and 
have been found to conduct K+ currents in afferent arterioles 127 and in distal but not proximal 
interlobar arteries 128. Barium (Ba2+) has been shown to depolarize and constrict rat renal afferent 
arterioles 127, 129, 130 and interlobular arteries 128 and to increase renal vascular resistance in isolated 
perfused kidneys 131 as well as in vivo 132. Regulation of Kir has in different vascular beds been shown 
to involve inhibition through PKC during agonist-induced contraction 34-36 or activation through 
cAMP/PKA-dependent pathways during vasodilation induced by adenosine 115 or hypoxia 116. 
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1.6.2 KATP  
ATP-sensitive KATP channels are named for their characteristic of being inhibited by elevated 
intracellular ATP 133, although they display additional features like activation by adenosine diphosphate 
(ADP) 134, independence of Vm 1 or regulation by a number of signaling pathways not including 
ADP/ATP, with the latter possibly being the more physiologically relevant feature in VSMCs 123. 
However, KATP have initially been hypothesized to participate in the vascular response to changes in 
the metabolic state, amongst others serving to increase blood flow to hypoxic regions 1. Besides, 
considerable evidence exists for involvement of KATP in both endogenous contractile and 
anticontractile pathways 123. KATP channels in VSMCs can be inhibited by PKC 36-41 to support agonist-
induced vasoconstriction or may participate in vasorelaxation when activated through cGMP/PKG- 78-
81 or cAMP/PKA- 1, 39, 99, 110-114 dependent pathways. 
KATP have been confirmed to exist in small renal artery branches 135. Pharmacologically, KATP can be 
blocked by sulfonylureas like glibenclamide 1 or higher concentrations of Ba2+ 136. Renal arterial 
relaxation has been observed following pharmacological activation of KATP in isolated perfused 
kidneys 137 as well as in vivo 138-140 in a manner reversible by glibenclamide, whereas glibenclamide 
itself had no effect on RBF 141 but was able to reduce hypoxia-induced renal afferent arteriolar 
vasodilation 142. Evidence for KATP implementation in cAMP/PKA signaling has also been presented in 
perfused hydronephrotic kidneys in form of glibenclamide inhibiting vasodilation induced by calcitonin 
gene-related peptide (CGRP) 143 or adenosine 144.  
1.6.3 BKCa  
Large conductance Ca2+-activated BKCa channels are voltage-gated K+ channels activated by both 
increases in intracellular Ca2+ and by depolarization of Vm 145. They display a big single channel 
conductance, which is why upon discovery they have been hypothesized to serve as a negative 
feedback mechanism for controlling the degree of Vm depolarization and pressure-induced 
vasoconstriction 146. When Ca2+ levels are low, BKCa behave as simple voltage-gated K+ channels 147, 
while an increase in intracellular Ca2+ left-shifts voltage-dependence, allowing BKCa to conduct K+ 
currents at physiological Vm ranges 148. In some vessels, presumably larger feed arteries, BKCa can be 
exposed to high Ca2+ ion concentration due to its close proximity to RyR 149, which may conduct Ca2+ 
sparks 146 promoted by T-type VOCC mediated Ca2+ influx to activate hyperpolarizing BKCa currents as 
a negative feedback mechanism towards the myogenic response 150, 151. In other vessels, supposedly 
smaller resistance arteries, it may be Ca2+ waves conducted by IP3R that promote BKCa activation 152, 
153. Overall, research has produced diverging results with regards to whether or not BKCa contribute to 
VSMC resting Vm and resting myogenic tone. Of the pore-forming α-subunit of BKCa, which contains 
both the voltage sensor and the Ca2+ sensor domains, more than 20 different spliced variants displaying 
different functional properties have been identified in different tissues, possibly explaining some of 
the controversy about their physiological role 123. 
In the renal vasculature, BKCa presence has been confirmed structurally in small preglomerular 
vessels 154 and juxtaglomerular cells 108 as well as functionally in preglomerular vessels 155 and 
mesangial cells 156. However, functional experiments have produced diverging results. Studies have 
found no effect of the highly specific BKCa blocker iberiotoxin (IBTX) 157 on arcuate artery VSMC Vm  
despite producing contractions of intact arteries 158 or reported no effect of IBTX on either in vivo 
resting RBF or agonist-induced decreases in RBF 154. Contrarily, others have demonstrated application 
of BKCa activator NS-1619 to increase afferent arteriolar diameter 159 but not resting RBF 154 or to 
attenuate agonist-induced contractions 159 and RBF decreases 154. It should be noted that these results 
may not be explicitly attributable to BKCa because NS-1619 can also affect Kv channels 160. Such 
discrepancies in the renal vasculature have been suggested to be due to differences in [Ca2+]i  or Ca2+ 
sensitivity of the channel 122. Other than BKCa, a few studies have suggested the presence of the two 
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additional KCa family members that conduct intermediate (IKCa) or small (SKCa) Ca2+-dependent K+ 
currents in renal VSMC, but functional evidence for a role in RBF regulation is so far lacking 122. 
BKCa are complexly regulated, with both contractile agonists and vasodilatory pathways modulating 
channel function 33, 123, 161. They may be inhibited or internalized PKC-dependently 28-31 or activated 
during cGMP/PKG-dependent 76, 82-85 as well as cAMP/PKA-dependent 105-109 signaling cascades of 
endogenous dilators. In the renal vasculature, BKCa have been implemented in cGMP-dependent 
relaxations of glomerular mesangial cells 85 and cAMP-induced hyperpolarization of juxtaglomerular 
cells in vitro 108, but not in cAMP-induced RBF increases in vivo 154. 
1.6.4 Kv  
Voltage-gated Kv channels are a large class of K+ channels composed of 12 families (Kv1-12) 162 that in 
general activate in response to Vm depolarization and inactivate during maintained depolarization 1. 
Structurally, Kv channels are composed of six transmembrane α-subunits (S1-S6), of which S6 along 
with the p-loop between S5 and S6 forms the ion-conducting pore, while S4 serves as a voltage sensor 
detecting changes in Vm 163.  Channel inactivation can happen fast through the N-terminus (N-type) or 
slow through the C-terminus (C-type) 164. Accessory subunits may associate with the pore-forming 
α-subunits to either themselves or through interaction with other signaling proteins modify channel 
properties, which along with α-subunit heteromerization, alternative splicing and post-translational 
modification contributes to considerable heterogeneity in Kv function within and among tissues 163.  
In VSMCs, Kv channels are ubiquitously present 165-167 and among them, the KV1, Kv2 and Kv7 families 
are recognized for both being highly expressed and contributing to resting Vm as well as negative 
feedback regulation of myogenic tone 167.  
1.6.4.1 Kv1-4 
Kv1-4 were among the first Kv channels to be associated with vascular reactivity based on early 
observations that the unselective Kv1-4 blocker 4-aminopyridine (4-AP) 165 caused isolated vessels 
contraction 168, 169, K+ current inhibition at potentials close to resting Vm 170, 171, VSMCs depolarization 171, 
172 and enhancement of the myogenic response 172. More recently, more specific inhibitors have 
revealed evidence for functional expression of KV1 and Kv2 173, 174 but not Kv3 or Kv4 family members 174. 
Kv1 channels can be specifically blocked with diphenyl phosphine oxide-1 (DPO-1) 175, 176 and Kv2 with 
stromatoxin (STX) 177. Regulation of 4-AP-sensitive channels appears to be predominated by Gs-coupled 
vasodilators acting through the cAMP/PKA pathway 95, 98-104.  
In the renal vasculature, Kv1 channels have been identified 141, 178 and 4-AP sensitive K+ currents 179-181 
have been recorded in preglomerular resistance artery VSMCs, just like 4-AP-induced vasoconstriction 
was observed in isolated perfused kidneys 131 or blood-perfused juxtamedullary nephrons 130. 
1.6.4.2 Kv7 
Kv7 channels, which are encoded by the KCNQ genes, have only more recently moved into focus of 
research on smooth muscle contractility 166, 182. In contrast to 4-AP-sensitive Kv channels, which are 
activated at Vm around -20mV 1, 165, the 4-AP-insensitive Kv7 channel family members are activated at 
more negative Vm values 183 closer to the resting Vm of renal resistance artery VSMCs 118-120, 129. The 
physiological role of Kv7 in the renal vasculature may therefore likely be different from that of Kv1 or 
Kv2 channels: Under resting conditions, Kv7 conduct repolarizing outward K+ currents, which reduce 
VSMC excitability. Closure of the Kv7 channels, supposedly induced by vasoconstrictive agonists, would 
cause depolarization, VOCC opening and vasoconstriction, whereas 4-AP-sensitive Kv could open in 
response to the Kv7-blockade-induced depolarization, providing a negative feedback mechanism to 
limit the extent of Vm depolarization and thus minimizing contraction 182.  
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1.6.4.2.1 KCNQ genes and Kv7 channel structure 
The KCNQ gene family consists of five members (KCNQ1-5) located at chromosomal loci 11p15, 20q13, 
8q24, 1p34 and 6q13 which express the α-subunit proteins Kv7.1-5 that assemble to form tetrameric 
K+ channels 183. Structurally, Kv7 subunits differ from other Kv families in 3 aspects 184: (i) they contain 
a well-conserved PIP2 binding domain in the proximal C-terminal region 185, 186 which is essential for the 
channel to be active 186, 187; (ii) they lack the N-terminal T1 domain which controls tetramerization in 
KV1-4 channels 188, 189 and (iii) instead possess a unique C-terminal tetramerization domain 190, 191. 
Furthermore, the Kv7 C-terminal is considerably longer than that of other Kv channels, providing a 
bigger number of interaction sites with regulatory kinases, scaffolding proteins or ubiquitin ligases 183 
Heteromerization of Kv7 α‐subunits produces either channel homotetramers or hetero‐oligomers 
containing different α‐subunits or auxiliary β‐subunits called KCNE 192. While all Kv7.1-5 may form 
homomeric channels in vitro, the formation of heteromers is apparently tissue-specific and restricted 
to certain combinations 192, 193: while the neuronal Kv7.3 assembles readily with Kv7.2/4/5 192, in VSMCs 
have thus far been found mostly Kv7.1/Kv7.5 heterotetramers 194 or Kv7.4/Kv7.5 heterotetramers 195, 196. 
Heteromerization with the β-subunits KCNE is especially observed in Kv7.1 channels, which can 
assemble with all five KCNE1-5 members, resulting in significant alterations of channel properties and 
suggesting different tissue-specific functions 182: 
Assembly of Kv7.1 with KCNE1 (formerly known as minK) is most prominent for producing the K+ 
channel conducting the cardiac slow delayed rectifier K+ current (IKs) that contributes to repolarization 
of action potentials in cardiac myocytes 197, 198. KCNE1 drastically enhances Kv7.1 current amplitudes, 
slows both activation and deactivation and suppresses partial inactivation 199, allowing KCNQ1/KCNE1 
heteromers to also contribute to endolymph production via transepithelial potassium secretion in the 
cochlea 200, 201 or to Na+ absorption in the kidney 202 and gastrointestinal tract 203, 204. By contrast, 
interaction with KCNE2 leads to a decreased current amplitude, instantaneous activation, rapid partial 
deactivation, and a linear current-voltage relationship, basically transforming Kv7.1 into a voltage-
independent channel 205. KCNQ1/KCNE2 heteromers are present in the parietal cells of the stomach, 
contributing to gastric acid secretion 203, as well as in thyrocytes, regulating thyroid hormone 
biosynthesis 206. KCNE3 similarly to KCNE2 abolishes Kv7.1 gating and causes instant activation, leading 
to constitutively open KCNQ1/KCNE3 channels 207 that in intestinal crypt cells contribute to chloride 
secretion 203, 207. Heteromerization with KCNE4 is relevant in blood vessels 193, 208-210. While in 
heterologous expression systems KCNE4 effectively suppresses Kv7.1 currents at physiological Vm 
values 209, in blood vessels KCNE4 may interact with other Kv7, for example with Kv7.4 subunits, to sex-
dependently participate in arterial tone regulation 211. Finally, KCNE5 affects Kv7.1 similarly as KCNE1, 
causing a right-shift of the Kv7.1 activation threshold by 140 mV towards Vm values around +40 mV and 
thus only allowing K+ currents during strong and continued depolarization 212. 
In VSMCs, all five KCNE genes have been identified in various vessels including renal arteries, and apart 
from the ubiquitous presence of KCNE4, expression of KCNE appears to be tissue-specific 193, 208, 210. 
Interestingly, KCNE4 depletion has been found to reduce the membrane abundance of Kv7.4 channels, 
resulting in decreased Kv7 currents and increased contractility in rat mesenteric arteries 210. Association 
with KCNE furthermore alters Kv7 channel pharmacology in a manner relevant for substances used to 
study or modify vascular reactivity 213-217.  
1.6.4.2.2 Kv7 expression 
Kv7 expression is highly tissue-specific. Important locations in which Kv7 have been found to be 
functionally expressed are the heart, the central nervous system, the cochlea and smooth muscle (for 
recent review see 183): Kv7.1 is highly expressed in the heart and functioning as a KCNQ1/KCNE1 
heterotetramer conducting the IKs current 197, 198. In the central nervous system, it is predominantly 
Kv7.2/Kv7.3 heteromers that conduct the M-current 218, 219 controlling neuronal action potential 
generation with smaller contributions from Kv7.5 220. The cochlea depends upon Kv7.4 channels being 
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expressed in the outer hair cells to enable normal hearing 221, 222. Smooth muscle of both vascular and 
intestinal type mostly expresses Kv7.1, Kv7.4 and Kv7.5 channels 166.  
In the vasculature, first evidence of KCNQ expression was presented in murine portal veins, where 
KCNQ1 was the highest expressed subtype 223, 224. Ever since, KCNQ gene products have been found in 
various rodent blood vessels, with either KCNQ1, KCNQ4 or less often KCNQ5 expression 
predominating 166, 193, 194, 208, 223, 225-238. KCNQ gene products are also expressed in human arteries 194, 239-
241. The Kv7 channel protein itself has been confirmed to be present in the cell membranes of various 
VSMCs 96, 193, 208, 235, 238, 240. 
Concerning the assembly of KCNQ subunits in order to form functional channels it has been reported 
for mesenteric 195, 242 and cerebral 196 artery myocytes that α-subunit heteromerization results in 
Kv7.4/Kv7.5 heterotetramers rather than Kv7.4 or Kv7.5 homomers. Alternatively, functional Kv7.1/Kv7.5 
heterotetramers were discovered in rat aortic myocytes, conducting currents that furthermore were 
enhanced by colocalization of KCNE1 194. Heteromerization of Kv7.1, Kv7.4 and Kv7.5 subunits has early 
been suggested based on functional studies 238.  
In the renal vasculature, studies on main renal arteries of rats have found expression of either KCNQ1 
alone 96, 243 or KCNQ1 along with KCNQ4 244 to predominate, the latter also being the case in main renal 
arteries of mice 245. In these vessels, KCNQ4 and KCNQ5 gene products were always, KCNQ3 only 
variably and KCNQ2 never detected 96, 243, 244. Immunodetection has also confirmed protein translation 
of Kv7.1, Kv7.4 and Kv7.5 in the rat main renal artery 96. Conversely, in rat renal preglomerular arterioles, 
positive immunofluorescence staining was found for Kv7.4 antibodies only, while Kv7.1, Kv7.2, Kv7.3 and 
Kv7.5 antibodies were tested negative although the same antibodies were used 246.  
Interestingly, KCNQ mRNA levels may change during maturation, as Kv7.1 and Kv7.5 expression levels 
are higher in muscular arteries of rats aged ~2 weeks, whereas in >2 month old rats Kv7.4 mRNA 
predominates 234. Also, Kv7 channel formation may be affected by prolonged presence of 
vasoconstrictive agonists, since it was recently discovered that longtime-incubation (1-7 hours) of 
mesenteric arteries with angiotensin II decreased Kv7.4 protein expression without reducing KCNQ4 
transcript levels 247. 
1.6.4.2.3 Kv7 pharmacology 
Several Kv7-specific and even some Kv7.x subunit-specific channel modulators are available. 
Unselective Kv7 blockers or activators typically display differential half maximal inhibitory 
concentrations (IC50) or half maximal effective concentrations (EC50), respectively, for individual Kv7.x 
subunits (for review, see 248).  
All Kv7 channels are blocked by the cognitive enhancer XE991 217, 219, 224, 249-253. Subunit-specific IC50 
values are reported to vary between Kv7.1 (0.75 µM 219 or 0.78 µM 217), Kv7.4 (1.2 µM 249 or 5.5 µM 250) 
and Kv7.5 (61 µM 253, 65 µM 251 or 75 µM 252). Another frequently used pan-Kv7 blocker is the structural 
relative linopirdine, which also displays differential IC50 values for Kv7.1 (8.9 µM 219 or 35 µM 223), Kv7.4 
(1.7 µM 249 or 14 µM 250) and Kv7.5 (16 µM 254 or 51 µM 251). Application of XE991 or linopirdine has 
been demonstrated to inhibit Kv7 currents in rodent 96, 223, 227, 229, 238, 244, 255-258 and non-rodent 
mammalian 259 VSMCs and to cause Vm depolarization, active contraction and enhancement of agonist-
induced vasocontraction in various blood vessels 193, 196, 208, 225-229, 232, 234, 243, 252, 256-261 including renal 
arteries of mice 245 and rats 77, 96, 107, 246, 255, 262. 
Subunit-specific blockers are currently available for Kv7.1 channels only. HMR1556 inhibits Kv7.1 at an 
IC50 of 0.54 µM 216 or 0.42 µM 215 and application of 10 µM reduces K+ currents through Kv7.1, but not 
through Kv7.4 or Kv7.5 channels 96. However, functional studies have revealed no effect on vascular 
reactivity in either absence 196, 228, 260 or presence of contractile stimuli like transmural pressure 245 or 
vasoconstrictive agonists 210, 263. Likewise, systemic application in vivo did not affect vessel tone 264 nor 
heart rate, blood pressure or GFR 265. Chromanol 293B is another substance that has been used to 
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study Kv7.1 channels, although chromanol 293B may unintendedly cause inhibition of other K+ 
channels 266-268 at concentrations relatively close to its IC50 for Kv7.1  (27 µM 269, 41 µM 270 or 67 µM 271). 
Nonetheless, while effectively inhibiting Kv7.1 currents in VSMCs, chromanol 293B does not affect 
rodent 193, 224, 232, 245, 263, porcine 259 or human 239 arterial contractility. 
Unselective Kv7 activators like the novel anticonvulsant retigabine do not affect Kv7.1 channels, since 
KCNQ1 is lacking a single tryptophan and three leucin residues that are necessary for retigabine 
sensitivity in KCNQ2-5 272, 273. Retigabine activates Kv7.4 channels at an EC50 of  ~1.4 µM 249, ~5.2 µM 273 
or ~5.9 µM 274 and Kv7.5 channels at an EC50 of ~3.45 µM 274 or ~6.4 µM 252. Besides left-shifting voltage-
dependence Kv7.2-5 to more negative Vm, retigabine also decreases their rate of deactivation and thus 
stabilizes the open channel configuration 275-277, which is more apparent under depolarized conditions 
like precontraction 166. Retigabine has been demonstrated to enhance Kv7 currents in native vascular 
myocytes 224, 255, 257 and to cause concentration-dependent relaxations of precontracted rat renal 
arteries with an EC50 of 9.21 ± 2.76 µM 243, while likewise relaxing other rodent 194, 196, 228, 229, 232, 243, 256, 
261 and human 239, 241 arteries at similar concentrations. However, Retigabine induces normal 
concentration-dependent relaxations in KCNQ1–/– arteries 263. Alternative substances with slightly 
different Kv7 subtype specificities 243, 248 like flupirtine, S-1, ML213 or BMS204352 have also been 
successfully used for Kv7.2-5 activation in blood vessels 77, 96, 243, 246, 262. 
Kv7.1 can be specifically activated by the benzodiazepine R-L3 (alternative name: L-364,373), which 
interacts with certain residues located in the S5 and S6 transmembrane domains of KCNQ1 subunits 
278. Pharmacological data is limited, but existing reports have suggested R-L3 to function as a partial 
agonist, left-shifting Kv7.1 activation Vm values, slowing both activation and deactivation rate and 
enhancing currents with an EC50 of <1 μM 213. Conversely, other reports found R-L3 to show little effect 
at 1 µM, while 10 µM increased KCNQ1 currents by ~100% 260. Importantly, association with KCNE1 
prevents R-L3 binding to KCNQ1 subunits 213, which is why R-L3 is effective on unsaturated 
(KCNQ1)4(KCNE1)n tetramers, but not on saturated (KCNQ1)4(KCNE1)4 channels 214. The effect of R-L3 
on blood vessels appears to vary between arteries from different vascular beds, with some studies 
finding no effect 196, 228, 279 and others reporting concentration-dependent relaxations of agonist-
induced precontraction 232, 260, 263, 280. In the renal vasculature, R-L3 has been shown to cause relaxations 
in both rats 280 and mice 263. However, at least in mice the anticontractile effect of R-L3 appears to rely 
upon mechanisms distinct from Kv7.1 activation 263.  
1.6.4.2.4 Kv7 regulation 
Regulatory factors that may dictate Kv7 function include membrane voltage, mechanical stimuli and 
various biochemical signals. 
Kv7 channel activity is most importantly regulated by Vm. Half maximum activation thresholds (V50) are 
somewhat different between Kv7.x subfamilies, ranging from approximately -20 mV (Kv7.1 and Kv7.4) 
over -30 mV (Kv7.2) to -40 mV (Kv7.3 and Kv7.5). Single channel conductance is similar for vascular 
Kv7.1/4/5 channels, namely ~1-4 pS. The rate of activation of vascular Kv7 channels at 0 mV is slower 
for Kv7.1 (~210 ms) than for Kv7.4/5 (~160-180 ms), which is reversed at more depolarized Vm (~90 ms 
for Kv7.1 or ~150-160 ms for Kv7.4/5 at +40 mV). At hyperpolarized Vm around -60 mV, Kv7.1 also display 
slower deactivation rates (~455 ms) than Kv7.4/5 (~100-125 ms) 183.  
Kv7 channels in VSMCs have recently been implemented in transduction of mechanical stimuli like 
transmural pressure inducing arterial myogenic response 245. It was found that activation of 
angiotensin II receptor type 1 (AT1R) via osmotically induced membrane stretch suppresses currents 
through XE991-sensitive Kv channels in mice. However, since the XE991 was used at a high 
concentration of 30 µM, which is known to inhibit Kv other than Kv7 208, 224, 281 and since myogenic tone 
was still evident in arteries from KCNQ4 knockout mice and KCNQ5 mutant mice while being entirely 
abolished by AT1R knockout 245 no firm conclusion can be drawn regarding the role of Kv7 channels in 
angiotensin II-suppressed Kv currents 282.  
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Besides regulation through membrane voltage, the effect Kv7 channels have on vascular reactivity is 
influenced by a remarkably large number of contractile or anticontractile biochemical signals. Kv7 
channels have been shown to be implemented in vasoconstrictive pathways mediated by VOCC, 
Ca2+/CaM, PIP2 and Gq/11-coupled receptor agonists as well as vasodilative pathways employing 
cGMP/PKG or cAMP/PKA 123.  
Considerably evidence exists for Ca2+-dependent contractile mechanisms involving Kv7 channels. 
Dependency on L-type Ca2+ channels has been demonstrated both for vasodilations induced by Kv7.2-5 
activator Retigabine as well as for vasoconstrictions induced by pan-Kv7 blockers XE991 or linopirdine 
in rat and murine arteries 193, 225, 226, 258. Also in the renal vasculature, reversibility of XE991-induced 
contractions via L-type Ca2+ channel blockade has been found in both isometric tension recordings of 
rat interlobar arteries and in vivo via ultrasound flowmetry of rat renal blood flow 246. Interestingly, 
another aspect in which Kv7.1 is different from Kv7.4 and Kv7.5 is Calmodulin (CaM)-dependent 
regulation. CaM binds to the C-terminus of Kv7 channels, where it is essential for correct folding of the 
intracellular domain 283, 284. Notably, CaM confers Ca2+ sensitivity only to KCNQ4 and KCNQ5, which 
after Ca2+ binding to CaM show strongly reduced K+ currents, but not to KCNQ1 or KCNQ1/KCNE1 
channels (Gamper et al., 2005). This might serve as a feed-forward mechanism in contraction, with 
Kv7.4 and Kv7.5 conducting K+ currents to stabilize Vm during resting state and thus preventing VOCC 
activation, whereas upon depolarization-induced Ca2+ influx and consecutive increase in Ca2+/CaM 
resulting in inhibition of Kv7.4 and Kv7.5, a decrease in these K+ currents would allow for contraction. 
Kv7 channels are unique in that they mandatorily require PIP2 in order to conduct currents 186, 187, 285, 
286. PIP2 increases Kv7 channel open probability by stabilizing their open configuration 287, 288. This effect 
has been best studied in Kv7.1 channels. PIP2 is required for coupling of the voltage sensing and the 
pore opening domain in Kv7.1 channels 289, slowing Kv7.1 deactivation kinetics 290 and shifting its voltage 
dependency towards negative potentials 290 and thus overall making Kv7.1 channel activation in 
response to Vm changes more efficient 289. PIP2-induced current enhancement has also been described 
for Kv7.4 channels, in which furthermore PIP2 depletion reduced retigabine-induced Kv7.4 current 
enhancement 291. This PIP2-mediated regulation of Kv7 channel properties may be initiated by Gq-
coupled receptor agonists like various vasoconstrictors 292. Notably, Kv7.1 interaction with PIP2 may be 
strengthened by stimulation of PKC or PKA 292. 
Gq/11-coupled receptor activation, a mechanism shared by many vasoconstrictors like vasopressin, 
serotonin and endothelin-1, can reduce Kv7 currents, leading to VSMC depolarization and 
contraction 195, 225, 230, 257. PKC has been shown to be involved in this process, yet evidence is somewhat 
contradictory. On the cellular level, Gq/11-coupled vasoconstrictors may mediate VSMC activation by 
PKC-dependent inhibition of Kv7 channels: In rat VSMCs, arginine vasopressin (AVP) by reducing 
retigabine- or flupirtine-sensitive currents causes depolarization in a manner reducible by PKC 
inhibitors 225, 230 or KCNQ5 knockdown 293, DAG analogons PKC-dependently inhibit KCNQ5 currents 293, 
direct PKCα activation supresses native Kv7 currents 195 and serotonin and endothelin-1 suppress 
Retigabine-sensitive currents in a similar fashion as direct PKC-inhibitors 257. However, on the whole-
vessel level, direct evidence for PKC-dependent Kv7 regulation is thus far missing: While direct PKC 
inhibition mimics the effect of XE991 in producing contractions in rat basilar artery 257, it is inefficient 
in preventing linopirdine-induced contractions in either absence or presence of AVP in rat mesenteric 
arteries 225. Indirectly suggestive for PKC involvement are existing reports of AVP-, endothelin-1- or 
phenylephrine-induced contractions being enhanced by XE991 193, 257 or diminished by retigabine and 
flupirtine 193, 258 in rat and mice arterial vessels. Interestingly, an alternative mechanism not dependent 
on PKC which may serve to explain Gq/11 mediated regulation of Kv7 has lately been offered when long-
term (> 1h) incubation of angiotensin II was discovered to decrease Kv7.4 protein expression without 
reducing KCNQ4 transcript levels via interaction with HSP90 247.  
More recently, cGMP-dependent regulation of Kv7 channels has been discovered as a mode of Kv7 
participating in endogenous vasodilator action. Atrial natriuretic peptide (ANP) endothelium-
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independently and cGMP-dependently relaxed methoxamine-precontracted rat aorta and renal 
arteries in a manner impaired by pan-Kv7 blocker linopirdine, but not by specific blockers of Kir, KATP, 
BKCa or Kv1-4 77. Since these relaxations were unaffected by PKA-inhibition, it is likely modulations of 
Kv7 currents are conducted by PKG.  However, mechanisms may differ between species or vascular 
beds, since in endothelium-denuded porcine coronary arteries, relaxations to NO donor sodium 
nitroprusside (SNP) induced equal vasodilatation in the absence or presence of XE991 259.  
More vast amounts of evidence suggest cAMP-dependent regulation of vascular Kv7 channels. The Kv7 
C-terminus contains binding domains for A-kinase-anchoring proteins (AKAP) 284, indicating the 
possibility of Kv7 channels forming signaling domains with PKA, which is commonly activated by 
cAMP 51. Consistently, PKA has been shown to phosphorylate the Kv7.1 N-terminus after forming a 
macromolecular complex with the KCNQ1 C-terminus, the AKAP Yoatio and protein phosphatase 1 294. 
This mechanism may underlie the upregulation of the cardiac IKs current achieved by β-adrenoceptor 
mediated cAMP elevation and PKA stimulation 295. In vascular smooth muscle cells, AKAP has been 
found to be localized with Kv7.4 channels, which in renal arteries increased with β-adrenoceptor 
stimulation 107  in a Gβγ-dependent manner 262. Overall, studies have identified a number of 
endogenous dilators like CGRP 196, 262 or adenosine 259 as well as pharmacological substances like β-
adrenoceptor agonist isoproterenol 96, 97, 107, 228, 262, 280 or AC stimulator forskolin 97, 227, 232, which by 
elevating intracellular cAMP produce vasorelaxation that amongst others depend upon 
hyperpolarizing outward Kv7 currents in various mammalian arteries including rat renal arteries 96, 107, 
262, 280. The individual Kv7.x subtypes may be differentially affected by cAMP, since Kv7.5 homotetramers 
in VSMC were shown to be more susceptible to PKA-dependent current enhancement than Kv7.4/Kv7.5 
heteromers or Kv7.4 homomers 97 and consistently forskolin-induced relaxations to be more marked 
in arteries with higher expression of KCNQ5 mRNA and Kv7.5 protein 232. Furthermore, the situation is 
complicated by the fact that cAMP may not only act through PKA, which appears to be the 
predominant mode of isoproterenol effects in renal, but not mesenteric, arteries, but may also cause 
relaxation by stimulating exchange protein directly activated by cAMP (EPAC), which may the 
prominent mechanism in mesenteric, but not renal, arteries 107. Thus, while cAMP-mediated 
mechanisms in general are recognized as an important modification of Kv7 function, the specific 
pathways involved may differ between vascular beds.  
Other endogenous substances that have been associated with Kv7 function in blood vessels include 
hydrogen sulfide (H2S), which produces vasorelaxations attenuated by blockade of Kv7 channels 229, 259, 
261, 296 and enhances Kv7 currents 296; bradykinin, the anticontractile effect of which is reduced by 
application Kv7 blockers 279, 297; and oxygen (O2), with hypoxic vasodilation likewise being reduced by 
Kv7 blockade 233, 259. 
1.6.4.2.5 Role of Kv7 in vascular physiology 
Due to the vast number of mechanisms and players involved as well as their variation between 
different vascular beds, understanding Kv7 channel function is very complex and thus far incomplete.  
Electrophysiological features like their activation threshold being closer to the resting Vm of VSMCs 
than that of most other Kv family members 183 suggest a role as important determinators of resting Vm 
and as mediators of negative-feedback regulation of mechanical or chemical signal transduction in 
vascular reactivity 123. With Kv7.1 activating faster at depolarized Vm levels and deactivating slower at 
hyperpolarized Vm compared to Kv7.4 or Kv7.5 183, it is possible that Kv7.1 may be more important for 
stabilizing resting Vm, while Kv7.4 and Kv7.5 more relevantly contribute to limiting depolarization. 
Other electrophysiological features like their considerably low degree of inactivation at constant Vm 
facilitate a role as signal transduction intermediates in the actions of vasoconstrictor and vasodilator 
stimuli 282. With Kv7 currents having been shown to on the one hand be reduced by Gq/11-coupled 
receptor activators like various vasoconstrictors, causing VSMC depolarization and contraction 195, 225, 
230, 257 and on the other hand be activated by various endogenous vasodilators dependent on 
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cGMP/PKG 77, cAMP-PKA 96, 97, 107, 196, 227, 228, 232, 259, 262, 280 or other mediators 229, 233, 259, 261, 279, 296, 297, 
inducing VSMC hyperpolarization and vasorelaxation, Kv7 channels appear to represent an important 
point of intersection in the fine-tuned balance of constrictive and dilative mechanisms of many arterial 
beds. 
In the renal vasculature, Joshi et al. 255 were the first to discover a constrictive effect of pan-Kv7 blockers 
XE991 and linopirdine on rat main renal arteries. Besides confirmation of these findings 77, 96, also in 
smaller resistance vessels 246, subsequent research found Kv7.2-5 activators like Retigabine 243, S-1 96, 
243, BMS204352 243 or flupirtine 246 to produce renal vasorelaxation. Consistently, KCNQ4 knockout with 
siRNA increases renal arterial vasoconstrictor sensitivity 96 and Kv7 blockers increased renal perfusion 
pressure in rat 96 and murine 245 isolated perfused kidneys and decreased rat renal blood flow in vivo 246. 
Notably, Kv7.2-5 activator flupirtine increased in vivo rat renal blood flow, but just like XE991 showed 
no effect on reductions of RBF induced by vasoconstrictors norepinephrine or angiotensin II 246. L-type 
Ca2+ channel blockers like nicardipine or nifedipine completely reverse the contractions induced by 
linopirdine 96 and XE991 246. The presence of linopirdine is associated with reduced renal artery 
relaxations to the cGMP-dependent endogenous vasodilator ANP 77. Implications for an involvement 
of Kv7 in cAMP-dependent dilation of renal arteries have been given in form of cAMP elevation 
stimulating linopirdine-sensitive channels 96, linopirdine attenuating cAMP-dependent relaxations 96, 
107 and Kv7.4 channels colocalizing with A-kinase anchoring protein 107. Overall, Kv7 channels in renal 
arterial vessels may play a functional role by contributing to vasoconstrictor actions in a manner 
dependent on L-type Ca2+ channels if Kv7 currents are reduced, as well as in vasodilator actions possibly 
including cGMP- and/or cAMP-dependent mechanisms where Kv7 currents are enhanced. 
1.6.4.2.6 Role of Kv7 in vascular pathology 
In the recent years, research has linked cardiovascular disease to Kv7 dysfunction. While in other 
organs like the heart, mutations of i.e. KCNQ1 are known to lead to autosomal-dominant long QT 
syndrome 192, short QT syndrome 298 or familial atrial fibrillation 299, there are no known hereditary 
disorders of the vasculature that can be pinpointed to specific KCNQ gene mutations 183. Nonetheless, 
Kv7 dysfunction has been implemented in a multitude of vascular diseases including both hypertension 
and hypotension, pulmonary arterial hypertension and coronary artery disease 300. Therefore, Kv7 
channels may be promising new drug targets for the treatment of these conditions. Giving further 
impetus to their relevance, the Kv7 channel characteristic of being controlled by perivascular adipose 
tissue (PVAT) 176, 229, 259, 261, 296, 301 makes them an especially interesting drug target for comorbid 
conditions like resistant hypertension along with obesity or metabolic syndrome 248. 
In hypertension, downregulation of Kv7 channels in VSMCs may be a contributing factor to high blood 
pressure 300. With Kv7 currents contributing to membrane hyperpolarization, decreased presence of 
Kv7 channels would leave VSMCs more depolarized, causing vasoconstriction resulting in increased 
vascular resistance and elevated blood pressure. Arteries from spontaneously hypertensive rats (SHR) 
as well as from angiotensin-induced hypertensive mice show attenuated responses to Kv7 blockers and 
activators and lower expression of Kv7.4 compared with normotensive vessels 77, 96, 228, 229, 237, 256, 302. In 
the aorta, of all 5 KCNQ genes only KCNQ4 was shown to be reduced 256. With SHR arteries displaying 
reduced responsiveness to pharmacological Kv7 activators, it may be questionable whether activating 
the remaining Kv7 channels is sufficient to induce the desired therapeutic vasodilation 300. However, as 
Kv7 activators have been shown to improve vasorelaxation by PVAT, which is impaired in hypertension 
and obesity 303, Kv7 modulators may be a specific pharmacological approach for this commonly 
observed comorbidity. 
Renovascular pathology like arteriolosclerosis of small renal arterioles or glomerulosclerosis has long 
been known to be associated with hypertension 304. Human autopsy studies have found renal afferent 
arteriopathy in 98% of kidneys from hypertensive subjects, contributing to the existing theory that 
renal resistance artery dysfunction in some cases is not only coincidental, but the primary mechanism 
inducing hypertension 305. Goldblatt 306 demonstrated in 1934 that creating renal artery stenosis, which 
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is detected in 5-10% of patients with hypertension 307, by reducing RPP leads to hypertension. Both 
passive renovascular stenosis and active constriction increase renal arterial resistance, which causes 
elevation of blood pressure via activation of the renin-angiotensin system 5. In mice, genetic deletion 
of KCNQ3, KCNQ4, or KCNQ5 produces constriction of isolated perfused kidneys 245. In SHRs, KCNQ4 
abundance in the renal artery is markedly reduced, and renal artery contractions or relaxations to Kv7 
blockers or activators is strongly diminished 96. Interestingly, downregulation of Kv7.4 channels in SHRs 
occurs without a decrease in KCNQ4 mRNA and is mediated by a specific regulatory microRNA 
(miR153), suggesting Kv7.4 abundance to be determined by post-transcriptional regulation 302. 
Moreover, impaired ANP-induced cGMP-mediated vasorelaxation in SHR renal arteries has been 
implicated as a consequence of reduced VSMC Kv7.4 levels 77. The combination of increasing 
renovascular Kv7 membrane abundance along with Kv7 activation, the latter of which has been shown 
to hyperpolarize renal VSMC and relax renal arterial vessels 96, 243, 246, 262 as well as to increase rat renal 
blood flow in vivo 246 may be a promising therapeutic strategy in hypertension, no matter whether 
renovascular pathology is coincidental or causative to the elevated blood pressure. 
Hypotension on the other hand can be a more acutely life-threatening condition i.e. during septic 
shock, in which Kv7 channel blockade has been demonstrated to oppose the effect of the tryptophane 
metabolite and sepsis-associated vasodilator kynurenine 308. Thus, targeting Kv7 may pose an approach 
for this otherwise therapeutically challenging condition culminating in multiple organ failure 300. 
Pulmonary arterial hypertension (PAH) is another disease in which current treatment options can be 
limited, especially when PAH is secondary to cardiac dysfunction, since in this case negative side effects 
of the common vasodilator therapy are especially undesirable 300. Tissue-specific vasodilators like 
activators of Kv7.2-5 channels, which are found in VSMCs but not cardiac myocytes, appear as an 
attractive solution to this dilemma. Kv7.2-5 specific activators have already been demonstrated to relax 
pulmonary arteries in isolated vessels 255 and in perfused lungs from hypoxic rats 231 and to attenuate 
PAH symptoms like cardiac hypertrophy and increased right ventricular pressure 309.  
In coronary artery disease, impaired hypoxia-induced coronary vasodilation is a major 
pathomechanism potentially to be addressed by modifying Kv7 channel function 300.  Kv7 channel 
activators are established to produce coronary artery relaxation 194, 227, 228, 232, 259 and oppositely Kv7 
blockers can reduce hypoxia-induced dilation of isolated coronary arteries 259  and reduce coronary 
flow rate in isolated perfused rat hearts 233. Conversely though, ischemia-reperfusion experiments in 
these same isolated perfused rat hearts found Kv7 blockers to reduce myocardial infarct size and to 
improve cardiac function, suggesting a direct drug effect on cardiomyocytes rather than through 
VSMC-mediated flow modification 233. 
1.7 Objective of this thesis 
Although research has increasingly focused on Kv7 in the last years, piece by piece unraveling their 
manifold contributions to vascular reactivity in various arterial beds, not too much is known about 
their role in the renal vasculature, which is of central relevance for the large number of physiological 
processes the kidney is involved in, most importantly blood pressure regulation. Only a handful of 
studies have focused on Kv7 function in isolated rat main renal arteries 77, 96, 107, 243, 255, 262 or smaller rat 
and murine renal resistance vessels 246, and even fewer data is available on their effect on the whole-
organ vasculature 96, 245 or on renal blood flow in vivo 246. These reports have unveiled that 
pharmacological blockade or activation of renal Kv7 channels may influence vascular tension on the 
cellular, vessel segment, whole-organ and in vivo level, and implications have been given for 
interactions with both endogenous vasodilators and vasoconstrictive agents. However, the renal 
vasculature is known to intrinsically determine arterial resistance in particular through the renal 
myogenic response 7 and tubuloglomerular feedback 8, 9 and thus largely independently of circulating 
hormones 6. Conclusively, some reports state that Kv7 channels do not seem to mediate or buffer 
agonist-induced renal vasoconstriction or vasodilation 121. 
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While some data is available on Kv7 channel function in context with cGMP 77- and cAMP 96, 107-
dependent relaxations in the main renal artery, a large conduit vessel conducting ~25% of cardiac 
output 6, no study so far has thoroughly examined the situation in smaller renal resistance arteries, 
which may be even more relevant to renal function as they are the key players among all vessels 
contributing to regulating renal blood flow and perfusion pressure. It is not known whether Kv7-
mediated vasoregulation of small renal resistance arteries depends upon or interferes with 
endogenous regulation of vascular tone by circulating hormones. We therefore tested the hypothesis 
that two endogenous vasodilators, the cGMP-dependent ANP and the cAMP-dependent Urocortin, 
either attenuate or enhance the therapeutically intended vasodilatory effect of the Kv7.1-specific 
activator R-L3 and the unspecific Kv7.2-5 activator Retigabine in small renal resistance arteries. 
Furthermore, Kv7 expression is highly tissue-specific and different Kv7.x subtypes tend to predominate 
depending on the location of the blood vessel within the body 248. In this regard, the renal vasculature 
appears to be different from other vascular regions: While quantitative expression analysis mostly find 
KCNQ1 96, 243-245 to predominate in rat renal arteries, other vessels from the coronary, pulmonary, 
cerebral or musculoskeletal circulation show higher expression of KCNQ4 or KCNQ5 248. Thus, 
renovascular Kv7.1 channels are an especially interesting pharmacological target, since inducing 
dilation by specifically activating Kv7.1 channels would be an elegant way of exclusively improving renal 
blood flow – thus addressing one majorly important contributing factor in hypertension – without 
lowering overall blood pressure and thus making sure that the drug effect actually comes to the benefit 
of renal perfusion while leaving other vascular beds unaffected. However, it is not known whether the 
Kv7.1 specific activator R-L3 is effective in producing vasodilation not only on a microscopic scale like 
isolated vessel segments, but also on the whole-organ level. We therefore tested the hypothesis that 
R-L3 causes specific Kv7.1-mediated and reversible vasodilation of the entire renal arterial vasculature 
using a novel isolated perfused rat kidney method.  
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2 METHODS 
2.1 Animal Model 
For all experiments male WISTAR albino rats of the strain RjHan:WI and the genotype Tyrc/Tyrc were 
used,  which are certified as specific pathogen free (SPF) and specific and opportunistic pathogen free 
(SOPF). Animals were purchased from Janvier Labs, France and delivered at the age of 8 weeks via ISO-
9001 certified transport logistics to reduce stress. Upon arrival in the in-house animal facility, animals 
were given at least one week to acclimatize to local conditions. They were held in IVC cages and had 
free access to tab water and complete feed pellets V1534-0 from ssniff®, Germany. At the time when 
used for experiments, animals were 10-12 weeks old. On the day of the experiment the rats were killed 
by asphyxiation with CO2 followed by cervical dislocation with a guillotine, upon which death occurred 
immediately. The treatment of the rats is in agreement with the Guide for the Care and Use of 
Laboratory Animals (8th edition. National Academies Press (US); 2011.) and legal regulations by the EU 
(directive 2010/63/EU) and Germany (TierSchG, 2013 (BGBl. I S. 2182) and TierSchVerV, 2013 (BGBl. I 
S. 3125, 3126)) and was approved by local authorities. 
2.2 Solutions 
When studying arteries in vitro, it is important to generate conditions similar to the in vivo environment 
by using solutions that can take over some of the functions blood and interstitial fluid have for the 
viability of the vessels. We thus used physiological salt solutions (PSS) that imitated physiological 
conditions with respect to electrolyte concentrations and pH, volatile gases like O2 and CO2, and 
temperature. In total, four slightly different PSS were used (Table 1). All solutions were either freshly 
prepared or stored at 4°C and renewed every week. 
PSS used for preparation does not contain NaHCO3 as a pH-buffer because it is not possible to aerate 
the solution during preparation. Gas bubbles would hinder the view and cause the small isolated 
vessels to move undesirably. Since CO2 leaves the NaHCO3-buffered solutions to the surrounding air 
and is thus continuously removed from its equilibrium with protons and bicarbonate, protons are 
bound into H2O and the pH rises. To avoid this, the artificial buffer 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) which does not need to be aerated was used to maintain the 
pH. The pH in refrigerated solution was adjusted to 7.3. Oxygenation of the solution occurred through 
equilibration with the surrounding air. Cooling the solution down to 4°C and its lack of glucose were 
intended to decrease tissue metabolism and avoid acidosis during the process of preparation.  
PSS for myography experiments was used at 37°C and continuously aerated with carbogen (95% O2 
and 5% CO2) to keep pH constant. Before starting and throughout the experiments, pH was repeatedly 
controlled and adjusted to 7.4 if necessary using HCl or NaOH. EDTA served to chelate traces of heavy 
ions that might be contained in the water. Once heated, experimental solution was not refrigerated 
again but discharged. 
Modified PSS without NaHCO3 for the isolated perfused kidney was kept at room temperature during 
the experiments and only heated while flowing through the perfusion system. The pH was adjusted 
to 7,55 at room temperature, so that the pH of the solution after passing the heat exchanger would 
amount to 7,4. Like in myography experiments, the solution was aerated to provide O2 needed for 
proper function of the kidney. Calcium-free PSS for viability testing was generated from Modified PSS 
without NaHCO3 by adding ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) 
in a concentration of 2 mM which selectively chelates free Ca2+, but not Mg2+ ions. 
Modified PSS containing 120 mM KCl was used for viability tests in both myography and isolated 
perfused kidney experiments. Some myography experiments required a solution containing 50 mM 
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KCl, which was generated by mixing regular experimental solution and 120 mM KCl solution in 
relations 3:2. 
 
Table 1: Solutions 
 Reagents MW Conc. [mM] Source 
Preparation solution NaCl 
KCl 
NaH2PO4xH2O 
MgSO4x7H2O 
CaCl2 x 2H2O 
EDTA 
HEPES 
58,4 
74,6 
137,99 
246,48 
147 
372,24 
238,3 
145 
4,5 
1,2 
1 
0,1 
0,025 
5 
Carl Roth 
Carl Roth 
Merck 
Merck 
Merck 
Carl Roth 
AppliChem 
PSS 
(for myography) 
NaCl 
NaHCO3 
KCl 
NaH2PO4 x H2O 
MgSO4 x 7H2O 
CaCl2 x 2H2O 
EDTA 
HEPES 
Glucose 
58,4 
84,01 
74,6 
137,99 
246,48 
147 
372,24 
238,3 
180,16 
120 
26 
4,5 
1,2 
1 
1,6 
0,025 
5 
5,5 
Carl Roth 
Carl Roth 
Carl Roth 
Merck 
Merck 
Merck 
Carl Roth 
AppliChem 
Carl Roth 
Modified PSS without 
NaHCO3 
(for isolated kidney) 
NaCl 
KCl 
NaH2PO4 x H2O 
MgSO4 x 7H2O 
CaCl2 x 2H2O 
EDTA 
HEPES 
Glucose 
58,4 
76,6 
137,99 
120,4 
147 
372,24 
238,3 
180,16 
146 
4,5 
1,2 
1 
1,6 
0,025 
5 
5,5 
Carl Roth 
Carl Roth 
Merck 
Merck 
Merck 
Carl Roth 
AppliChem 
Carl Roth 
Modified PSS with 120mM 
KCl 
(for viability tests) 
NaCl 
NaHCO3 
KCl 
NaH2PO4 x H2O 
MgSO4 x 7H2O 
CaCl2 x 2H2O 
EDTA 
HEPES 
Glucose 
58,4 
84,01 
74,6 
137,99 
246,48 
147 
372,24 
238,3 
180,16 
4,5 
26 
120 
1,2 
1 
1,6 
0,025 
5 
5,5 
Carl Roth 
Carl Roth 
Carl Roth 
Merck 
Merck 
Merck 
Carl Roth 
AppliChem 
Carl Roth 
Further reagents used HCl 
NaOH 
EGTA 
Aqua dest. 
  AppliChem 
Carl Roth 
Sigma Aldrich 
 
Conc. = concentration; EDTA = ethylenediaminetetraacetic acid; EGTA = ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-
tetraacetic acid; HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; MW = molecular weight; PSS = physiological salt 
solution 
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2.3 Drugs 
Stock solutions were prepared of all drugs according to manufacturer sheets (Table 2) and stored at -
20°C. Appropriate dilutions depending on the concentration needed were prepared right before 
performing the experiment. 
When used for myography experiments, the drugs were directly pipetted into the myograph chambers. 
The myograph chambers have a volume of 5ml. For example, to achieve a concentration of 10-5 M in 
the chamber, a volume of 5 µl from a 10-2 stock solution was applied. Some drugs were used in multiple 
concentrations, such as methoxamine for concentration-response relationships and ANP, Urocortin, 
Retigabine and R-L3 for precontraction experiments. In that case, dilution series were produced using 
the appropriate solvent H2O or dimethyl sulfoxide (DMSO). Special care was taken in protocols using 
multiple drugs solved in DMSO or precontraction protocols using R-L3 or Retigabine. As DMSO can be 
cytotoxic at concentrations higher than 10-3 M we were careful not to use more than 5 µl of DMSO at 
a time and always applied the same concentration of DMSO in the control channels. Exceptions of this 
rule were made only in precontraction protocols examining the effect of multiple K+ channel blockers 
on ANP- and Urocortin-induced vasorelaxation, where 10 µl of DMSO were permitted since the control 
channel showed no signs of functional damage. 
When used for isolated perfused kidney experiments, drugs were applied in two different ways. First, 
Methoxamine was applied directly into the perfusate in a final concentration of 3*10-6 M. With 
approximately 500 ml of perfusate being needed per kidney for one experiment, 150 µl of 
Methoxamine 10-2 stock solution were required. Second, drugs were added onto the Methoxamine-
induced precontraction by using syringe pumps. Two sizes of syringes were used, 1 ml syringes 
(Omnifix-F Tuberkulin from B. Braun Melsungen, Germany) and a 100 µl Microsyringe (MS*N100 from 
Ito Corporation Exmire, Japan). The syringes were filled with stock solutions in concentrations x times 
higher than the desired concentration and the flow rate of the syringe pumps was set to values x times 
lower than the flow rate for the kidney perfusion. For example, at a kidney perfusion rate of 3ml/min, 
the syringe was filled with a 3*10-4 M stock solution of XE991 and the syringe flow rate was set to 30 
µl/min, achieving the desired concentration of 3*10-6 M XE991. Two syringe pumps were used serially 
connected, so that two drugs could be given at the same time, but independently. 
 
Table 2: Drugs 
Drugs MW Stock [M] Conc. [M] Solvent Source 
Acetylcholine chloride 181.66 10-2 10-5 H2O Sigma Aldrich 
ANP rat 3062.41 10-4 10-9-10-7 H2O Sigma Aldrich 
Barium chloride dihydrate 244.26 10-2 3*10-5 H2O Riedel de Haën  
DPO-1 340.44 10-1 10-6 DMSO Tocris 
Glibenclamide 494 10-2 10-6 DMSO Tocris 
HMR1556 411.44 10-2 10-5 DMSO Tocris 
Iberiotoxin 4230.9 10-4 10-7 H2O Alomone Labs 
L-NNA 233,2 10-2 10-4 H2O Alexis  
Methoxamine hydrochloride 247.72 10-2 10-8-10-4 H2O Sigma Aldrich 
Retigabine 303.33 3*10-2 3*10-7-
3*10-5 
DMSO Valeant 
R-L3 (L364,373) 397.44 10-2 10-8-10-6 DMSO Tocris 
Stromatoxin 3792 10-4 10-7 H2O Alomone Labs 
Urocortin rat 4707.26 10-4 10-10-10-7 H2O Sigma Aldrich 
XE991 dihydrochloride 449.37 10-2 3*10-6 H2O Tocris 
ANP = atrial natriuretic peptide; conc. = working concentration; DMSO = dimethyl sulfoxide; DPO-1 = (+)-Neomenthyl 
diphenylphosphine oxide; HMR = N-[(3R,4S)-3,4-Dihydro-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-2H-1-benzopyran-
4-yl]-N-methylmetanesulfonamide; L-NNA = NG-Nitro-L-arginine-methyl ester; MW = molecular weight; stock = concentration 
of the stock solution; XE = 10,10-bis(4-Pyridinylmethyl)-9(10H)-anthracenone dihydrochloride 
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To avoid high concentrations of DMSO, two strategies were pursued. The first strategy was to use a 
Microsyringe, allowing higher concentrations of stock solutions and thus smaller amounts of solvent 
to be given. For example, at a kidney perfusion rate of 3 ml/min, the 100 µl microsyringe was filled 
with a  10-2 M stock solution of HMR1556 and the syringe flow rate was set to 3 µl/min, achieving a 
desired concentration of 10-5 M HMR1556. The second strategy was to create stock solutions for 1 ml 
syringes that were diluted in parts with DMSO and in parts with H2O. For example, the original stock 
solution of 10-2 M R-L3 solved in DMSO was diluted 1:100 with H2O, creating a new syringe stock 
solution containing 10-4 M R-L3 that could be administered in the way as described above while 
avoiding concentrations of DMSO higher than 10-3 M. 
2.4 Myography 
Myography is the study of muscle function. In this thesis, the muscles investigated were smooth 
muscles in the walls of the renal vasculature and the methodical approach chosen was isometric 
myography. In isometric myography, the contractile state of a blood vessel can be studied by 
measuring isometric force exerted by vessels isolated from their original vascular beds and mounted 
on two parallel wires having a fixed distance, one of which is connected to a force transducer. With 
this setup, functional aspects like vasoconstriction and vasorelaxation in response to action potentials, 
electrical stimulation, agonists or antagonists, and to changes in ion concentrations can be studied. 
Our methodical approach is based on the method first described by Mulvany and Halpern 310, 311 which 
has been further refined since 312, 313. 
2.4.1 The myography setup 
All myography experiments were performed on four-chamber wire myographs from Danish Myo 
Technology A/S, Denmark. Two different generations of the same model myograph were used, the 
DMT610M and its successor DMT620M. The force readout from the myograph interface was 
transferred via BNC cables to a data acquisition hardware unit (PowerLab 4/26 and 4/30 from 
ADInstruments, New Zealand) digitalizing and sampling at 1 kHz, being connected via USB to a PC hard 
drive with a data acquisition and analysis software (LabChart 7.3.7 from ADInstruments, New Zealand) 
installed. All four myograph chambers are separately connected to a vacuum gas pump (VP 86 from 
VWR International, USA) with a suction bottle interposed. Each chamber has its own connection to gas 
supply, for which carbogen (95% O2 and 5% CO2) was used. Constant temperature of the chambers 
was guaranteed by an internal heater and thermometer integrated in the Myograph interface. 
Constant temperature of the experimental solution applied into the chambers was guaranteed by an 
external circulation thermostat (ED-5 from Julabo, Germany). The force transducers in the myograph 
chambers were calibrated once a month. 
2.4.2 Macroscopic preparation 
In the following, the steps of preparation for which no microscope was needed are described. All 
anatomical terms are derived from the Nomina Anatomica Veterinaria 314. 
After euthanization the abdominal cavity of the rat was opened via midline laparotomy using surgical 
forceps and pointed operating scissors. The entire gastrointestinal tract from distal esophagus to distal 
colon was carefully removed, giving view to the spatium retroperitoneale with the kidneys surrounded 
by the capsula adiposa. The fascia renalis was opened from the lateral side. The kidneys were elevated 
from the situs, avoiding direct touching by leaving a small part of the capsula fibrosa adherent to the 
organ, by which it could be grabbed. The renal artery was truncated close to its branching from the 
aorta. The organ was immediately transferred to 4°C cold preparation solution in a large petri dish 
coated with Sylgard polymer, to facilitate immobilization with fixation pins. Using a pointed scalpel, 
the kidney was split almost in half in the coronal plane, cutting longitudinally into the margo lateralis 
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of the kidney until it could be flipped open like a book while leaving the hilum intact, and then be 
pinned into position with cannulas for microscopic preparation.  
2.4.3 Microscopic preparation 
In the following, the steps of preparation for which a microscope was needed are described. 
Microscopic preparation was performed under a stereomicroscope (Stemi 2000-C from Zeiss, 
Germany) with a cold light source (Schott KL750 from Leica, Germany) using fine forceps (No. 5 Inox 
from Dumont, Switzerland) and fine spring-type scissors (Vannas Capsulotomy Scissors from Geuder, 
Germany). First, the calices renales and adipose tissue surrounding the pelvis renalis had to be 
removed to display the venae interlobares underneath which the arteriae interlobares are located. 
Usually, 3-4 pairs of the arteriae et venae interlobares were observed in every half kidney. Next, the 
front walls of all the venae interlobares were opened lengthwise so that the arteriae interlobares 
became visible through the almost transparent rear wall of the vein. The rear wall and the surrounding 
fat and connective tissue were then carefully loosened from the arteries until they were only attached 
at their proximal end at the branching from the renal artery and at their distal end where entering the 
columnae renales to become arteriae interlobares renis. Finally, short vessel segments at a length of 
3-4 mm were cut off the arteriae interlobares and transferred to the myograph chambers filled with 
4°C preparation solution. This was done with special attention paid not to longitudinally stretch the 
arteries and not to directly touch the parts which would be mounted onto the myograph wires, in 
order not to damage the vessel. Only vessels without visible damage were used for experiments and 
lateral branches were allowed only if sized smaller than 10% of the circumference.  
The mounting of the vessel segments onto the stainless steel wires was performed as recommended 
in the user’s manual. The first 20-25 mm piece of wire was fixated at one end to one of the jaws, while 
the vessel segment was threaded onto the other end, shortened at appropriate length and positioned 
to fit into the space between the jaws. An optimal length of 2mm was attained in most cases, while at 
times shorter segments down to 1,8 mm were tolerated. After fixation of the other end of the wire, 
the second piece of wire was carefully pushed through the vessel lumen and likewise fixated at both 
ends. Once mounted, remaining blood within the vessel lumen was flushed out using a custom-made 
plastic Pasteur pipette with fine tip to ensure that all vessels were equally and fully surrounded by PSS. 
The endothelium was not removed mechanically. The last step under the microscope was to 
approximate both jaws as close as possible without allowing the two wires to touch and leaving some 
space for the jaws to expand when heating up. When all four chambers were loaded with vessels they 
were set on the Myograph interface and slowly warmed up to 37°C. Once target temperature had been 
reached the preparation solution was replaced with pre-heated PSS. The vessels were given at least 10 
minutes to equilibrate before starting Normalization. 
The whole process of preparation from euthanization of the rat until setting all four chambers on the 
Myograph lasted no longer than 60-90 minutes. 
2.4.4 Principles of measurement 
Each myograph chamber contains two jaws holding a wire on which the vessel is mounted. One of 
them is connected to a micrometer screw, the other to a force transducer. The micrometer is used to 
set the optimal pretension during the normalization procedure, the force transducer transmits its 
signal (F = force) to the data acquisition software which calculates the effective pressure (Pi) exerted 
by the vessel wall according to Laplace’s Law as described by Mulvany and Halpern 311. 
The physiological transmural pressure of a vessel in vivo may be approximated by the effective 
pressure Pi in vitro, which is described in the Laplace relation: 
Pi = 2π (T / IC) 
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Pi = effective pressure; T = wall tension; IC = internal circumference 
The wall tension (T) is defined as the circumferential wall force per unit length. It is a sum of active 
forces generated by smooth muscle, and passive force caused by structural components of the vessel 
wall and adventitia. In the absence of agonists, only passive force is exerted and at constant passive 
force the wall tension is inversely proportional to the length of the vessel segment (g):  
T = F / 2g 
T = wall tension; F = force; g = vessel length 
The internal circumference (IC) of small vessels with sufficiently thin walls when mounted on two 
myograph wires can be approximated with the following formula, as illustrated in Figure 1. 
 
Figure 1: Cross-section of a vessel mounted on two myograph wires 
IC = (2 x gap) + (4 x d/2) + (2 x π d/2) 
IC = internal circumference; gap = distance between myograph wires; d = diameter of myograph wires 
Merging the formulas for T and IC into the equation of Laplace’s Law one can calculate the effective 
pressure Pi based on force (F, which is recorded by the force transducer), the length of the vessel (g, 
which is determined under the stereomicroscope during mounting), the diameter of the wires (d, 
which is known to be 40 µm) and the distance between myograph wires (gap, which is set by the 
micrometer screw): 
Pi = 2π x ((F / 2g) / ((2 x gap) + (4 x d/2) + (2 x π d/2))) 
or simply: 
Pi = 2πF x (gap + d + ½πd) / g) 
This equation can be set equal to the desired Pi representing the transmural pressure during the 
normalization procedure, allowing the normalization software to calculate the optimal distance of the 
myograph wires at which the micrometer screw should be set. 
2.4.5 Normalization 
Normalization is the procedure of pre-stretching a vessel segment to an internal circumference (IC) at 
which the actin-myosin interaction is at an optimal state in its length/tension relationship of both 
maximal contact and room to contract, creating a physiological resting tension that enables optimal 
contractile responses. The goal of normalization is to standardize the vessel circumference in a way 
that on the one hand, responses to vasoactive agents are maximal, and on the other hand, baseline 
conditions are set to make results reproducible. 
For normalization procedures, the DMT Normalization Module addon for LabChart was used. 
Normalization starts with both myograph wires almost touching each other, indicating that gap = 0. 
The force readout is set to zero before starting measurements. Upon starting, the distance between 
the jaws is increased stepwise by turning on the micrometer screw. The new gap value is entered into 
the software and force is measured for intervals of 90 seconds in a resolution of 0,1 mN and the value 
then plotted on a passive length/tension graph. The software also plots an isobar line for the target 
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pressure of 100 mmHg (13,3 kPa). Once a point has reached a force readout above 13,3 kPa, the 
software calculates the point at which the isobar line is intersected by the parabolic length/tension 
curve and displays this value as IC100.  
Finally, the IC100 value is multiplied with the normalization factor in order to calculate the optimal gap 
value for active contraction, at which the micrometer screw is subsequently turned back. The 
normalization factor is the ratio of the IC at which a maximum response to a vasoconstrictor is 
observed (IC1) divided by the IC at which the transmural wall pressure is 100mmHg (IC100).  
Normalization factor = IC1 / IC100 
The normalization factor has to be determined for each type of vessel. A normalization factor of 0.9 
has been established to be appropriate for rat mesenteric arteries by the manufacturer and has been 
successfully used for rat renal arteries as well 96, 107, 315. Thus, a normalization factor of 0.9 was chosen 
for our experiments. 
In conclusion, all myography experiments are performed on vessels exposed to a pre-tension that was 
estimated to correspond to a pre-stretching to 90% of the diameter that can be observed in vessels 
exposed to wall tensions of 100 mmHg (13.3kPa). Since these calculations are based on passive 
length/tension relations, it is necessary to stress the importance of a good preparation technique 
where all connective tissue is accurately removed in order not to distort the normalization procedure. 
2.4.6 Viability testing 
Viability tests were performed as a standard starting procedure to rule out damage having occurred to 
the vessels during preparation. This was done at the beginning of each experiment after giving the 
vessels 10 minutes to equilibrate to the pre-tension established by the normalization procedure. 
Before the first test, the endothelium was chemically inactivated using NG-Nitro-L-arginine-methyl 
ester (L-NNA), an irreversible inhibitor of endothelial nitric oxide synthase (eNOS) and reversible 
inhibitor of inducible nitric oxide synthase (iNOS). This measure was repeated several times throughout 
the experiment prior to every concentration-response relationship or precontraction curve used for 
data collection.  
In total, five viability tests were run. Between two tests the substances or solutions applied were 
washed out by replacing PSS at least 5 consecutive times at 5 minute intervals. 
The first test examined the response to the standard vasoconstrictor Methoxamine, which acts as an 
agonist to α1-adrenoreceptors. Methoxamine was applied for 5 minutes in the highest concentration 
(10-5 M). The test was deemed successful and the vessels declared viable when the active force 
measured in response to the vasoconstrictor was at least as high as the passive force measured in the 
last step of normalization, corresponding to an effective pressure of at 100 mmHg (13,3 kPa) or higher. 
If a vessel did not meet this requirement, the test was repeated two times. Only if the vessel failed to 
produce an adequate contraction at the third time was the vessel replaced or the experiment 
terminated. 
The second test examined whether the endothelium had been successfully inactivated. Like in the first 
test, Methoxamine was applied for 5 minutes at 10-5 M, followed by Acetylcholine 10-5 M, a vasodilator 
activating endothelial nitric oxide synthase which was inhibited by L-NNA having been applied priorly. 
The test was deemed successful if no sustained decrease in the level of contraction was observed 
within the 3 minutes following application of Acetylcholine. This was the case in all experiments. 
The third test evaluated the maximum force generated by the vessels by supplying the strongest 
contraction stimulus available in form of Modified PSS containing 120 mM K+ applied simultaneously 
with Methoxamine 10-5 M for 5 minutes. High levels of extracellular potassium substantially decrease 
K+ efflux, representing a strong depolarizing stimulus which leads to contraction. The test was deemed 
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successful when the level of the contraction plateau surpassed the level of the plateau at Methoxamine 
10-5 M. This was always the case.  
In the fourth test, again Methoxamine 10-5 M was applied for 5 minutes. The contraction produced 
was compared to the contraction in the first viability test. If the curves looked similar with regards to 
shape and height, the test was deemed successful and the force readout prior to and 5 minutes after 
application of Methoxamine was set as reference for maximum force (Fmax) for all further experiments 
performed on the vessels. 
The fifth test consisted of a concentration-response relationship (CRR) with Methoxamine as 
vasoconstrictor. Prior to this, L-NNA was applied again and allowed 10 minutes to exert its effect. 
Initially, the force readout after 10 minutes was recorded as baseline (Fbase) wall tension. Methoxamine 
was then applied in increasing concentrations (10-8 M → 3x10-8 M → 10-7 M → 3x10-7 M → 10-6 M → 
3x10-6 M → 10-5 M) and each concentration incubated for 3 minutes. In some protocols using strong 
vasodilators, two more concentration steps were added up to a maximum of 10-4 M. The force readout 
at each concentration step was recorded to calculate pD2, the negative logarithm of the concentration 
at which methoxamine causes 50% of its maximum effect (EC50) for later comparison after application 
of the drugs to be tested. 
For each concentration-response relationship or precontraction curve a new baseline was recorded 
(Fbase before x). The normalized force (Fnorm) for any force readout later recorded at a given time point (Fx) 
could then be calculated as  
Fnorm = (Fx – Fbase before x) / (Fmax – Fbase). 
Since in the above cited Laplace relation all other variables besides F are constant during one 
experimental series, the effective pressure Pi is directly proportional to F and consequently relations 
between the four force readout curves recorded by one myograph may be interpreted as relations 
between effective pressures exerted by the vessels. 
2.4.7 Experimental protocols 
The ability of vessels to contract and dilate in response to drugs was investigated using two different 
types of protocols. The first type consisted of multiple consecutive concentration-response 
relationships with Methoxamine, prior to which both vasoconstricting or vasodilating drugs could be 
applied both separately or combined. The second type consisted of sustained precontraction induced 
by Methoxamine or other vasoconstrictive agents, on top of which vasodilating drugs could be applied 
in increasing concentrations, thus creating inverse concentration-response relationships. 
2.4.7.1 Concentration-response relationship protocols 
Protocols using multiple consecutive CRRs allow the study of multiple drugs and how they interact. 
This can be achieved by only changing one parameter at a time between two consecutive CRRs, 
allowing to differentiate between the effect of a single drug and the effect of the same drug in 
combination with another drug (Table 3). 
In some experiments, the effect of a 3rd drug was studied within the same experiment. This was done 
by incubating the 3rd drug in all four channels prior to incubation with drug 1 and drug 2. This required 
a 4th CRR to be added prior to the 2nd CRR, serving as an additional control CRR, at the beginning of 
which the solvent of the 3rd drug was incubated. Such protocols were used to study the effect of ANP 
resp. Urocortin on HMR1556 and R-L3, with R-L3 being the “3rd drug” added in all channels. 
In some experiments, a 4th CRR was added to examine the effect of different concentrations of one of 
the two drugs. This was done by incubating the same drug/solvent combination as in the 3rd CRR, but 
with the low concentration of e.g. drug 2 in the 3rd and the high concentration in the 4th CRR. Such a 
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protocol was used to examine the effect of ANP on R-L3 and HMR1556, with two concentrations of 
ANP (10-8 M and 10-7 M) being used. 
 
Table 3: Basic structure of a concentration-response relationship protocol 
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2.4.7.2 Precontraction protocols 
Two different types of precontraction protocols were used. In the first type, a sustained level of 
precontraction was induced using the standard vasoconstrictor Methoxamine  (in the following called 
“precontraction plateau”), on top of which a range of dilating or contractile agents were incubated 
(Table 4). The second type generated a precontraction plateau using a range of different 
vasoconstrictive agents like Methoxamine, KCl 50 mM or various K+ channel blockers, which could also 
be combined in a cocktail, on top of which only one dilating agent was incubated (Table 5). In both 
types, the first precontraction plateau served as a control with which to compare the vasorelaxation 
induced by the dilator drug added during the second precontraction plateau. 
 
Table 4: Basic structure of a precontraction protocol using Methoxamine for precontraction 
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Methoxamine-induced precontractions usually reached their plateau within 20-30 minutes. The 
precontraction plateau had to be at constant force for at least 10 minutes before inverse CRRs with 
solvent or reagent were initiated. Protocols using Methoxamine for precontraction were used to study 
the effect of dilating agents Retigabine, R-L3, ANP and Urocortin in the presence and absence of XE991 
resp. HMR1556.  
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In the case of Retigabine resp. R-L3, one channel served as Methoxamine-only control, one channel 
was incubated with HMR1556, and two channels were incubated with XE991 but unequally 
precontracted with different concentrations of Methoxamine to evaluate whether the level of 
precontraction played a role for the interaction of XE991 and Retigabine resp. R-L3. 
In the case of ANP resp. Urocortin, the Methoxamine-only control channel was left out entirely since 
the effect of ANP resp. Urocortin on Methoxamine alone had already been examined in protocols 
described below. Instead, two channels were incubated with XE991 and two with HMR1556, and one 
of each pair was then dilated using ANP resp. Urocortin. 
In the case of ANP, Retigabine and R-L3, the inverse CRRs contained 5 concentration steps, for 
Urocortin 7 steps were used. Incubation times for each concentration step were 10 minutes for 
Retigabine and R-L3 and 5 minutes for ANP and Urocortin. 
 
Table 5: Basic structure of a precontraction protocol using different vasoconstrictive agents for precontraction 
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Protocols using different vasoconstrictive agents for precontraction were used to study the effect of 
dilating agents ANP resp. Urocortin on contractions produced by various K+ channel blocker 
combinations including iberiotoxin, stromatoxin, glibenclamide, DPO-1 and BaCl with XE991 (“K+ 
blockers 1”) resp. without (“K+ blockers 2”) XE991. 
Blocker precontractions needed more time to reach their plateau. Usually it took 30-40 minutes, but 
sometimes up to one hour was required. Many times, strong oscillations occurred ranging up to heights 
of 50% of the maximum Methoxamine reference. When oscillations did not decrease or disappear, 
minor concentrations of Methoxamine were used to stabilize the plateau without increasing its level. 
Before starting inverse CRRs with vasodilators the plateau had to be stable for at least 10 minutes. 
Vasodilators were always applied simultaneously in all four channels, also when the plateau in the 
Methoxamine or KCl channel had been reached much earlier. The concentration of Methoxamine was 
adjusted adequately to generate the same plateau level as induced by KCl 50 mM. In most cases 
Methoxamine concentrations in the range of 5x10-7 M to 10-6 M were required. 
2.4.8 Data analysis 
All data points obtained by the data acquisition and analysis program (LabChart 7.3.7) were first 
transferred to Microsoft Excel (2010 and 2016) for basic calculations and analysis.  
Data points were obtained in the following way:  At most times, vasoconstrictive and vasodilating 
agents produced a stable plateau which distinctively represented the force readout to be recorded. If 
after an initial peak the plateau sloped down during Methoxamine CRRs, a representative value of 80-
90% of the maximum force was obtained in accordance to the steepness of the slope. If minor 
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oscillations occurred in precontraction experiments, oftentimes when precontraction was induced 
with a cocktail of K+ blockers, a representative average was recorded over longer spans of time (up to 
60 seconds) if the plateau of oscillation was horizontal. 
The normalized force (Fnorm) values were calculated for all data points within Microsoft Excel data 
sheets using the above described equation (see: Chapter 2.4.6) and plotted onto dose-response graphs 
for each channel individually. Mean values and standard error of the mean (SEM) were calculated and 
displayed in a common graph for all four channels. The following comparisons were made within each 
series of experiments to guarantee validity of the results: 
In all concentration-response relationship protocols, the mean values of Fnorm at each concentration 
step of the 1st CRRs during viability testing had to be equal in all four channels resp. experimental 
groups. This was to serve as an indicator that on average the vessels were equally strong and sensitive 
to Methoxamine in all four channels, being a necessary requirement to allow comparison of the pD2 of 
the 2nd CRRs resp. the plateau of the precontraction curves obtained from different channels resp. 
experimental groups. Analogously, in multiple-CRR protocols testing two or more drugs, mean values 
of Fnorm at each concentration step of the 2nd CRR had to be equal in the two channels resp. 
experimental groups in which the same first drug resp. solvent was applied. This was to serve as an 
indicator that on average the vessels were equally affected by the first drug, being a necessary 
requirement to allow comparison of the pD2 of the 3rd (and 4th) CRRs with one another and thus be 
able to draw adequate conclusions on the effect of the 2nd drug. 
In all precontraction protocols, the mean values of Fnorm at the plateau of the 1st precontraction curve 
(using the vasodilator solvent as control), had to be equal to the mean values of Fnorm at the plateau of 
the 2nd precontraction curve (using the real vasodilator agent), within the same channel. This equal 
level of precontraction within one channel was a necessary requirement to draw adequate conclusions 
on the effect of the vasodilators. 
In precontraction protocols using Methoxamine for precontractions, the mean values of Fnorm at the 
plateau of both the 1st and 2nd precontraction curve after application of the vasoconstrictive drugs 
(XE991 and HMR) had to be equal in all four channels resp. experimental groups. This equal level of 
precontraction between channels was a necessary requirement to draw adequate conclusions on the 
effect of the vasoconstrictors. 
In precontraction protocols using KCl 50 mM, Methoxamine and various blockers, it was not possible 
to generate equal precontraction levels in all four channels, because the blocker combinations in total 
produced stronger contractions. Instead, the mean precontraction levels of the two channels with K+ 
blockers had to be equal, and likewise the mean precontraction levels of KCl 50 mM and Methoxamine. 
This equal level of precontraction between the two pairs of channels was a necessary requirement to 
draw adequate conclusions on (i) different effects of the vasodilators between vessels treated with the 
two K+ blocker cocktails and (ii) different effects of the vasodilators between vessels treated with KCl 
and Methoxamine. 
Furthermore, in all precontraction protocols, after having demonstrated that average precontraction 
levels were equal, the force readouts of each inverse CRR concentration step (Fx inverse) were normalized 
(Fx inverse norm) to their corresponding precontraction level (Fprecontraction) and subsequently expressed as a 
percentage of the precontraction using the formula: 
Fx inverse norm = (Fx inverse) / (Fprecontraction) x 100 
2.5 Isolated perfused kidney 
This isolated perfused kidney method was developed in our laboratory to study the function of vascular 
smooth muscle in the walls of the renal arterial system on a whole-organ level and thus in a 
macroscopic and more physiological setting in comparison to myography. In the following, the practical 
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course of action of the method will be highlighted, while the scientific validation of the method will be 
elaborated as part of the discussion. 
2.5.1 Isolated perfused kidney setup 
The setup was designed as a flow-rate controlled, no-reperfusion system. A pressure transducer was 
connected in parallel to the high-pressure part of the system between the perfusion pump and the 
perfused kidney. Two tube systems of the same design (Figure 2) were connected to one perfusion 
pump, each separately perfusing one kidney. 
 
Figure 2: Isolated perfused rat kidney setup 
The perfusate was kept in regular laboratory bottles (Wide-mouth rectangular bottles from Nalge Nunc 
International, USA), but equipped with specially prepared lids containing two holes for the tubes, one 
allowing carbogen to be administered to the perfusate and one allowing the perfusate to be extracted 
by the pump. This way the pO2 of the perfusate was maximized and the loss of CO2 to the surrounding 
air was kept at a minimum. This same issue was solved for the two modified solutions used in viability 
testing, of which only small amounts were needed each day, by using volumetric flasks with long 
narrow necks (Blaubrand volumetric flask from Brand, Germany). For Details concerning the perfusate 
solutions, see (Table 1). A three-way stopcock at the entry of the tube system allowed for 
instantaneous switching between two perfusate solutions. 
Drugs were applied using syringe pumps as described above (see: Chapter 2.3). Two syringe pumps 
(SP100 Microprocessor Controlled Syringe Pump from World Precision Instruments, USA) per kidney 
were used serially connected. 
As a perfusion pump, a roller pump with a 16 roller pump head (Perimax 16/3 Antipuls from Spetec, 
Germany) was used that generated almost pulse-free perfusion pressures. Pulsatile pressure waves 
have early proven not to confer any advantage in isolated perfused rat kidney experiments 316. The 
flow rate is continuously adjustable in single digit steps from 1-999 speed digits [sd] representing pump 
head revolutions from < 1 to 33 revolutions per minute (rpm). In our experimental setting, the pump 
was set on speed digits ranging from 25-800 [sd]. The actual flow rates are further determined by the 
lumen of the plastic tubes the pump is equipped with and by adjustment of the contact pressure at 
the roller pump head. In our setup, tubes with an internal circumference of 1,524 mm (PVC Standard 
double pump tubing 38-0352 from Spetec, Germany) were used. To confirm the flow rates provided 
by the manufacturer, own measurements were performed by clocking the time needed to pump a 
certain volume of solution at different speed digits. Considerable deviation of our own measured flow 
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rates from the flow rates declared in the manufacturer’s sheet made a manual calibration necessary. 
Calibration consisted of repeated measurements at four set speed digits, of which the mean value was 
calculated. This procedure was performed twice, with and without the perfusion cannula attached 
(Table 6). 
 
Table 6: Flow rate calibration 
Speed digit 
(perfusion pump) 
Flow rate (ml/min) 
without cannula 
Flow rate (ml/min) 
with cannula attached 
 Mean SEM Mean SEM 
100 1,62 0,01 1,63 0,01 
200 2,74 0,01 2,67 0,01 
400 4,85 0,04 4,84 0,02 
800 9,92 0,03 9,88 0,04 
 
The mean values of the four flow rates measured with cannula attached were used to generate a 
trendline, which could be justified by the strictly linear relation between speed digits and flow rates 
according to the manufacturer’s sheet. Using this trendline, the corresponding flow rates of the 
other speed digits that were used for pressure-flow relationships in the experiments were calculated 
(Table 7). 
 
Table 7: Flow rates calculated from calibration for each speed value 
Speed digit 
(perfusion pump) 
 Flow rate (ml/min) 
without cannula 
Flow rate (ml/min) 
with cannula attached 
25  0,62 0,48 
50  0,92 0,78 
100  1,51 1,38 
200  2,7 2,57 
300  3,89 3,76 
400  5,08 4,96 
600  7,46 7,34 
800  9,84 9,72 
 
In a second step we confirmed the flow rate with the cannula attached and an actual rat kidney being 
mounted and perfused and thus the pump actually creating perfusion pressure remaining to be on 
average 2,57 ml/min for a speed digit of 200, which is the perfusion rate at which all later experiments 
following the viability tests on perfused kidneys were performed. Calibration was performed once in 
the beginning, and a second time when the system was duplicated. 
All glass parts (perfusate heating chamber, kidney heating chamber, and air bubble traps) were 
handcrafted by a local glassblowing company. Both heating chambers were connected via large lumen 
tubes (Suction tube CH 25 from Oriplast, Germany) to a circulation thermostat (UC-5B from Julabo, 
Germany) which continually exchanged the heating fluid (Aqua dest). The circulation thermostat was 
set to a temperature of 42°C, which corresponded to an actual temperature of 37°C measured both 
on the surface of the heating chambers and in the perfusate itself. 
The heating chamber for the perfusate was designed as a spiral-shaped glass tube within a glass 
container, with the space in between being filled with water when connected the circulation 
thermostat. The glass tube, containing a volume of approximately 2 ml, allowed for a time span of 
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approximately 45 seconds for the perfusate to be heated whilst travelling through at the perfusion 
rate of 2,57 ml/min used during the pharmacological part of the experiments. 
The air bubble trap was designed as a small glass cylinder with a volume of 3 ml. Perfusion tubes may 
be attached to one connecting socket at its top and one at its bottom. Perfusate would flow through 
the air trap from top to bottom with a screwable lid allowing for release of air and filling of the cylinder 
with fluid. Air traps had to be filled with perfusate once only at the beginning and last throughout the 
experiment since refilling of the traps would require stopping the perfusion of the kidney. Air bubbles, 
which were either sucked in with the perfusate or developed within the perfusion system during 
passage of the heating chamber would get caught by rising to the top of the bubble trap, slowly filling 
the glass cylinder with air or gas. Two bubble traps were needed per kidney, since the average gas 
volume that developed throughout an average four-hour experiment exceeded the volume of one 
bubble trap. The perfusion pressure within the system was not affected by the amount of air being 
caught in a trap. 
The heating chamber for the kidney was designed as a bell-shaped double-walled container with two 
connecting sockets for the circulation bath and with an outlet at its bottom for the discharge of used 
perfusate. The container was positioned with its opening facing obliquely upwards at a 45° angle and 
a pedestal entered to allow the kidney to be rested upon pedestal and container wall, thus avoiding 
stretching of the renal artery due to the weight of the kidney when being hung up. With a setup design 
as a non-reperfusion system, the perfusate flowing from the truncated renal vein immediately left the 
kidney heating chamber through a hole in its bottom and was discharged, thus avoiding a continuous 
effect after stopping the administration of a drug. 
The pressure transducer (PT-F from Living Systems Instrumentation, USA) was set in parallel to the 
perfused kidney and connected to a perfusion pressure monitor (PM-4 from Living Systems 
Instrumentation, USA), which communicated the pressure readout to a data acquisition device 
(PowerLab 4/26 from ADInstruments, New Zealand) digitalizing and sampling at 1 kHz and transferring 
the data to a laptop hard drive with a data acquisition and analysis software (LabChart 8.0 from 
ADInstruments, New Zealand) installed. Two three-way stopcocks attached on both sides of the 
pressure transducer allowed for switching between monitoring perfusion pressure and performing 
system pressure calibration. Calibration of the pressure transducer was performed every day before 
equipping the setup with a kidney. To do so, a fluid-filled container positioned at the height of the 
pressure transducer would serve as a water level gauge for calibrating 0 mmHg, while an analogue 
manometer (Big Ben Round from Riester, Germany) was used for calibrating 100 mmHg. 
The kidney itself was mounted on a handcrafted perfusion cannula. The cannula was fabricated from 
a glass capillary (1B200F-4 from World Precision Instruments, USA) using a micropipette puller (PC-10 
from Narishige, Japan). The pulling process was interrupted shortly before the two ends of the glass 
capillary were entirely separated, thus creating an hourglass-shaped capillary. The capillary was 
manually cut with a glass cutter a short distance beside its narrowest point, creating a slightly 
biconcave shaped tip (Figure 3). The sharp ends of the cut surface were smoothened with a microforge 
(Carl Zeiss, Germany) to avoid damage to the wall of the artery.  
 
Figure 3: Biconcave glass cannula used for perfusing the rat kidney 
The special design of the perfusion cannula is significant for two main reasons: First, the tying of the 
renal artery firmly to the narrowest point of the biconcave shaped tip prevented its sliding off the tip 
up to perfusion pressures above 200mmHg. Second, the relative shortness of the narrowness of tip 
keeps its intrinsic flow resistance considerably low, allowing for high perfusion rates to be applied 
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without falsely high perfusion pressures narrowing the validity of measurements during viability 
testing. 
The flow resistance of the cannula was assessed in repeated measures of baseline perfusion pressures 
at different speed digits with and without the perfusion cannula attached (Table 8). With perfusion 
pressures of only 4,0 mmHg being produced at a speed digit of 200 (corresponding to the flow rate of 
2,57 ml/min used for the pharmacological part of the experiments) even with the perfusion cannula 
attached, intrinsic resistance was considered neglectable. Two perfusion cannulas with similar intrinsic 
resistance were produced and used for all experiments. 
 
Table 8: Perfusion pressure with vs. without perfusion cannula attached 
Speed digit 
(perfusion pump) 
Perfusion pressure [mmHg] 
without cannula 
Perfusion pressure [mmHg] 
with cannula attached 
 Mean SEM Mean SEM 
100 0,49 0,11 3,13 0,03 
200 0,35 0,14 4,04 0,09 
400 1,09 0,12 6,30 0,15 
800 2,56 0,12 13,90 0,13 
 
2.5.2 Macroscopic preparation 
Similar to myography experiments, preparation started with midline laparotomy and removal of the 
entire gastrointestinal tract, displaying the kidneys surrounded by the capsula adiposa in the spatium 
retroperitoneale. Starting at this point, in total three preparation procedures are described, for the 
removal of one or two kidneys, and with or without heparinization. 
First, in most cases, only one kidney was needed for perfusion experiments. In that case, the right 
kidney was used due to its favorable more caudal position in the abdomen and because right renal 
arteries are longer than left ones 317, which may facilitate mounting onto the perfusion cannula. In a 
first step the left kidney was removed for myography experiments as described above (see: Chapter 
2.4.2). Next, the spatium retroperitoneale was cleared of fat until aorta abdominalis and vena cava 
were displayed proximally and distally to their junction with the renal artery and vein. The fat 
surrounding the renal artery was left in place in order not to damage the vessel. Then aorta 
abdominalis and vena cava were grabbed at their proximal end with anatomical forceps and truncated, 
first proximally from the point where grabbed, and next distally from the junction with the renal 
vessels. This way, the kidney could be elevated and removed en bloc with renal vessels and short 
segments of aorta and vena cava attached, supported only by a few scissor cuts at the margo lateralis 
to strip the kidney from its capsula adiposa. The kidney was transferred to the same 4°C cold 
preparation solution as vessels for myography, fixated with pins, and washed several times to clear 
away blood. 
Second, in some cases, both kidneys were needed for perfusion experiments. In that case, additionally 
to clearing the fat from aorta abdominalis and vena cava, the kidneys itself had to be peeled out of 
their capsula adiposa while leaving the same protective fat cushion around the renal vessels as 
mentioned before. The kidneys each had to be flipped to the contralateral side in order to detach their 
facies dorsalis from the capsula adiposa. This done, both kidneys could be grabbed and elevated by 
the abdominal vessels and removed en bloc in the same way as described above. 
Third, in few cases, heparin had to be infused into the kidneys before removal. This was done with the 
kidneys still in situ. Again, the abdominal vessels initally had to be cleared from fat, in which case a 
longer segment of the caudal aorta needed to be displayed. First, the aorta and vena cava were ligated 
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proximal to their junction with the renal vessels. In case only one kidney was to be used, the vessels of 
the other kidney were ligated before removal. Second, a ligature around the aorta and vena cava 
approximately 1 cm distal to their junction with the renal vessels was put into place, but not fastened 
yet. Third, the distal aorta was punctured with a 27 G cannula attached with 30 mm tubing to a 1 ml 
syringe (Omnifix-F Tuberkulin from B. Braun Melsungen, Germany) in such a manner that the ligature 
positioned earlier could easily be fastened over the cannula now positioned within the lumen of the 
aorta. Fourth, the distal ligature was fastened and the vena cava segment in between the proximal and 
distal ligatures was incised to permit blood flow exiting the kidney. Finally, the syringe content of 100 
I.U. heparin sodium (Heparin-Natrium 25.000 I.E. in 5ml from Ratiopharm, Germany) dissolved in 1 ml 
Modified PSS without NaHCO3 was carefully injected over a time period of at least 30 seconds. Blood 
flowing from the vena cava incision was observed as confirmation for successful application into the 
renal vasculature. The remaining preparation was performed as described above. 
2.5.3 Microscopic preparation 
All remaining steps up to connecting the isolated kidney to the perfusion system were performed 
under the microscope, using the same tools as for myography preparation. 
Preparation started with the removal of all perivascular adipose tissue surrounding the arteria renalis 
and aorta. During this process, the entire vena cava and most of the vena renalis were removed as 
well, leaving only a short stump of the vena renalis. The ureter was usually not discernable and was 
thus removed with the fat. The arteria renalis was than truncated as close to the aorta as possible. As 
an additional step, the capsula fibrosa of the kidney was removed bluntly using two forceps. This was 
perceived necessary because perfusing the kidney with a colloid-free perfusate might cause organ 
edema and thus swelling of the kidney, which in turn could cause pressure to rise within the rigid 
capsula fibrosa to an extent which could possibly affect arterial perfusion pressures. Before mounting 
the arteria renalis to the perfusion cannula, the cannula had to be thoroughly cleared from air and 
filled with preparation solution. A fine surgical thread (Ethilon nylon suture 7-0 from Ethicon, USA) was 
used to tie the artery around the cannula. First, an air knot was tied and pulled over the cannula 
without fastening. Next, the opening of the arteria renalis was widened and held open with forceps 
and the cannula was inserted. The air knot was then tightened over the artery on the perfusion 
cannula, fixating the arteria renalis firmly at the narrowest point of the biconcave tip. Three more 
surgical knots were added on top to secure the position. 
 
Figure 4: Perfusion cannula connected to renal artery 
Only if the artery was at least 2-3 mm long, the kidney could be used for perfusion. Although in about 
20-40% of the rats an early division of the arteria renalis into a dorsal and a ventral branch was 
observed, the common trunk proximal to the division in most cases was sufficiently long. The tip of the 
cannula was not permitted to be inserted into one of the two branches, but always had to remain in 
the common trunk, where it maintained a visually controllable distance from the division to ensure 
that the entire arterial vasculature would be perfused and perfusion pressures thus be comparable. 
Preparation took no longer than 30-40 minutes from euthanization of the rat to connecting the isolated 
kidney to the perfusion system. An additional 5-10 minutes were required in case the kidney was 
heparinized. 
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2.5.4 Preparation of the isolated perfused kidney setup 
In the following, all necessary preparations to the perfusion system are described. The pressure 
transducer was calibrated daily as described (see: Chapter 2.5), setting the perfusion pressure readout 
without the isolated kidney attached to zero. The circulation thermostat was switched on at least 30 
minutes before starting experiments to give the heating chambers time to reach 37°C. Perfusate was 
adjusted to room temperature and gassed with carbogen starting at least 30 minutes before the 
experiment. After filling the perfusion system with Modified PSS without NaHCO3 as perfusate, the 
tubes between the bubble trap and the connecting socket for the perfusion cannula were carefully 
examined for air bubbles, which had to be removed. The perfusion pump was started at a flow rate 
below 0,5 ml/min (speed value 25/). Recording of the perfusion pressure was started and as soon as a 
waveline oscillating tightly around 0 mmHg was observed on the screen, the perfusion cannula was 
connected to the system. To do this, the kidney had to be carefully lifted from the preparation solution, 
grabbing the perfusion cannula with the kidney hanging vertically downwards and connecting the 
cannula to its socket in vertical position, with the kidney resting upon the 45° angled wall of the heating 
chamber and supported at its margo lateralis by a pedestal priorly inserted into the chamber. In 
consequence, a steep increase in perfusion pressure was observed in kidneys with intact renal 
vasculature, reaching a sharp peak followed by an equally steep drop in perfusion pressure, which 
occurred simultaneously with blood flowing from the vena renalis. The renal artery was then inspected 
for leaks or jets of perfusate. Only if blood flow was observed immediately and no leak was discovered, 
the experiment would be concluded.  
2.5.5 Viability testing 
At the beginning of each experiment, viability tests were performed. Unless otherwise specified, 
Modified PSS without NaHCO3 was used as perfusate. Viability testing included (i) examination for 
complete perfusion by macroscopic appearance, (ii) confirmation of an intact vascular bed using a 
pressure-flow relationship, (iii) testing for myogenic response by application of calcium-free perfusate 
at high flow rates and (iv) testing for maximum active vasoconstriction of the renal vasculature by 
application of Modified PSS containing 120 mM KCl. 
 
Table 9: Viability tests for isolated perfused kidney 
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Macroscopic 
appearance 
Pressure-flow 
relationship 
Calcium-free 
PSS 
120 mM KCl 
PSS 
40 min 5 min 5 min 10 min 10 min 
PSS = physiological salt solution 
 
First, complete perfusion of the entire renal vasculature had to be ascertained in order to warrant 
comparability of the perfusion pressure readouts to be recorded in our flow-rate controlled setup. 
Incomplete perfusion of the kidney for example due to blood clots developed during no-flow time in 
the preparation procedure that obstructed the vessels, thus resulting in a lower cross section of 
vasculature, would in our flow-rate controlled setup lead to measurement of false-high perfusion 
pressures. For complete perfusion to be assumed, the entire kidney had to undergo a color change 
from dark maroon to a spotless pale brown, indicating washout of all blood and thus patency of all 
major arterial vessels. In case this change in macroscopic appearance did not occur until the end of the 
pressure-flow relationship, the kidney was declared unviable and the experiment would not be used 
for data collection. 
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Second, integrity of the vascular bed and absence of major leaks due to vessel damage during 
preparation had to be demonstrated, indicated by an adequate rise of perfusion pressure with 
increasing flow rates. This was ascertained by exposing the kidneys to stepwise increasing flow rates 
up to a maximum of 9,72 ml/min and monitoring for unreasonably low perfusion pressures in a 
pressure-flow relationship. Perfusion of the isolated kidney started at a flow rate < 0,5 ml/min and was 
increased in seven additional steps by setting speed digits corresponding to approximately 0,8  1,4 
 2,6  3,8  5,0  7,3  9,7 ml/min as calculated above (see: Chapter 2.5.1) with each step lasting 
5 minutes. Increasing the flow rate would result in a steep increase in perfusion pressure leveling into 
a higher horizontal plateau. Data points were collected for each plateau and plotted in a pressure-flow 
relationship. Only if each increase in flow rate produced a marked increase in perfusion pressure and 
if at the highest flow rate a perfusion pressure of at least 80 mmHg was obtained would the experiment 
be continued. 
Third, the myogenic response to flow-induced perfusion pressure as an indicator of autoregulation in 
the renal arterial vasculature was examined. This test was performed subsequently to the pressure-
flow relationship, maintaining the maximum flow rate of 9,7 ml/min. After recording pressure for 5 
minutes, the regular perfusate was switched for calcium-free perfusate (see: Table 1) by quickly 
flipping the three-way stopcock, allowing perfusate to be changed without time loss or interrupting 
perfusion. The calcium-free perfusate was administered for 5 minutes. A deprivation of extracellular 
calcium would cause inhibition of active vasoconstriction and thus a decrease in perfusion pressure. 
Next, the calcium-free perfusate was washed out again applying regular perfusate for 5 minutes. 
Resupply of extracellular calcium thus achieved would reenable active vasoconstriction resulting in 
another increase in perfusion pressure. Data points were collected at the horizontal plateaus before, 
during and after application of calcium-free perfusate and plotted in a column diagram. Only if a 
significant drop in perfusion pressure levelling into a lower horizontal plateau could be recorded as an 
indicator of an intact myogenic response as a basic requirement for autoregulation being present 
would the kidney be used for further experiments. 
Fourth, the maximum degree of active vasoconstriction in response to 120 mM KCl was examined. To 
do so, the flow rate first had to be reduced from 9,7 ml/min after 5 minutes washout of calcium-free 
perfusate to 2,57 ml/min (correlating to a speed digit of 200) in order to reach a new baseline perfusion 
pressure below 60 mmHg, low enough not to be likely to induce a myogenic response. After reaching 
a new baseline plateau of perfusion pressure, the regular perfusate was switched for Modified PSS 
containing 120 mM KCl (see: Table 1) und applied for 10 minutes. High extracellular concentrations of 
K+ would represent a strong vasoconstrictive stimulus leading to a marked increase in perfusion 
pressure. Next, the 120 mM KCl perfusate was washed out applying regular perfusate for at least 10 
minutes. Deprivation of the depolarizing stimulus thus achieved would terminate vasoconstriction and 
perfusion pressure readouts return to the baseline. Data points were collected at the peak of 120 mM 
KCl-induced pressure increase and at the horizontal plateau before and after application and plotted 
on a column diagram. Only if active vasoconstriction resulted in an increase of perfusion pressure to 
absolute values above 160 mmHg and a subsequent drop of a least -120 mmHg back to baseline 
perfusion pressure could be observed as a sign of functional integrity of the arterial vasculature of the 
kidney would the kidney be used for further experiments. 
2.5.6 Experimental protocols 
The ability of the renal arterial vasculature to constrict and dilate in response to drugs was investigated 
using two types of protocols. In both protocols, viability tests were followed by a brief period of 
perfusing PSS only at a flow rate of 2,57 ml/min to establish baseline perfusion pressure over at least 
5 minutes. Next, precontraction was induced by switching the regular perfusate PSS for PSS 
preincubated with 3 µM Methoxamine, which was applicated for at least 60 minutes until achieving a 
horizontal plateau before additional drugs were added. 
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The first type of protocol, applied if only vasoconstrictive drugs like HMR1556 or XE991 were to be 
tested, then proceeded to continuous application of the drug via syringe pump for at least 20 minutes 
in the above described manner (see: Chapter 2.3). Upon having been administered for an appropriate 
time, the application of the drug via syringe pump was stopped while perfusion with Methoxamine 
was continued to monitor for the occurrence of decrease in perfusion pressure in absence of the 
vasoconstrictive drug to be examined. Finally, after continuing perfusion with Methoxamine for at least 
another 30 minutes, the perfusate was switched back to regular PSS to confirm an adequate return of 
perfusion pressure to the baseline. Data points were collected every 5 minutes, starting 20 minutes 
before until 20 minutes after initiating application of the vasoconstrictive drug. 
 
Table 10: Experimental protocol for testing a vasoconstrictive substance alone 
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Perfusion Precontr. Contraction Postcont. Postperf. 
  + Drug 1 (via syringe pump)   
 Methoxamine 3 µM (via direct application into perfusate)  
Regular PSS 
Postcont. = post-contraction; Postperf. = post-perfusion; Precontr. = precontraction; PSS = physiological salt solution;  
 
The second type of protocol, applied if a vasodilative drug like R-L3 with an antagonist like HMR155 or 
XE991 were to be tested, proceeded to continuous application of the vasodilative drug via syringe 
pump for 20 minutes, followed by the likewise continuous coadministration of the antagonist via a 
second syringe pump. Afterwards, the application of drugs or Methoxamine was reduced stepwise as 
described for the first type of protocol, always monitoring for the effect of washout of the substance. 
Data points were collected every 10 minutes starting at 20 minutes before initiating application of the 
first drug until 10 minutes after initiating application of the second drug. 
 
Table 11: Experimental protocol for testing a vasodilative substance combined with an antagonist 
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Perfusion Precontr. Dilation Antagon. Postdilat. Postcont. Postperf. 
   
+ Drug 2 
(syringe) 
   
  + Drug 1 (via syringe pump)   
 Methoxamine 3 µM (via direct application into perfusate)  
Regular PSS 
Antagon. = Antagonization; Postcont. = post-contraction; Postdilat. = post-dilation; Postperf. = post-perfusion; Precontr. = 
precontraction; PSS = physiological salt solution; 
 
2.5.7 Data analysis 
All data points obtained by the data acquisition and analysis program (LabChart 8.0) as described above 
(see: Chapter 2.5.6) were first transferred to Microsoft Excel (2010 and 2016) for basic calculations and 
analysis.  
During viability testing, the raw perfusion pressure readouts in mmHg were used either for direct 
statistical analysis and graphing or to calculate parameters of viability criteria like the area under the 
curve for pressure-flow relationships or the delta for the drop or increase in perfusion pressure in 
response to calcium-free or KCl 120 mM-containing perfusate. 
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During the actual pharmacological experiments, only raw perfusion pressure readouts in mmHg, 
subtracted by the baseline perfusion pressure prior to starting precontraction with Methoxamine, 
were used for direct statistical analysis and graphing without any normalization being necessary. Only 
for two graphs simple calculations were made, such as for comparison of (i) the degree of vasodilation 
induced by two different concentrations of R-L3 and (ii) their antagonization by HMR1556. In detail, (i) 
the delta of the decline in perfusion pressure induced by R-L3 was calculated by subtracting the 
baseline pressure recorded before application from the pressure readout after 20 minutes of 
application of R-L3 and then (ii) normalizing the delta of the increase in perfusion pressure induced by 
coadminstration of HMR1556 as a percentage of that R-L3-induced drop in perfusion pressure (see: 
Figure 64). This same calculation was performed for comparison of the degree of antagonization of R-
L3-induced vasodilation by HMR1556 and XE991 (see: Figure 66). 
2.6 Statistics 
GraphPad Prism version 7.03 for Windows (GraphPad Software, La Jolla California USA) was used both 
for calculating statistics and drawing and formatting graphs. Tables were formatted using Microsoft 
Word (2016) or Microsoft PowerPoint (2016).  
All values are presented as arithmetic mean and standard error of the mean (SEM), with n representing 
the number of experiments conducted, corresponding to the number of animals used for the series. 
Significance was assumed at p≤0.05. 
The area under the curve (AUC) was calculated for all CRRs and inverse CRRs in myography experiments 
as well as for pressure-flow relationships during viability testing in isolated perfused kidney 
experiments. 
The negative logarithm of the half maximal effective concentration (pD2) as an expression of 
Methoxamine sensitivity was estimated from concentration-response curves by fitting the Hill 
equation using least squares regression as a fitting method 
Paired t-tests were used for comparing perfusion pressure at different time points in isolated kidney 
perfusion experiments. 
Unpaired t-tests were used for comparing precontraction levels between two groups in myography 
experiments as well as for comparison of AUCs in myograph experiments.  
Ordinary one-way ANOVA was used for comparing precontraction levels between three or more 
groups in myography experiments.  
One-way repeated-measures ANOVA without assuming sphericity and therefore using Geisser-
Greenhouse correction was used to separately analyze perfusion pressure amplitudes before and after 
application of drugs in isolated perfused kidney experiments. 
Two-way repeated-measures ANOVA was used for comparing amplitudes of force between both CRRs 
and inverse CRRs in myography experiments. 
Dunnett's multiple comparisons test was performed as a post-hoc test when comparing means of 
perfusion pressure amplitudes before and after application of drugs in isolated perfused kidney 
experiments 
Pearson’s r was calculated for demonstrating a correlation between the level of flow-induced pressure 
and the magnitude of the myogenic response caused by it in isolated perfused kidney experiments. 
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3 RESULTS 
3.1 Validation of the isolated perfused kidney model 
The results presented later (see: Chapter 3.6) are the first data collected using this isolated perfused 
kidney method newly established in our laboratory. For the sake of validation, the following sections 
will set out the results of the viability tests performed prior to the actual experiments. Data was 
collected for viability tests including (i) confirmation of an intact arterial vasculature indicated by an 
appropriate pressure-flow relationship, (ii) testing for an intact myogenic response via calcium-free 
perfusate and (iii) testing for maximum active vasoconstriction of the renal vasculature via application 
of Modified PSS containing 120 mM KCl. Furthermore, we present data addressing the question 
whether kidney viability depends upon possible confounding factors like (a) prolonged cold storage of 
the kidney in PSS during the process of preparation, (b) usage of heparin prior to the extracorporeal 
preparation procedure or (c) accidental perfusion with air bubbles. These results will be addressed in 
detail later as part of the discussion on the validity of the method (see: Chapter 4.1). 
The following scatter plot serves as an overview of viability test results and subsequent agonist-
induced vasoconstriction with Methoxamine (Figure 5). It represents data derived from all kidneys that 
were used to collect experimental data in this thesis. 
 
Figure 5: Viability tests and Methoxamine-induced contraction in isolated perfused rat kidneys 
Time course of viability tests and subsequent precontraction induced by 3 µM Methoxamine performed prior to experiments 
on Kv7 modulators (n=48). Values are presented as original perfusion pressure recordings. Mean values of perfusion pressure 
readouts are given (in mmHg) below the data point clouds for each time point at which data was collected. The perfusion rate 
of the isolated kidneys is indicated by the “flow rate” timeline. The type of perfusate used is indicated by the color of the data 
point clouds as listed in the legend. 
Pressure-flow relationships were obtained by stepwise increasing flow rates and typically displayed 
themselves in form of a steep increase in perfusion pressure leveling into a horizontal plateau of 
elevated pressure (Figure 6). Out of all 48 experiments used for analysis, the mean perfusion pressure 
at the maximum flow rate (after 40 minutes), was 108.9 ± 2.0 mmHg (mean ± SEM; n=48). 
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Figure 6: Pressure-flow relationship indicating an intact arterial vasculature during viability testing of isolated perfused rat 
kidneys 
Representative recording of flow-induced increases in perfusion pressure immediately after starting perfusion. Values are 
presented as original perfusion pressure recordings. The perfusion rate of the isolated kidneys is indicated by the “flow rate” 
timeline. The area under the curve was calculated for each pressure-flow relationship from the data points collected towards 
the end of the pressure plateau as indicated by the grey dotted line. 
Data points collected towards the end of each pressure plateau were used to calculate the area under 
the curve of the pressure-flow relationships. Having completed all experimental series, a retrospective 
statistical analysis of these AUC values was performed, finding no differences amongst the kidneys 
used as part of different experimental series (Figure 6). 
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Figure 7: Pressure-flow relationship in different experimental series during viability testing of isolated perfused rat kidneys 
Area under the curve calculated for each pressure-flow relationship and grouped for experimental series (One-way ANOVA: 
p=0,29). Values are presented as mean ± SEM. 
Testing for an intact myogenic response at the maximum flow rate occurred by demonstrating the 
presence of pressure-induced vasoconstriction in form of a steep decrease in perfusion pressure 
following application of calcium-free perfusate and afterwards a steep increase in perfusion pressure 
when switching back to regular perfusate (Figure 8). 
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Figure 8: Effect of calcium-free perfusate indicating an intact myogenic response during viability testing of isolated 
perfused rat kidneys 
Representative recording of a reversible decrease in perfusion pressure caused by application and weening of calcium-free 
perfusate. Values are presented as original perfusion pressure recordings. The short delay between change of perfusate and 
onset of effect is due to the dead space of the tubing system proximal of the perfused kidney. 
Data points were collected prior to and towards the end of perfusion with calcium-free solution. Out 
of all 48 experiments, the average perfusion pressure dropped from 108.9 ± 2.0 mmHg to 96.6 ± 1.4 
mmHg in response to calcium free perfusate and rose again to 102.3 ± 1.5 mmHg (mean ± SEM; n=48) 
after washout with regular perfusate (see: Figure 5). Statistical analyses performed for each 
experimental series found no differences between the deltas of perfusion pressure decreases between 
experimental series (Figure 9).  
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Figure 9: Effect of calcium-free perfusate in different experimental series during viability testing of isolated perfused rat 
kidneys 
Perfusion pressure before and towards the end of application of calcium-free perfusate grouped for experimental series 
(paired Student‘s t test: *p<0,05). Not visually displayed: statistical comparisons of the Calcium-free induced delta in perfusion 
pressure (One-way ANOVA: p=0,44). Values are presented as mean ± SEM. 
Aiming to support the assumption that the pressure drop to calcium-free perfusate was actually due 
to inhibition of pressure-induced vasoconstriction and thus an indicator of an intact myogenic 
response, the Pearson correlation coefficient was calculated, revealing a strong correlation between 
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initial flow-induced perfusion pressure and the delta of perfusion pressure decrease induced by 
calcium-free perfusate (Figure 10). 
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Figure 10: Correlation between flow-induced perfusion pressure and decrease in perfusion pressure to Calcium-free 
perfusate in isolated perfused rat kidneys 
Scatter plot of the Calcium-free pressure drop plotted against initial flow-induced perfusion pressure (****p<0,0001; Pearson 
r=0,71; 95% confidence interval 0,54 to 0,83). Values are presented as original perfusion pressure recordings prior to 
application of Calcium-free perfusate or the same subtracted by the pressure readout towards the end of application of 
Calcium-free perfusate. 
The maximum active vasoconstriction of the renal vasculature was tested via application of perfusate 
containing 120 mM KCl. This typically resulted in a marked increase in perfusion pressure that was 
entirely reversible after switching back to regular perfusate (Figure 11).  
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Figure 11: Effect of KCl initiating maximum active vasoconstriction during viability testing of isolated perfused rat kidneys 
Representative recording of a reversible increase in perfusion pressure caused by application and weening of perfusate 
containing 120 mM KCl. Values are presented as original perfusion pressure recordings. The short delay between change of 
perfusate and onset of effect is due to the dead space of the tubing system proximal of the perfused kidney. 
On average, KCl induced increases in perfusion pressure from 44.2 ± 0.6 mmHg to 228.9 ± 4.4 mmHg 
(mean ± SEM; n=48) (see: Figure 5). These data collected at the plateau before and at the peak of 
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elevated perfusion pressure caused by KCl was also statistically analyzed for groups of experimental 
series. There was an increase in perfusion pressure in all series and there were no differences among 
the KCl-induced delta in perfusion pressure between series (Figure 12).  
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Figure 12: Effect of KCl 120 mM in different experimental series during viability testing of isolated perfused rat kidneys 
Perfusion pressure before and after 10 minutes application of perfusate containing 120 mM KCl grouped for experimental 
series (paired Student‘s t test: *p<0.05). Not visually displayed: statistical comparisons of the KCl 120 mM induced delta in 
perfusion pressure (One-way ANOVA: p=0,70). Values are presented as mean ± SEM. 
After finalizing the above described viability tests, perfused kidneys were precontracted by switching 
to regular perfusate containing Methoxamine at 3 µM, which resulted in a gradual but sustained 
increase in perfusion pressure within usually 40-80 minutes (Figure 13). At this point, the actual 
experiments on Kv7 modulators started, the results of which will be presented later (see: Chapter 3.6). 
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Figure 13: Effect of Methoxamine initiating agonist-induced vasoconstriction in isolated perfused rat kidneys 
Representative recording of a sustained increase in perfusion pressure caused by regular perfusate containing 3 µM 
Methoxamine. Values are presented as original perfusion pressure recordings. 
To expose a possible influence of renal organ edema caused by long-term perfusion with colloid-free 
perfusate on baseline perfusion pressure or agonist-induced contraction, we obtained pressure 
readouts (i) prior to application of Methoxamine; at the peak of Methoxamine-induced contraction 
both (ii) before wash-in and (iii) after wash-out of Kv7 modulators; and again (iv) at the baseline after 
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wash-out of Methoxamine. This was done in all experiments except for the series “XE991 only” (see: 
Figure 59 + Figure 60) and “HMR1556 only” (see: Figure 61), in which experiments were terminated 
after application of HMR1556 or XE991. Analyses revealed slightly lower baseline perfusion pressures 
at the end of the experiments, while the maximum perfusion pressure during Methoxamine-induced 
perfusion pressure increase did not change over the time of the experiment (Figure 14). 
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Figure 14: Effect of long-term perfusion on baseline perfusion pressure and maximum agonist-induced contraction in 
isolated perfused rat kidneys 
Baseline perfusion pressure before and after the experiment (black) and peak perfusion pressure during application of 3 µM 
Methoxamine before and after wash-in or wash-out of Kv7 modulators (paired Student‘s t test: n=27; *p<0.05; ns = not 
significant). Baseline perfusion pressure decreased slightly from 44,5 ± 0,9 mmHg to 40,6 ± 1,7 mmHg. Values are presented 
as mean ± SEM. 
One possible confounding factor we suspected for influencing isolated perfused kidney viability and 
thus the ability of the renal vasculature to properly respond to vasoconstrictive or -dilative stimuli or 
agents was prolonged cold storage. Prolonged cold storage had to occur sometimes during preparation 
since the capacity to perfuse multiple kidneys simultaneously was limited to the number of perfusion 
systems and could last up to ~4 hours prior to starting perfusion, as compared to ~30 minutes when 
starting preparation immediately after cervical dislocation. To evaluate whether cold storage was 
relevant for viability of the renal arterial vasculature we performed statistical analyses of viability test 
results between stored and immediately-prepared perfused kidneys. Although the initial perfusion 
pressure after starting kidney perfusion at a low flow rate was found to be higher in kidneys that had 
been stored, pressure-flow responses were similar and no differences in peak perfusion pressures 
induced by either depolarization-induced contraction to 120 mM KCl or by agonist-induced contraction 
to 3 µM Methoxamine  were quantifiable (Figure 15). 
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Figure 15: Effect of prolonged cold storage during preparation on viability tests in isolated perfused rat kidneys 
Comparison of perfused kidneys prepared immediately after cervical dislocation (no storage) or stored at 4°C for ~4 hours 
(cold storage). Values are presented as mean ± SEM (unpaired Student’s t test: n=5; **p<0,01; ns = not significant). (A) Area 
under the curve calculated for pressure-flow relationship (95% confidence interval -23,53 to 76,05). (B) Initial perfusion 
pressure recording of the pressure peak observed immediately after starting perfusion of the kidneys at a flow rate of ~0,5 
ml/min (95% confidence interval 16,71 to 72,01). (C) Original perfusion pressure recording of the pressure peak induced by 
perfusate containing 120 mM KCl (95% confidence interval -70,75 to 39,73). (D) Original perfusion pressure recording of the 
pressure peak induced by application of 3 µM Methoxamine (95% confidence interval -52,88 to 66,00). 
A second possible confounding factor we accounted for was the formation of blood clots in the renal 
vasculature during no-flow time while preparing the perfused kidneys. Blood clots might influence 
vascular resistance and thus contort perfusion pressure recordings. We investigated whether 
intraaortal application of 100 I.U. heparin immediately after laparotomy as has been described (see: 
Chapter 0) affected the results of viabilty tests. Evidently, pretreatment with heparin had no effect on 
either pressure-flow relationships, decreases in perfusion pressure induced by calcium-free perfusate 
or increases in perfusion pressure induced by perfusate containing 120 mM KCl or 3 µM Methoxamine 
(Figure 16). 
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Figure 16: Effect of heparinization during preparation on viability tests in isolated perfused rat kidneys 
Comparison of perfused kidneys with no postmortal treatment (without heparin) or with intraaortal infusion of 100 I.U. 
heparin immediately after laparotomy (with heparin). Values are presented as mean ± SEM (unpaired Student’s t test: n=7; ns 
= not significant). (A) Area under the curve calculated for pressure-flow relationship (95% confidence interval -77,58 to 63,75). 
(B) Original perfusion pressure recording of the pressure drop induced by calcium-free perfusate (95% confidence interval -
24,73 to 9,12). (C) Original perfusion pressure recording of the pressure peak induced by perfusate containing 120 mM KCl 
(95% confidence interval -48,45 to 43,70). (D) Original perfusion pressure recording of the pressure peak induced by 
application of 3 µM Methoxamine (95% confidence interval -20,90 to 46,65). 
Thirdly, accidental perfusion with air was a problem we were unable to entirely undermine. Minor air 
bubbles developed in the final part of the perfusion system tubing between the last bubble trap and 
the perfusion cannula. This most often occurred towards the end of recording pressure-flow 
relationships, when flow rates were highest and thus the air-induced effect on perfusion pressure most 
distinctive. Perfusion with air bubbles typically resulted in either a small hump or a sharp down-and-
up spike in perfusion pressure that usually levelled back to previous perfusion pressure levels within 1 
minute (Figure 17).  
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Figure 17: Examples of accidental perfusion with air bubbles during viability testing of isolated perfused rat kidneys 
Representative recordings for reversible humps or down-and-up spikes increase in perfusion pressure caused by accidental 
perfusion with air bubbles recorded at maximum flow rate towards the end of pressure-flow relationships. Values are 
presented as original perfusion pressure recordings subtracted by pressure readouts at 0 seconds. 
Evaluating whether accidental air perfusion affected vasoconstrictive or dilative responses of perfused 
kidneys in subsequent experiments, no differences were found in pressure-flow relationships, pressure 
decreases to Calcium-free perfusate or pressure increases to KCl or Methoxamine between the two 
groups (Figure 18). 
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Figure 18: Effect of accidental perfusion with air bubbles on viability tests in isolated perfused rat kidneys 
Comparison of perfused kidneys in which accidentally air bubbles were dragged and perfused (with air) or in which no 
accidental air perfusion was observed (without air). Values are presented as mean ± SEM (unpaired Student’s t test: n=8; ns = 
not significant). (A) Area under the curve calculated for pressure-flow relationship (95% confidence interval -205,8 to 183,3). 
(B) Original perfusion pressure recording of the pressure drop induced by calcium-free perfusate (95% confidence interval -
12,36 to 8,73). (C) Original perfusion pressure recording of the pressure peak induced by perfusate containing 120 mM KCl 
(95% confidence interval -66,33 to 8,23). (D) Original perfusion pressure recording of the pressure peak induced by application 
of 3 µM Methoxamine (95% confidence interval -20,24 to 22,83). 
In summary, our results demonstrate that isolated perfused kidney viability tests including (i) pressure-
flow relationships for confirmation of an intact arterial vasculature, (ii) pressure decreases to calcium-
free perfusate for confirmation of an intact myogenic response, (iii) increases in perfusion pressure to 
perfusate containing 120 mM KCl for testing of maximum depolarization-induced vasoconstriction and 
also (iv) increases in perfusion pressure to perfusate containing 3 µM Methoxamine for testing agonist-
induced vasoconstriction were all unaffected by possible confounding factors like (a) prolonged cold 
storage during preparation, (b) heparinization as part of the preparation procedure or (c) accidental 
air perfusion and were furthermore similar when grouped for the experimental series conducted 
subsequently. 
 
3.2 Contribution of Kv7.2-5 to agonist-induced renal vasoconstriction 
To ascertain the effect of the Kv7.2-7.5 activator Retigabine 249, 273 in context with the pan-Kv7 blocker 
XE991 217, 219, 249, 250 and the selective Kv7.1 activator HMR1556 215, 216 in agonist-induced 
vasoconstriction of isolated renal small arteries, a series of precontraction experiments was conducted 
using a protocol with the selective α1-adrenoceptor agonist Methoxamine as a precontracting agent 
(see: Table 4). 
Application of Retigabine (0.3-30 µM) caused concentration-dependent relaxations of Methoxamine-
induced precontractions (Figure 19).  
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Figure 19: Effect of Retigabine activating Kv7.2-5 channels on agonist-induced contraction in rat renal interlobar arteries 
Original recording of relaxant responses to Retigabine (0.3 – 30 µM) in rat renal interlobar artery after precontraction with 
0.7 µM Methoxamine. 
To exclude the possibility of DMSO being responsible for the dilating effect of DMSO-solved Retigabine 
we conducted a series of concentration-response relationships comparing the effects of DMSO and 
Retigabine. We observed a stable plateau of precontraction during administration of DMSO (maximum 
concentration 1 µl/ml), compared to which Retigabine induced considerable concentration-dependent 
relaxations (Figure 20). 
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Figure 20: Effect of Kv7.2-5 activation on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Retigabine (0.3 – 30 µM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force 
(Student‘s t test: n=9; 95% confidence interval -8,62 to 8,92). 
To evaluate whether pan-Kv7 block with XE991 would prevent relaxations to the Kv7.2-5 activator 
Retigabine, vessels were preincubated with XE991 prior to precontraction and subsequently 
Retigabine applied as before. We found that Retigabine-induced concentration-dependent relaxations 
were still observable in the presence of XE991 (Figure 21). 
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Figure 21: Effect of Kv7.2-5 activation during Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Retigabine (0.3 – 30 µM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force 
(Student‘s t test: n=9; 95% confidence interval -8,93 to 9,75) and preincubated with 3 µM XE991. 
Similarly, we tested the effect of preincubation with the selective Kv7.1 blocker HMR1556 prior to 
Retigabine CRRs and likewise observed Retigabine-induced concentration-dependent relaxations in 
the presence of HMR1556 (Figure 22). 
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Figure 22: Effect of Kv7.2-5 activation during Kv7.1 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Retigabine (0.3 – 30 µM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force 
(Student‘s t test: n=9; 95% confidence interval -7,88 to 5,56) and preincubated with 10 µM HMR1556. 
To discern a possible antagonizing effect of the pan-Kv7 blocker XE991 and the selective Kv7.1 blocker 
HMR1556 on relaxations to the Kv7.2-7.5 activator Retigabine, an additional analysis comparing the 
above described concentration-response relationships (Figure 20 – Figure 22) was performed. We 
found that Retigabine-induced concentration-dependent relaxations were reduced by XE991, but not 
by HMR1556 (Figure 23). 
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Figure 23: Effect of Kv7.2-5 activation during Kv7 or Kv7.1 blockade on agonist-induced contraction in rat renal interlobar 
arteries 
Concentration-dependent relaxation to Retigabine (0.3 – 30 µM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: n=9/9/8; ****p<0,0001; ns = not significant). Arteries were preincubated with either 3 µM XE991 or 10 µM 
HMR1556 and precontracted with Methoxamine to a similar percentage of maximum force (One-way ANOVA: n=9/9/8; 
p=0,87). 
To test for a dependency of Retigabine-induced relaxations on the level of precontraction, we 
conducted the above described experiment (Figure 21) in two groups of vessels which were 
precontracted to either higher or lower tone using different concentrations of Methoxamine. We 
discovered that the different levels of Methoxamine+XE991-induced precontraction achieved in these 
experiments did not change the degree by which arteries were relaxed by Retigabine (Figure 24). 
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Figure 24: Effect of Kv7.2-5 activation during Kv7 blockade at different levels of agonist-induced contraction in rat renal 
interlobar arteries 
Concentration-dependent relaxation to Retigabine (0.3 – 30 µM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ns = not significant). Arteries were preincubated with 3 µM XE991 and precontracted with Methoxamine 
to either high tone or low tone  (Student‘s t test: n=9; **** 95% confidence interval -20,44 to -10,44) 
To test whether the chronological order in which Kv7 modulators are applied, as well as whether the 
concentration of XE991 used in our above described experiments (Figure 21 + Figure 24) had been too 
low to block Kv7 sufficiently, both of which might represent possible reasons for the inability of XE991 
to entirely abolish Retigabine-induced relaxations, we conducted additional experiments on 
Results 
 
52 
 
Methoxamine precontractions in which we first applied the maximum concentration of Retigabine 
used before (30 µM) and only afterwards administered XE991 at concentrations of 3 µM and 
subsequently 10 µM. We found that Retigabine-induced relaxations were fully antagonized by XE991 
at 3 µM, and increasing concentration to 10 µM did not cause any additional increases in vessel tone 
(Figure 25). 
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Figure 25: Effect of Kv7 blockade during Kv7.2-5 activation on agonist-induced contraction in rat renal interlobar arteries 
Relaxation induced by 30 µM Retigabine antagonized over time with 3 µM and 10 µM XE991 compared to time control 
(Student‘s t test: ****p<0,0001; ns = not significant) in arteries precontracted with Methoxamine to a similar percentage of 
maximum force (Student‘s t test: n=9; ns = not significant; 95% confidence interval -2,19 to 18,11). 
In summary, our results demonstrate that Retigabine causes marked vasorelaxations in Methoxamine-
precontracted rat renal resistance arteries which are unaffected by the Kv7.1 blocker HMR1556 but 
diminished by the pan-Kv7 blocker XE991 independently of the level of precontraction. 
 
3.3 Contribution of Kv7.1  to agonist-induced renal vasoconstriction 
To determine the role of Kv7.1 in renal resistance artery vasoconstriction, an experimental series 
similar to the previous one done on Retigabine (see: Chapter 3.2) was conducted using the selective 
Kv7.1 activator R-L3 213, 318 in context with the pan-Kv7 blocker XE991 and the selective Kv7.1 activator 
HMR1556 on the basis of a Methoxamine precontraction protocol (see: Table 4). 
Application of R-L3 produced concentration-dependent relaxations in Methoxamine-induced 
precontractions. These relaxations differed from the stable plateau of precontraction observed during 
application of equivalent concentrations of its solvent DMSO (maximum concentration 0.64 µl/ml) 
(Figure 26).  
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Figure 26: Effect of Kv7.1 activation on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to R-L3 (0.01 – 1 µM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force (Student‘s 
t test: n=10; 95% confidence interval -8,10 to 8,75) 
To address whether pan-Kv7 blockade with XE991 would antagonize the concentration-dependent 
relaxations induced by R-L3, vessels were preincubated with XE991 prior to Methoxamine 
precontraction. We found that R-L3-induced relaxations were still observable in the presence of XE991 
(Figure 27). 
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Figure 27: Effect of Kv7.1 activation during Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to R-L3 (0.01 – 1 µM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were preincubated with 3 µM XE991 and precontracted with Methoxamine to a similar 
percentage of maximum force (Student‘s t test: n=10; 95% confidence interval -8,72 to 8,69). 
Analogously, to test whether relaxations to R-L3 would persist in the presence of the Kv7.1 specific 
blocker HMR1556, vessels were preincubated with HMR1556 prior to Methoxamine precontractions. 
We likewise observed R-L3-induced concentration-dependent relaxation in the presence of HMR1556 
(Figure 28). 
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Figure 28: Effect of Kv7.1 activation during Kv7.1 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to R-L3 (0.01 – 1 µM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were preincubated with 10 µM HMR1556 and precontracted with Methoxamine to a similar 
percentage of maximum force (Student‘s t test: n=9; 95% confidence interval -9,58 to 10,25). 
Aiming to ascertain whether the pan-Kv7 blocker XE991 and the selective Kv7.1 blocker HMR1556 
antagonized relaxations to R-L3, an analysis comparing the above described CRRs was performed 
(Figure 26 – Figure 28). We established that both XE991 and HMR1556 were effective in reducing R-
L3-induced concentration-dependent relaxations (Figure 29). 
****
****
-8 -7 -6
0
50
100
lg[R-L3] (M)
%
 o
f 
p
re
c
o
n
tr
a
c
ti
o
n
Control R-L3
XE991 + R-L3
HMR1556 + R-L3
Methoxamine precontraction
25
50
75
Precontraction
  
%
 o
f 
m
a
x
im
u
m
 f
o
rc
e
 
Figure 29: Effect of Kv7.1 activation during Kv7 or Kv7.1 blockade on agonist-induced contraction in rat renal interlobar 
arteries 
Concentration-dependent relaxation to R-L3 (0.01 – 1 µM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: n=8/8/7; ****p<0,0001). Arteries were preincubated with either 3 µM XE991 or 10 µM HMR1556 and precontracted 
with Methoxamine to a similar percentage of maximum force (One-way ANOVA: n=8/8/7; p=0,81). 
Finally, to differentiate whether the level of agonist-induced precontraction influences the degree by 
which XE991 diminishes relaxations to R-L3, we performed analogous experiments as earlier with 
Retigabine (see: Figure 27), having two groups of arteries precontracted to either high or low tone with 
different concentrations of Methoxamine. We confirmed that different levels of Methoxamine-
induced precontraction did not affect the dimension of R-L3-induced relaxations after preincubation 
with XE991 (Figure 30).   
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Figure 30: Effect of Kv7.1 activation during Kv7 blockade at different levels of agonist-induced contraction in rat renal 
interlobar arteries 
Concentration-dependent relaxation to R-L3 (0.01 – 1 µM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ns = not significant). Arteries were preincubated with 3 µM XE991 and precontracted with Methoxamine to either 
high tone or low tone (Student‘s t test: n=10; **** 95% confidence interval -18,06 to -8,25). 
In summary, our results demonstrate that R-L3 causes marked vasorelaxations in Methoxamine-
precontracted rat renal resistance arteries which are diminished by both the Kv7.1 blocker HMR1556 
and the pan-Kv7 blocker XE991 independently of the level of precontraction. 
 
3.4 Contribution of Kv7 to the anticontractile effect of ANP in agonist-induced renal vasoconstriction 
Endogenous dilators sometimes employ K+ channels as effectors for their anticontractile effects. In 
search for interference between the cGMP-dependent vasodilator ANP 319 and Kv7 channels in 
regulating renal artery tone, we performed experiments with a protocol using concentration-response 
relationships for estimation of pD2 as an indicator of Methoxamine sensitivity (see: Table 3). By 
preincubation with ANP and subsequent application of Kv7 activators R-L3 or Retigabine or Kv7 blockers 
HMR1556 (in the presence of R-L3) we were able to conduct a detailed functional analysis of Kv7 
channel contribution to agonist-induced renal resistance artery contractility. 
Previous unpublished experiments have shown that XE991 (3 µM) increases, while ANP (100 nM) 
decreases concentration-dependent contractions to Methoxamine in renal interlobar arteries, with 
their contractile or anticontractile effects, respectively being both unimpaired by the presence of the 
other. This implicates that elevated Methoxamine sensitivity induced by Kv7 block is independent of 
cGMP-mediated pathways, and that vice versa reduced Methoxamine sensitivity mediated by cGMP-
mediated pathways is unaffected by blockade of Kv7 channels. To further elucidate the question 
whether oppositely, the anticontractile effect of Kv7.2-5 activation would similarly be independent of 
ANP-induced vasorelaxation, we first performed concentration-response relationships with 
Methoxamine after preincubation with either Retigabine, ANP, both substances combined or solvent 
only for control. We observed that Retigabine (30 µM) and ANP (100 nM) both diminish concentration-
dependent contractions to Methoxamine, with their decrease being both additive and unimpaired in 
the presence of the other (Figure 31). 
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Figure 31: Functional role of ANP in context with Kv7.2-5 channel activation in rat renal interlobar arteries  
(A) Methoxamine-induced contraction in absence of Retigabine and ANP (control), in presence of 30 µM Retigabine only 
(Retigabine), in presence of 100 nM ANP only (ANP) and in presence of both Retigabine and ANP (Retigabine + ANP) (Two-
way repeated measures ANOVA: n=6; *p<0,05). (B) ANP-induced ∆pD2 in absence (control) and in presence of Retigabine 
(Student‘s t test: n=6; 95% confidence interval -0,24 to 0,26). (C) Retigabine-induced ∆pD2 in absence (control) and in presence 
of ANP (Student‘s t test: n=6; 95% confidence interval -0,02 to 0,04). 
Next, we examined the anticontractile effect of the Kv7.1 activator R-L3 for interference with ANP-
induced vasorelaxation and analogously found that R-L3 (1 µM) and ANP (100 nM) both diminish 
concentration-dependent contractions to Methoxamine, with their decrease likewise being both 
additive and unimpaired by the presence of the other (Figure 32). 
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Figure 32: Functional role of ANP in context with Kv7.1 channel activation in rat renal interlobar arteries 
(A) Methoxamine-induced contraction in absence of R-L3 and ANP (control), in presence of 1 µM R-L3 only (R-L3), in presence 
of 100 nM ANP only (ANP) and in presence of both R-L3 and ANP (R-L3 + ANP) (Two-way repeated measures ANOVA: n=6; 
*p<0,05). (B) ANP-induced ∆pD2 in absence (control) and in presence of R-L3 (Student‘s t test: n=6; 95% confidence 
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interval -0,079 to 0,026). (C) R-L3-induced ∆pD2 in absence (control) and in presence of ANP (Student‘s t test: n=6; 95% 
confidence interval -0,10 to 0,055. 
Previous unpublished experiments have demonstrated that application of HMR1556 alone has no 
effect, whereas HMR is effective in antagonizing R-L3, as indicated by its increase in the contractile 
response to Methoxamine following preincubation with R-L3. Therefore, we conducted experiments 
testing the contractile effect of HMR1556 for ANP-dependency after preincubation of all vessels with 
R-L3. We again confirmed that in the presence of R-L3 (1 µM), HMR1556 (10 µM) enhanced, while ANP 
(100 nM) reduced contractile responses to Methoxamine and further demonstrated that the increase 
or decrease in Methoxamine sensitivity caused by HMR1556 resp. ANP were unimpaired by the 
absence or presence of one another (Figure 33). 
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Figure 33: Functional role of ANP in context with Kv7.1 channel blockade following Kv7.1 activation in rat renal interlobar 
arteries 
(A) Methoxamine-induced contraction in arteries preincubated with 1 µM R-L3 in absence of HMR1556 and ANP (control), in 
presence of 10 µM HMR1556 only (HMR1556), in presence of 100 nM ANP only (ANP) and in presence of both HMR1556 and 
ANP (HMR1556 + ANP) (Two-way repeated measures ANOVA: n=6; *p<0,05). (B) ANP-induced ∆pD2 in arteries preincubated 
with 1 µM R-L3 in absence (control) and in presence of HMR1556 (Student‘s t test: n=6; 95% confidence interval -0,064 to 
0,10). (C) HMR-induced ∆pD2 in arteries preincubated with 1 µM R-L3 in absence (control) and in presence of ANP (Student‘s t 
test: n=6; 95% confidence interval -0,11 to 0,075). 
The anticontractile effect of ANP at 100 nM when coadministered with R-L3 was so strong that even 
in the presence of HMR1556 the maximum contractile response to Methoxamine at the highest 
concentration (100 µM) did not reach the level of the control group (Figure 33). Since by our methods, 
Methoxamine sensitivity was estimated by fitting concentration-response curves to the Hill equation 
using least squares regression, the accuracy of the estimate may be reduced in such circumstances. 
Therefore, to confirm the validity of our results, we conducted another series of the same protocol, 
only this time with a lower concentration of ANP (30 nM). This as intended brought the maximum 
contractile response back up to control level, but otherwise confirmed our results (Figure 34). 
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Figure 34: Functional role of ANP in context with Kv7.1 channel blockade following Kv7.1 activation in rat renal interlobar 
arteries 
(A) Methoxamine-induced contraction in arteries preincubated with 1 µM R-L3 in absence of HMR1556 and ANP (control), in 
presence of 10 µM HMR1556 only (HMR1556), in presence of 30 nM ANP only (ANP) and in presence of both HMR1556 and 
ANP (HMR1556 + ANP) Two-way repeated measures ANOVA: n=6; *p<0,05). (B) ANP-induced ∆pD2 in arteries preincubated 
with 1 µM R-L3 in absence (control) and in presence of HMR1556 (Student‘s t test: n=6; 95% confidence interval -0,095 to 
0,084). (C) HMR-induced ∆pD2 in arteries preincubated with 1 µM R-L3 in absence (control) and in presence of ANP (Student‘s 
t test: n=6; 95% confidence interval -0,12 bis 0,13). 
In summary, our results this far demonstrate that Methoxamine sensitivity of renal resistance arteries 
is decreased by the Kv7.1 activator R-L3 as well as by the Kv7.2-5 activator Retigabine and is increased 
by the Kv7.1 blocker HMR1556 in the presence of R-L3, with all of these effects reciprocally being both 
unaffected by, and itself not affecting, the anticontractile effect caused by preincubation with ANP. 
We thus provide substantial evidence that on a functional level, both the contractile and the 
anticontractile effect of Kv7 channels depicted by increased or decreased sensitivity to the 
vasoconstrictive α1-adrenoceptor agonist methoxamine are unaffected by the cGMP-dependent 
endogenous vasodilator ANP. 
Having demonstrated this, we next conducted experiments following a protocol using either 
Methoxamine or KCl or various K+ channel blockers (see: Table 5) to study the concentration-
dependent effect of ANP not only on agonist-induced, but also on depolarization-induced 
vasoconstriction. This way, we were able to investigate the role of Kv7 channels in context with ANP in 
vessels differentially preconstricted through activation of different signaling pathways, allowing us to 
later draw more detailed conclusions on intracellular signaling of Kv7- and ANP-mediated modification 
of renal resistance artery reactivity (see: Chapter 4.4). 
First, the effect of ANP on Methoxamine-induced precontraction was examined to ascertain its 
effectiveness in counteracting agonist-induced vasoconstriction. Agonist-induced vasoconstriction 
involves a multitude of mechanistic elements, including Ca2+-dependent and Ca2+-sensitizing 
mechanisms (see: Chapter 1.4.2). We found ANP (1-100 nM) to cause marked concentration-
dependent relaxations of Methoxamine-precontracted renal interlobar arteries (Figure 35). 
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Figure 35: Effect of ANP on contraction induced by α1-adrenoceptor agonist Methoxamine in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force (Student‘s 
t test: n=13; 95% confidence interval -8,53 to 9,29). 
Second, the effect of ANP on KCl-induced contraction was studied to evaluate its potential to 
counteract depolarization-induced vasoconstriction caused by functional elimination of all K+ channels 
present. We established that ANP likewise causes concentration-dependent relaxations of renal 
interlobar arteries precontracted with 50 mM KCl (Figure 36). 
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Figure 36: Effect of ANP on contraction induced by KCl in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were precontracted with 50 mM KCl to a similar percentage of maximum force (Student‘s t 
test: n=13; 95% confidence interval -8,36 to 9,83). 
Subsequently, in search for differential effectiveness of ANP in counteracting agonist-induced or 
depolarization-induced vasoconstriction, a comparison of both responses (Figure 35 + Figure 36) was 
performed and revealed concentration-dependent relaxation caused by ANP to be more marked in 
arteries precontracted with Methoxamine than in arteries precontracted with 50 mM KCl (Figure 37). 
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Figure 37: Effect of ANP on contraction induced by KCl or α1-adrenoceptor agonist Methoxamine in rat renal interlobar 
arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: **p<0,01). Arteries were either precontracted with 50 mM KCl or with Methoxamine to a similar percentage of 
maximum force (Student‘s t test: n=13; 95% confidence interval -8,12 to 10,65). 
Having demonstrated that ANP is able to relax vasoconstriction induced by KCl and thus via functional 
elemiination of K+ channels (Figure 36), we proceeded towards investigating the role of Kv7 channels 
in this process. This was achieved by first testing the effect of ANP on precontraction induced by 
blockade of all known K+ channels expressed in the artery’s VSMCs, using a cocktail of pharmacological 
blockers for BKCa (iberiotoxin, 0.1 µM) 157, KATP (glibenclamide, 1 µM) 320, Kir2 (BaCl, 30 µM) 321, KV1 (DPO-
1, 1 µM) 175, 176, Kv2 and Kv4 (stromatoxin, 0.1 µM) 177 and Kv7 (XE991, 3 µM). We found that ANP was 
similarly effective in producing relaxations in precontractions induced by individual pharmacological 
blockade of all known K+ channels, specifically including Kv7 blockers (Figure 38). 
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Figure 38: Effect of ANP on contraction induced by various K+ blockers in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were preincubated with 3 µM XE991 and precontracted with blockers for BKCa 
(iberiotoxin, 0.1 µM), KATP (glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM) and Kv2 and Kv4 (stromatoxin, 0.1 µM) 
to a similar percentage of maximum tension (Student‘s t test: n=14; 95% confidence interval -7,14 to 7,86). 
In parallel, we applied ANP in arteries precontracted with the same K+ channel blocker cocktail as 
before (Figure 38), only this time not including the Kv7 blocker XE991. This likewise resulted in 
concentration-dependent relaxations to ANP (Figure 39). 
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Figure 39: Effect of ANP on contraction induced by various K+ blockers excluding XE991 in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were precontracted with blockers for BKCa (iberiotoxin, 0.1 µM), KATP (glibenclamide, 1 µM), 
Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM) and Kv2 and Kv4 (stromatoxin, 0.1 µM), but not Kv7 to a similar percentage of maximum 
tension (Student‘s t test: n=14; 95% confidence interval -5,72 to 6,22). 
Eventually, to address whether in depolarization-induced vasocontraction, the anticontractile effect of 
ANP would differ dependently on Kv7 remaining the only un-blocked K+ channel as compared to Kv7 
being blocked along with all other K+ channels, we analyzed and compared both of the above 
concentration-response curves (Figure 38 + Figure 39). Interestingly, no differences were detected, 
giving no implication for a functionally relevant involvement of Kv7 channels in concentration-
dependent relaxations to ANP in depolarization-induced renal resistance artery contraction (Figure 
40). 
-9 -8 -7
0
50
100
with vs. without XE991 precontraction
lg[ANP] (M)
%
 o
f 
p
re
c
o
n
tr
a
c
ti
o
n
all K+ blockers + ANP
all without XE991 + ANP
ns
25
50
75
Precontraction
  
%
 o
f 
m
a
x
im
u
m
 f
o
rc
e
 
Figure 40: Effect of ANP on contraction induced by various K+ blockers including or excluding XE991 in rat renal interlobar 
arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ns p=0,35). Arteries were either preincubated with 3 µM XE991 (with) or not (without) and precontracted with 
blockers for BKCa (iberiotoxin, 0.1 µM), KATP (glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM) and Kv2 and Kv4 
(stromatoxin, 0.1 µM) to a similar percentage of maximum tension (Student‘s t test: n=14; 95% confidence interval -1,16 to 
12,33). 
Having demonstrated that ANP is able to counteract vasoconstriction induced by α1-adrenoceptor 
antagonist Methoxamine (Figure 35), and thus via contractile mechanisms including both 
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depolarization-mediated Ca2+ influx and increasing Ca2+ sensitivity (see: Chapter 1.4.2), we further 
investigated the role of Kv7 channels in this process. This was done starting with testing ANP in 
Methoxamine-induced precontraction of vessels preincubated with pan-Kv7 blocker XE991 (3 µM), 
which produced concentration-dependent relaxations (Figure 41). 
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Figure 41: Effect of ANP during Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were preincubated with 3 µM XE991 and precontracted with Methoxamine to a similar 
percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -6,27 to 8,26). 
In parallel, ANP was applied to Methoxamine-precontracted arteries that were preincubated with the 
Kv7.1 blocker HMR1556 (10 µM), producing similar concentration-dependent relaxations (Figure 42). 
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Figure 42: Effect of ANP during Kv7.1 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ****p<0,0001). Arteries were preincubated with 10 µM HMR1556 and precontracted with Methoxamine to a similar 
percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -5,03 to 8,49). 
To establish whether ANP-induced relaxations of Methoxamine-precontracted arteries depend upon 
Kv7, we compared these dose-dependent relaxations in the presence or absence of XE991, 
demonstrating no difference in the effect of ANP (Figure 43). 
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Figure 43: Effect of ANP with or without Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ns p=0,44). Arteries were preincubated either with or without 3 µM XE991 and precontracted with Methoxamine to 
a similar percentage of maximum force (Student‘s t test: n=7; 95% confidence interval -11,27 to 4,16). 
Finally, to adress whether blockade of either all Kv7 or only Kv7.1 specifically would differentially affect 
ANP-induced relaxations in agonist-induced vasoconstriction, we analyzed and compared the two 
above results (Figure 41 + Figure 42). There was no difference in the degree by which ANP relaxed 
Methoxamine precontractions in vessels preincubated with either the Kv7.1-specific blocker HMR1556 
(10 µM) or the pan-Kv7 blocker XE991 (3 µM) (Figure 44).  
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Figure 44: Effect of ANP during Kv7.1 or Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to ANP (1 – 100 nM) normalized to precontraction levels (Two-way repeated-measures 
ANOVA: ns p=0,46). Arteries were preincubated with either 10 µM HMR1556 or 3 µM XE991 and precontracted with 
Methoxamine to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -6,81 to 6,00). 
In summary, our results demonstrate that ANP-induced vasorelaxation in renal interlobar arteries (i) is 
more marked in Methoxamine- than in KCl-induced precontraction, (ii) does not depend upon Kv7 in 
depolarization-induced precontraction achieved by pharmacological blockade of VSMC K+ channels, 
and (iii) is similarly marked in Methoxamine-induced precontractions when either Kv7.1 or all Kv7 are 
blocked. 
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3.5 Contribution of Kv7 to the anticontractile effect of Urocortin in agonist-induced renal 
vasoconstriction 
As was done for the cGMP-dependent vasodilator ANP, we screened the cAMP-dependent vasodilator 
Urocortin 88, 322, 323 for interference with Kv7 function in renovascular reactivity, following an analog 
protocol of concentration-response relationships for calculation of pD2 as an indicator of Methoxamine 
sensitivity (see: Table 3), this time incubating Urocortin prior to application of Kv7 activators R-L3 or 
Retigabine and Kv7 blockers HMR1556 (in the presence of R-L3) or XE991. 
Previous unpublished experiments, as mentioned earlier, have shown that XE991 (3 µM) increases 
concentration-dependent contractions to Methoxamine, and furthermore that Urocortin, just like 
ANP, has an anticontractile effect in renal interlobar arteries. In search for interdependency of these 
effects we recorded Methoxamine concentration-response relationships after preincubation with 
either XE991, Urocortin, both substances combined or solvent only for control and calculated changes 
in pD2. We confirmed that XE991 increases, whereas Urocortin decreases Methoxamine sensitivity, 
and furthermore demonstrated both of these effects were each unimpaired in the presence of the 
other agent (Figure 45).  
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Figure 45: Functional role of Urocortin in context with Kv7  blockade in rat renal interlobar arteries 
(A) Methoxamine-induced contraction in absence of XE991 and Urocortin (control), in presence of 3 µM XE991 only (XE991), 
in presence of 100 nM Urocortin only (Urocortin) and in presence of both XE991 and Urocortin (XE991 + Urocortin) (Two-way 
repeated measures ANOVA: n=10; *p<0,05). (B) Urocortin-induced ∆pD2 in absence (control) and in presence of XE991 
(Student‘s t test: n=10; 95% confidence interval -0,094 to 0,06). (C) XE991-induced ∆pD2 in absence (control) and in presence 
of Urocortin (Student‘s t test: n=10; 95% confidence interval -0,04 to 0,08). 
The same was done to examine the anticontractile effect of both the Kv7.2-5 activator Retigabine and 
the Kv7.1 activator R-L3 for interference with the anticontractile effect of Urocortin, analog to 
experiments done on ANP (Figure 31 + Figure 32). We demonstrated that Retigabine (30 µM) and R-L3 
(1 µM) as well as Urocortin (100 nM) reduce the concentration-dependent contractile effect of 
Methoxamine, with their decrease in Methoxamine sensitivity all being both additive and unimpaired 
in the presence of the other (Figure 46 and Figure 47).  
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Figure 46: Functional role of Urocortin in context with Kv7.2-5 channel activation in rat renal interlobar arteries 
(A) Methoxamine-induced contraction in absence of Retigabine and Urocortin (control), in presence of 30 µM Retigabine only 
(Retigabine), in presence of 100 nM Urocortin only (Urocortin) and in presence of both Urocortin and Retigabine (Retigabine 
+ Uro) (Two-way repeated measures ANOVA: n=9; *p<0,05). (B) Urocortin-induced ∆pD2 in absence (control) and in presence 
of Retigabine (Student‘s t test: n=9; 95% confidence interval -0,13 to 0,053). (C) Retigabine-induced ∆pD2 in absence (control) 
and in presence of Urocortin (Student‘s t test: n=9; 95% confidence interval -0,11 to 0,03). 
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Figure 47: Functional role of Urocortin in context with Kv7.1 channel activation in rat renal interlobar arteries 
(A) Methoxamine-induced contraction in absence of R-L3 and Urocortin (control), in presence of 1 µM R-L3 only (R-L3), in 
presence of 100 nM Urocortin only (Urocortin) and in presence of both R-L3 and Urocortin (R-L3 + Urocortin) (Two-way 
repeated measures ANOVA: n=9; *p<0,05). (B) Urocortin-induced ∆pD2 in absence (control) and in presence of R-L3 (Student‘s 
t test: n=9; 95% confidence interval -0,12 to 0,05). (C) R-L3-induced ∆pD2 in absence (control) and in presence of Urocortin 
(Student‘s t test: n=9; 95% confidence interval -0,11 to 0,04). 
Because The Kv7.1 blocker HMR1556 exerts its anticontractile effect only in the presence of R-L3, as 
described earlier (see: Chapter 3.4), testing of HMR1556 for interference with the anticontractile effect 
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of Urocortin was done after preincubation of all vessels with R-L3. We observed that HMR1556 (10 
µM) enhanced, while Urocortin (100 nM) reduced the contractile response to Methoxamine (Figure 
48). Furthermore, we observed that the increase or decrease in Methoxamine sensitivity caused by 
Urocortin resp. HMR1556 was unaffected by the absence or presence of the other. 
-8 -7 -6 -5 -4
0
50
100
lg[Methoxamine] (M)
%
 o
f 
m
a
x
im
u
m
 f
o
rc
e
HMR1556
HMR1556 + Urocortin
Control
Urocortin
*
*
*
*
Control HMR
0.0
0.2
0.4
0.6
0.8
1.0
U
ro
c
o
rt
in
-i
n
d
u
c
e
d

p
D
2 ns
Control Urocortin
0.0
0.2
0.4
0.6
0.8
1.0
H
M
R
-i
n
d
u
c
e
d

p
D
2 ns
In presence of R-L3
(A)
(B)
(C)
 
Figure 48: Functional role of Urocortin in context with Kv7.1 channel blockade following Kv7.1 activation in rat renal 
interlobar arteries 
(A) Methoxamine-induced contraction in arteries preincubated with 1 µM R-L3 in absence of HMR1556 and Urocortin (control), 
in presence of 10 µM HMR1556 only (HMR1556), in presence of 100 nM Urocortin only (Urocortin) and in presence of both 
HMR1556 and Urocortin (HMR1556 + Urocortin) (Two-way repeated measures ANOVA: n=9; *p<0,05). (B) Urocortin-induced 
∆pD2 in arteries preincubated with 1 µM R-L3 in absence (control) and in presence of Urocortin (Student‘s t test: n=9; 95% 
confidence interval -0,17 to 0,01). (C) HMR-induced ∆pD2 in arteries preincubated with 1 µM R-L3 in absence (control) and in 
presence of HMR1556 (Student‘s t test: n=9; 95% confidence interval -0,04 to 0,214). 
In summary, our results demonstrate that Methoxamine sensitivity of renal interlobar arteries is 
decreased by the Kv7.1 activator R-L3 or by the Kv7.2-5 activator Retigabine and is increased by the 
Kv7.1 blocker HMR1556 in the presence of R-L3 as well as by the pan-Kv7 blocker XE991, with all of 
these effects reciprocally being bothunaffected by, and itself not affecting, the anticontractile effect 
caused by preincubation with Urocortin.  
With all Kv7 activators and blockers displaying no interaction with Urocortin regarding their modulating 
effect on Methoxamine sensitivity, we next performed a series of precontraction experiments 
following a protocol with either Methoxamine (see: Table 4) or with KCl and various pharmacological 
K+ channel blockers (see: Table 5) to differentiate the concentration-dependent effect of Urocortin in 
not only agonist-induced but also in depolarization-induced vasoconstriction. As has been elaborated 
earlier (see: Chapter 3.4), this served to examine the effect of endogenous vasodilators like Urocortin 
in vessels preconstricted by activation of different signal transduction pathways, allowing us to draw 
conclusions on possible intracellular effects of the cAMP-dependent vasodilator Urocortin in context 
with Kv7 channel function. 
In a first step, we examined the effect of Urocortin on agonist-induced precontraction with 
Methoxamine as a vasoconstrictor, which acts through both increases in [Ca2+]i and increases in Ca2+ 
sensitivity. We found that Urocortin causes concentration-dependent relaxations of Methoxamine 
precontractions in renal interlobar arteries (Figure 49). 
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Figure 49: Effect of Urocortin on contraction induced by α1-adrenoceptor agonist Methoxamine in rat renal interlobar 
arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with Methoxamine to a similar percentage of maximum force 
(Student‘s t test: n=10; 95% confidence interval -7,98 to 6,50). 
In parallel, Urocortin was applied during KCl-induced precontraction to evaluate its effectiveness in 
antagonizing depolarization-induced vasoconstriction due to functional elimination of all K+ channels. 
We recorded concentration-dependent relaxations to Urocortin (0.1 – 100 nM) in renal interlobar 
arteries precontracted with 40 mM KCl (Figure 50). 
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Figure 50: Effect of Urocortin on contraction induced by KCl in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with 40 mM KCl to a similar percentage of maximumforce 
(Student‘s t test: n=10; 95% confidence interval -7,12 to 16,84). 
Eventually, to discern differences in the anticontractile effect of Urocortin on agonist-induced versus 
depolarization-induced vasoconstriction, we analyzed both graphs (Figure 49 + Figure 50), discovering 
that concentration-dependent relaxation caused by Urocortin were profoundly more marked in 
arteries precontracted with Methoxamine than with 40 mM KCl (Figure 51). 
Results 
 
68 
 
-10 -9 -8 -7
0
50
100
KCl vs Methoxamine precontraction
lg[Urocortin] (M)
%
 o
f 
p
re
c
o
n
tr
a
c
ti
o
n
KCl + Urocortin
Methoxamine + Urocortin ****
25
50
75
Precontraction
  
%
 o
f 
m
a
x
im
u
m
 f
o
rc
e
 
Figure 51: Effect of Urocortin on contraction induced by KCl or α1-adrenoceptor agonist Methoxamine in rat renal interlobar 
arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were either precontracted with either 40 mM KCl or with Methoxamine to a similar 
percentage of maximum force (Student‘s t test: n=10; 95% confidence interval -16,93 to 5,16). 
Having demonstrated that Urocortin is effective in antagonizing precontraction induced by KCl and 
thus functional elimination of K+ channels (Figure 50), we further evaluated Kv7 channels for their 
contribution to this phenomenon. As described before for ANP, we tested the effect of Urocortin on 
precontraction induced by simultaneous preincubation with pharmacological blockers of the K+ 
channel subfamilies known to be expressed in VSMCs, including BKCa (iberiotoxin, 0.1 µM), KATP 
(glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM), Kv2 and Kv4 (stromatoxin, 0.1 µM) and 
Kv7 (XE991, 3 µM) (for references, see: Chapter 3.4). We established that Urocortin caused 
concentration-dependent relaxations of precontraction thus created by pharmacological blockade of 
all known K+ channels including Kv7 (Figure 52).  
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Figure 52: Effect of Urocortin on contraction induced by various K+ blockers in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were preincubated with 3 µM XE991 and precontracted with blockers for BKCa 
(iberiotoxin, 0.1 µM), KATP (glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM) and Kv2 and Kv4 (stromatoxin, 0.1 µM) 
to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -7,27 to 9,47). 
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Next, precontraction was induced with the same cocktail of K+ channel blockers, but this time without 
the pan-Kv7 blocker XE991. We demonstrated that such precontraction was likewise relaxed by 
Urocortin in a concentration-dependent manner (Figure 53). 
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Figure 53: Effect of Urocortin on contraction induced by various K+ blockers excluding XE991 in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were precontracted with blockers for BKCa (iberiotoxin, 0.1 µM), KATP 
(glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), KV1 (DPO-1, 1 µM) and Kv2 and Kv4 (stromatoxin, 0.1 µM), but not Kv7 to a similar 
percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -12,39 to 16,61). 
An analytical comparison of the two graphs (Figure 52 + Figure 53) was undertaken to address whether 
Kv7 blockade versus Kv7 remaining the only un-blocked K+ channel in the vessel wall would differentially 
affect Urocortin-induced concentration-dependent relaxations. Notably, no differences were 
observed, providing no evidence for a contribution of Kv7 channels in the anticontractile effect of 
Urocortin during depolarization-induced precontraction (Figure 54).  
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Figure 54: Effect of Urocortin on contraction induced by various K+ blockers including or excluding XE991 in rat renal 
interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ns = p=0,26). Arteries were either preincubated with 3 µM XE991 (with) or not (without) and precontracted 
with blockers for BKCa (iberiotoxin, 0.1 µM), KATP (glibenclamide, 1 µM), Kir2 (BaCl, 30 µM), Kv1 (DPO-1, 1 µM) and Kv2 and Kv4 
(stromatoxin, 0.1 µM) to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -16,06 to 
7,79). 
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Having demonstrated that Urocortin is effective in antagonizing precontraction induced by α1-
adrenoceptor antagonist Methoxamine and thus via contractile mechanisms including both [Ca2+]i 
increases as well as Ca2+ sensitization (Figure 49), we further investigated whether this process 
functionally included Kv7 channels. We started by testing Urocortin in Methoxamine-induced 
precontraction and subsequent preincubation with the pan-Kv7 blocker XE991 (3 µM), which resulted 
in concentration-dependent relaxations to Urocortin (Figure 55). 
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Figure 55: Effect of Urocortin during Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were preincubated with 3 µM XE991 and precontracted with Methoxamine to a 
similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -11,03 to 8,88). 
In parallel, Urocortin was applied in arteries precontracted with Methoxamine and subsequently 
preincubated with the Kv7.1 blocker HMR1556 (10 µM), which likewise produced concentration-
dependent relaxations (Figure 56). 
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Figure 56: Effect of Urocortin during Kv7.1 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ****p<0,0001). Arteries were preincubated with 10 µM HMR1556 and precontracted with Methoxamine 
to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -10,44 to 6,35). 
To establish whether Urocortin-induced relaxations of Methoxamine-precontracted arteries depend 
upon Kv7, we compared these relaxations in the presence or absence of XE991, demonstrating no 
difference in the dose-dependent anticontractile effect of Urocortin (Figure 57). 
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Figure 57: Effect of Urocortin with or without Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ns p=0,13). Arteries were preincubated either with or without 3 µM XE991 and precontracted with 
Methoxamine to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -7,858 to 9,455). 
A comparison of the two graphs (Figure 55 + Figure 56), adressing whether in agonist-induced 
vasocontraction, Urocortin-induced relaxations would be differently affected by blockade of either all 
Kv7 or only Kv7.1 channels specifically, revealed no difference. We thus found no evidence for a 
functionally relevant interaction of Kv7 channels with the cAMP-dependent vasodilator Urocortin in 
agonist-induced precontractions of renal resistance arteries (Figure 58). 
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Figure 58: Effect of Urocortin during Kv7.1 or Kv7 blockade on agonist-induced contraction in rat renal interlobar arteries 
Concentration-dependent relaxation to Urocortin (0.1 – 100 nM) normalized to precontraction levels (Two-way repeated-
measures ANOVA: ns p=0,16). Arteries were preincubated with either 10 µM HMR1556 or 3 µM XE991 and precontracted with 
Methoxamine to a similar percentage of maximum force (Student‘s t test: n=8; 95% confidence interval -5,30 to 12,11). 
In summary, our results demonstrate that Urocortin-induced vasorelaxation of renal interlobar arteries 
(i) is more marked in Methoxamine- than in KCl-induced precontraction, (ii) does not depend upon Kv7 
channels in depolarization-induced precontraction achieved through pharmacological blockade of 
VSMC K+ channels, and (iii) is similar in Methoxamine-induced precontraction when only Kv7.1 is 
blocked as compared to when all Kv7 are blocked. 
 
Results 
 
72 
 
3.6 Contribution of Kv7 to agonist-induced vasoconstriction in isolated perfused kidneys 
With isometric tension myography experiments indicating a role for Kv7, specifically including Kv7.1 
channels, in regulating vascular tension in short segments of renal interlobar arteries (see: Chapters 
3.2 and 3.3), our next step towards recreating the in vivo circumstances was to conduct renal perfusion 
pressure measurements in isolated perfused rat kidneys as a more integrative approach. We were thus 
able to examine Kv7 channel contribution to myogenic tone in the intact renal arterial bed. All following 
experiments were conducted during perfusion with PSS containing α1-adrenoceptor agonist 
Methoxamine (3 µM) to induce a certain degree of agonist-induced vasoconstriction, simulating 
adrenergic hormones circulating in the blood or being released from efferent intrarenal sympathetic 
nerves. 
We first investigated the effect of the pan-Kv7 blocker XE991 on the renal arterial vasculature using 
the protocol described earlier (see: Table 10). Beforehand, experiments were performed testing XE991 
(3 µM) over a longer incubation time up to 40 minutes in order to establish how long it took for XE991 
to develop its full vasoconstrictive potential. A representative recording is given to demonstrate that 
this was the case within less than 20 minutes, indicating that further prolongation of the observation 
period would reveal no additional changes in perfusion pressure (Figure 59).  
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Figure 59: Representative recording over 40 minutes application of XE991 in Methoxamine-preconstricted isolated perfused 
rat kidneys 
Values are presented as original perfusion pressure recordings subtracted by baseline pressure prior to application of 3 µM 
Methoxamine. 
When applied for 20 minutes, XE991 (3 µM) during Methoxamine-induced preconstriction caused an 
increase in renal perfusion pressure which was observed after approximately 5 minutes of application 
(Figure 60). 
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Figure 60: Effect of XE991 on perfusion pressure in Methoxamine-preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of 3 µM XE991 (XE991) (One-way repeated-measures ANOVA 
with Geisser-Greenhouse correction, followed by Dunnett's multiple comparisons test: n=7; *p<0,05; ***p<0,001; 95% 
confidence interval 0,30 to 4,95 at 5 min; 6,60 to 16,61 at 10 min; 9,11 to 22,66 at 15 min; 9,19 to 22,97 at 20 min). Values 
are presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to application of 
3 µM Methoxamine. 
Previous unpublished myography experiments had found no effect of Kv7.1 channel specific blocker 
HMR1556 on Methoxamine-induced vasoconstriction in isolated renal interlobar artery segments. For 
independent support, we conducted perfusion experiments to verify these findings on a whole-organ 
level. We found that in isolated perfused kidneys, application of HMR1556 (10 µM) for a minimum of 
20 minutes during agonist-induced precontraction did not affect perfusion pressure (Figure 61), 
confirming that HMR1556 alone has no effect on agonist-induced vasoconstriction. 
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Figure 61: Effect of HMR1556 on perfusion pressure in Methoxamine-preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of 10 µM HMR1556 (HMR1556) (One-way repeated-measures 
ANOVA with Geisser-Greenhouse correction, followed by Dunnett's multiple comparisons test: n=12; ns = not significant, 95% 
confidence interval -1,98 to 0,82 at 5 min; -1,53 to 2,31 at 10 min; -0,98 to 3,33 at 15 min; -2,51 to 2,00 at 20 min). Values are 
presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to application of 3 
µM Methoxamine. 
Earlier myography experiments had demonstrated a concentration-dependent (0.01-1 µM) 
anticontractile effect of the Kv7.1 activator R-L3 on Methoxamine-induced precontraction (see: Figure 
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26) and the ability of the Kv7.1 blocker HMR1556 to diminish these (Figure 29). Thus, we conducted 
perfusion experiments to test R-L3 using an extended type of protocol as described before (see: Table 
11) that allows superfusion of R-L3 with its antagonists HMR1556 or XE991. We started with the 
highest concentration of R-L3 used in myography experiments (1 µM) to examine its maximum effect 
on Methoxamine-induced renal arterial pressure and to study the effect of coapplication of HMR1556. 
A profound decrease in perfusion pressure reaching a plateau within 20 minutes of continuous 
application of R-L3 (1 µM) was observed which was partially reversed by HMR1556 (10 µM) during 
coapplication for 10 minutes (Figure 62). 
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Figure 62: Effect of R-L3 and HMR1556 on perfusion pressure in Methoxamine-preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of 1 µM R-L3 and additional superfusion with 10 µM HMR1556 
(HMR) (a-priori paired Student‘s t test: n=7; **p<0,01; ***p<0,001; 95% confidence interval -41,19 to -21,31 from 0-20 min; 
1,61 to 6,88 from 20-30 min; -38,10 to -15,90 from 0-30 min). Values are presented as mean ± SEM of original perfusion 
pressure recordings subtracted by baseline pressure prior to application of 3 µM Methoxamine. 
As the maximum concentration of R-L3 we used (1 µM) caused a decrease in perfusion pressure only 
partially antagonized by HMR1556, we aimed to investigate whether the effect of the minimum 
effective concentration of R-L3 could be completely reversed by HMR1556. To do so, we followed the 
same protocol, only this time starting with R-L3 at 0.1 µM and successively raising concentrations by 
0.2 µM until a distinct decrease in perfusion pressure would be recorded over 10 minutes, to then 
begin application of HMR1556. Eventually, concentrations of R-L3 used ranged from 0.3-0.9 µM (n=6; 
mean ± SEM 0.6 ± 0.08 µM). Interestingly, we observed a more marked, but still only partial reversal 
of the R-L3-induced pressure drop during coapplication of HMR1556 (Figure 63). 
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Figure 63: Effect of minimum effective concentrations of R-L3 and HMR1556 on perfusion pressure in Methoxamine-
preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of minimum effective concentrations of R-L3 (R-L3 ~0.6 µM) 
and additional superfusion with 10 µM HMR1556 (HMR) (a-priori paired Student‘s t test: n=7; *p<0,05; **p<0,01; 95% 
confidence interval -30,11 to -12,55 from 0-20 min; 3,82 to 12,59 from 20-30 min; -21,56 to -4,68 from 0-30 min). Values are 
presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to application of 3 
µM Methoxamine. 
To objectify the observed differences in concentration-dependent decreases in perfusion pressure 
induced by R-L3 and the potential of HMR1556 to antagonize these, the data presented in the two 
graphs (Figure 62 + Figure 63) were analyzed with regards to precontraction level, R-L3-induced 
pressure drop and its percentual reversal by HMR1556. We were able to display that at a similar degree 
of Methoxamine precontraction, the perfusion pressure-decreasing effect of R-L3 at minimum 
concentrations was approximately 60% of that at maximum concentration (means ± SEM -21.3 ± 3.4 
mmHg (n=6) vs. -33.9 ± 3.7 mmHg (n=7)) and the percentage of that reversed by HMR1556 was almost 
4 times higher at minimum concentrations of R-L3 (means ± SEM 42.6 ± 9.1 % (n=6) vs. 11.7 ± 3.6 % 
(n=7)) (Figure 64). 
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Figure 64: Effect of HMR1556 on fixed or minimum effective concentrations of R-L3 in Methoxamine-preconstricted isolated 
perfused rat kidneys 
(A) Perfusion pressure during Methoxamine-induced precontraction prior to application of R-L3 at fixed (1 µM) or minimum 
effective concentrations (~0.6 µM) (unpaired Student‘s t test: n=6; ns = not significant; 95% confidence interval -17,60 to 
18,93). Values are presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to 
application of 3 µM Methoxamine. (B) R-L3-induced decrease in perfusion pressure in Methoxamine-induced precontraction 
at fixed (1 µM) or minimum effective concentrations (~0.6 µM) of R-L3 (unpaired Student‘s t test: n=6; *p<0,05; 95% confidence 
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interval 1,36 to 23,72). Values are presented as mean ± SEM of original perfusion pressure recordings subtracted by perfusion 
pressure recorded prior to application of R-L3 as shown in (A). (C) Percentage of HMR1556-induced reversal of the R-L3 induced 
decrease in perfusion pressure at fixed (1 µM) or minimum effective concentrations (~0.6 µM) of R-L3 (unpaired Student‘s t 
test: n=6; *p<0,05; 95% confidence interval 9,12 to 52,70). Values are presented as mean ± SEM of original perfusion pressure 
recordings subtracted by perfusion pressure recorded prior to application of HMR1556 and normalized to R-L3-induced 
increase in perfusion pressure as shown in (B). 
Earlier myography experiments had also demonstrated effectiveness of the pan-Kv7 blocker XE991 in 
diminishing R-L3-induced vasorelaxation of Methoxamine-precontracted renal interlobar arteries (see: 
Figure 29). We therefore conducted perfusion experiments testing the effect of XE991 on R-L3-induced 
changes in perfusion pressure, again applying the minimum effective concentration of R-L3 as 
described earlier (Figure 63). In this series, concentrations of R-L3 used ranged from 0.3-1 µM (n = 6; 
mean ± SEM ~0.6 ± 0.04 µM). We observed that the pressure drop following application of R-L3 was 
again only partially reversed by coapplication of XE991 (Figure 65).  
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Figure 65: Effect of minimum effective concentrations of R-L3 and XE991 on perfusion pressure in Methoxamine-
preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of minimum effective concentrations of R-L3 (R-L3 ~0.6 µM) 
and additional superfusion with 3 µM XE991 (XE991) (a-priori paired Student‘s t test: n=6; **p<0,01; ***p<0,001; 95% 
confidence interval -33,05 to -15,52 from 0-20 min; 4,54 to 12,71 from 20-30 min; -22,82 to -8,51 from 0-30 min). Values are 
presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to application of 3 
µM Methoxamine. 
To discern any possible differences in the degree by which either HMR1556 or XE991 are able to 
antagonize perfusion pressure decreases induced by minimum effective concentrations of R-L3, the 
corresponding data (Figure 63 + Figure 65) was analyzed with regards to precontraction level, R-L3-
induced pressure drop and its percentual reversal by HMR1556 or XE991. We found no difference in 
the percentage by which HMR1556 or XE991 reversed the similarly large decrease in perfusion 
pressure caused by R-L3 in equally strong Methoxamine precontractions (Figure 66). 
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Figure 66: Effect of XE991 or HMR1556 on minimum effective concentrations of R-L3 in preconstricted isolated perfused rat 
kidneys 
(A) Perfusion pressure during Methoxamine-induced precontraction prior to application of minimum effective concentrations 
of R-L3 (~6 µM) and later 3 µM XE991 (XE991) or 10 µM HMR1556 (HMR) (unpaired Student‘s t test: n=6; ns = not significant; 
95% confidence interval -11,61 to 17,44). Values are presented as mean ± SEM of original perfusion pressure recordings 
subtracted by baseline pressure prior to application of 3 µM Methoxamine. (B) R-L3-induced decrease in perfusion pressure in 
Methoxamine-induced precontraction at minimum effective concentrations of R-L3 (~6 µM) prior to application of 3 µM XE991 
(XE991) or 10 µM HMR1556 (HMR) (unpaired Student‘s t test: n=6; ns = not significant; 95% confidence interval -7,80 to 13,71). 
Values are presented as mean ± SEM of original perfusion pressure recordings subtracted by perfusion pressure recorded prior 
to application of R-L3 as shown in (A). (C) Percentage of reversal of the R-L3 (~6 µM) induced decrease in perfusion pressure 
after application of 3 µM XE991 (XE991) or 10 µM HMR1556 (HMR) (unpaired Student‘s t test: n=6; ns = not significant; 95% 
confidence interval -32,58 to 31,81). Values are presented as mean ± SEM of original perfusion pressure recordings subtracted 
by perfusion pressure recorded prior to application of XE991 or HMR1556 and normalized to R-L3-induced increase in perfusion 
pressure as shown in (B). 
As our results show that the effect of XE991 in reversing R-L3 decreasing pressure was only partial 
when given 10 minutes to incubate (Figure 65), while XE991 may require up to 20 minutes to develop 
its full perfusion pressure-increasing effect in Methoxamine precontractions (Figure 60), we more 
extensively examined whether longer incubation times would reveal full antagonization of the 
anticontractile effect of R-L3. Subsequent experiments demonstrated that coadministration of XE991 
(3 µM) for 20 minutes after an initial 20 minute period of R-L3 incubation resulted in a return of 
perfusion pressure to a level not different than before application of R-L3 (Figure 67). Interestingly, we 
discovered that the effect of XE991 even persisted for at least 20 minutes after stopping application, 
although R-L3 was still being administered. 
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Figure 67: Effect of minimum effective concentrations of R-L3 before, during and after XE991 superfusion on perfusion 
pressure in Methoxamine-preconstricted isolated perfused rat kidneys 
Time course of perfusion pressure before and during application of minimum effective concentrations of R-L3 (R-L3 ~0.6 µM) 
and additional superfusion with 3 µM XE991 (XE991) (a-priori paired Student‘s t test: n=6; **p<0,01; ***p<0,001; ns = not 
significant; 95% confidence interval -33,05 to -15,52 from 0-20 min; 7,10 to 30,41 from 20-40 min; -14,06 to 2,00 from 0-40 
min). Values are presented as mean ± SEM of original perfusion pressure recordings subtracted by baseline pressure prior to 
application of 3 µM Methoxamine. 
In summary, our results demonstrate that renal perfusion pressure in isolated rat kidneys is increased 
by the pan-Kv7 blocker XE991, but not by the Kv7.1 specific blocker HMR1556. Furthermore, perfusion 
pressure is decreased by the Kv7.1 activator R-L3 in a concentration-dependent manner which is at 
least partially reversible by HMR1556 and fully reversible by XE991. 
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4 DISCUSSION 
4.1 Validating the isolated perfused kidney model 
The isolated perfused kidney model described earlier (see: Chapter 2.5) that was used to collect the 
data presented in Chapters 3.1 and 3.6 represents a novel approach of studying vascular reactivity in 
our laboratory. Therefore, in the following we will provide a brief discussion on the validity of the 
method and a listing of its limitations. Special focus is brought to elaborating the background of the 
viability tests performed (Figure 5 – Figure 13) and the potential confounding factors examined (Figure 
14 – Figure 18). 
4.1.1 Perfusion flow rate 
Since vascular resistance as a depiction of vascular reactivity is the relation of perfusion pressure over 
flow rate, it is necessary to reflect on those two fundamentally important parameters in our setup. 
Flow rates that have previously been used for perfusion of rat kidneys tend to vary considerably. 
Especially earlier studies used lower perfusion rates, starting at 10 ml/min 324, 325, while flow rates 
increased with sophisticated perfusion techniques towards 15-20 ml/min 326-328 and eventually 25-40 
ml/min 329-331. However, such high flow rates must be regarded as not physiological, considering that 
with an average male WISTAR rat weighing 350-400 g, its blood volume accordingly amounting to no 
more than 20-25 ml 332 and its resting cardiac output ranging from ~90-110 ml/min 333, these high flow 
rates do not correspond with the ~25% of cardiac output that RBF is typically considered to account 
for 6. This is most probably due to the lower viscosity of the perfusate compared to blood, owing mainly 
to its lack of red blood cells, which may lead to a three- to fivefold increase in the flow rate of the 
isolated kidney compared to the kidney in vivo 334. Actually, the flow rate we used for experiments (~3 
ml/min) and the maximum perfusion rate used during viability testing (~10 ml/min) more closely 
resembles values of RBF measured in vivo in ~3 month old Wistar Kyoto rats like ours, which is 2.33 
ml/min/100g animal weight 335 or 4.4-5.5 ml/min 336 for one single left kidney, though there appear to 
be considerable variations depending on the technique used. However, since we used cell-free 
perfusate, one may object that the flow rates we used appear unphysiologically low. We justify the use 
of such flow rates by the observation that these were evidently sufficient to generate perfusion 
pressures averaging ~110 mmHg (see: Figure 5 + Figure 6), which is within the physiological range of 
renal perfusion pressure in rats 316. Furthermore, taking into account that in some of the earlier kidney 
perfusion studies, such flow rates have been successfully used to study renal hemodynamics 324, 325, we 
conclude that this usage of supposedly low perfusion rates can be tolerated. With regards to the 
accuracy of perfusion pressure measurements, we made sure to rule out erroneously measuring high 
pressures at high flow rates potentially caused by the intrinsic resistance of the perfusion cannula, 
which is a major confounder in flow-rate controlled perfusion setups 337, by hand-crafting a low-
resistance glass cannula that we initially demonstrated to not produce exceedingly high perfusion 
pressures without a kidney connected to the perfusion system (see: Chapter 2.5.1). 
4.1.2 Viability tests 
During viability testing, we demonstrated that the perfused kidneys were able to adequately respond 
to three different contractile stimuli: (i) flow-induced perfusion pressure, which elicited a myogenic 
response (see: Figure 8), (ii) KCl, which resulted in depolarization-induced vasoconstriction (see: Figure 
12), and (iii) Methoxamine, which caused agonist-induced contraction (see: Figure 13).  
(i) The myogenic response is the fastest and quantitatively most influential one of the three 
mechanisms involved in renal autoregulation of blood flow 338. Thus, demonstrating an intact myogenic 
response was essential for demonstrating the functional integrity of the renal arterial vasculature in 
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our experiments. We did so by recording condiderable and reversible decreases in perfusion pressure 
following application of Ca2+-free perfusate (see: Figure 8 + Figure 9), which is a common method to 
abolish the active contractile component of vascular resistance that has previously been used in 
perfused kidneys 245. Data derived from rat hydronephrotic kidney models 339 show that active 
vasoconstriction as part of the myogenic response starts at perfusion pressures above 60 mmHg 340 
and in vivo experiments have found an especially high degree of autoregulatory efficiency at mean 
arterial pressure between 105-145 mmHg 341. This corresponds well to the range of perfusion pressure 
at which we applied Ca2+-free perfusate (~105-110 mmHg, see: Figure 8 + Figure 9). We further 
supported our evidence for an intact myogenic response by showing a strong correlation between the 
level of flow-induced pressure and the delta by which this was reduced during perfusion with Ca2+-free 
solution (Figure 10), which accords to the higher degree of autoregulatory efficiency at higher 
pressures described by Arendshorst et al. 341. Thus, we state that our perfused kidney setup is proficient 
in keeping the renal vasculature viable enough to show evidence of a properly functioning myogenic 
response. 
(ii) When extracellular NaCl is replaced with equimolar concentrations of KCl, the K+ equilibrium 
potential is shifted so that K+ currents across the membrane are inhibited, representing a strong 
depolarizing stimulus that causes activation of VOCC, Ca2+ influx and subsequent release from 
intracellular stores and eventually contraction of blood vessels, which is referred to as 
electromechanical coupling 19, 342. KCl has also been successfully used to induce contraction in isolated 
perfused organ systems 245, 343. However, to differentiate between active depolarization-induced 
contraction and contractions as part of myogenic autoregulation, flow rate had to be reduced so that 
perfusion pressure decreased as can be seen in Figure 5 (n=48; mean ± SEM 44.2 ± 0.6 mmHg). This 
was done because in order to obtain passive dynamics, it may be necessary to reduce renal perfusion 
pressure up to ~40 mmHg 340. Subsequently, we showed that all perfused kidneys responded to KCl 
with a marked increase in perfusion pressure (n=48; mean ± SEM 228.9 ± 4.4 mmHg) (see: Figure 5 + 
Figure 11). This provides clear evidence for their ability to produce active arterial vasoconstriction. We 
therefore conclude that our setup depicts kidneys that are capable to respond to electromechanical 
coupling as a mechanism of contractile stimulation.  
(iii) KCl-induced depolarization represents a strong, yet not a very physiological contractile stimulus. 
By contrast, agonist-induced contraction more closely resembles the in vivo situation, where 
vasoactive substances are freely circulating in the blood stream. We found in our experiments that 
Methoxamine, an α1-adrenoceptor agonist not taken up by sympathetic nerves 344 that has long been 
known to contract renal arteries 345, to produce sustained increases in perfusion pressure (see: Figure 
13). 
Confirmingly, by demonstrating that our isolated perfused kidney model was successful in depicting 
three different modes of active vasoconstriction, we argue that it fulfills the necessary requirements 
to serve as a valid instrument for the study of renal vascular reactivity. 
4.1.3 Comparability of kidneys from different rats 
In our experiments on Kv7 modulators, some statistical analyses required comparison of experimental 
groups of kidneys that were not taken from the same rat. Therefore, to guarantee the validity of our 
comparison, we screened for differences in viability tests including pressure-flow relationships (see: 
Figure 7) and responses to Ca2+-free (see: Figure 9) or KCl-containing PSS (see: Figure 12) between 
experimental groups. Additionally, the level of agonist-induced perfusion pressure increases recorded 
prior to application of Kv7 modulators was documented whenever comparison between experimental 
groups were conducted (Figure 64 + Figure 66). With none of these analyses revealing any differences 
in either of the parameters tested, we may safely assume that comparability is warranted.  
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4.1.4 Confounding factors 
As a benefit of performing viability tests, we were able to rule out three potential confounding factors 
we initially suspected to influence renal perfusion pressure recordings. As we found no differences in 
either pressure-flow relationships or the three above mentioned mechanisms of active 
vasoconstriction between control kidneys and those that had been (a) stored in cold PSS prior to 
starting perfusion (Figure 15), (b) treated with heparin during the preparation procedure (Figure 16) 
or (c) accidentally perfused with minor amounts of air (Figure 18), we conclude that these were not 
relevant to our subsequently conducted perfusion pressure measurements. The only parameter in 
which we noted a deviation was the initial perfusion pressure, which was higher when kidneys had 
been exposed to prolonged storage in cold PSS up to ~4 hours. This can easily be explained, since cold 
temperature represents a reversible contractile stimulus 346, which is relevant at the moment when 
the kidney is transferred from the cold PSS, but is soon eliminated by both the heating chamber and 
the perfusion with warm perfusate. However, perfusion pressures adapted within 5 minutes of 
perfusion and no variation was seen in the overall comparison of pressure-flow relationships. As it is 
known from vessel myography experiments that small resistance arteries stored in PSS at 4°C remain 
viable for up to four days with no altered sensitivity to vasodilators within the first three days 347, we 
can be sufficiently sure that the ~4 hours of cold storage our kidneys were exposed are unlikely to 
affect our perfusion pressure recordings in an undesirable fashion.  
4.1.5 Organ edema 
One possibly problematic phenomenon of our technique we had to account for was the induction of 
organ edema following long-term perfusion with colloid-free perfusates. Many isolated perfused 
kidney models use perfusate to which colloid agents are added, like dextran 324, 325, 348, bovine serum 
albumin (BSA) 326, 327, or even combinations of BSA with dextran 329, 331. We deferred from doing so, 
owing to not only simplicity reasons but also to our intention to provide similar experimental 
conditions in both vessel myography and isolated perfused kidney experiments by using similar PSS 
and thus avoid unforeseeable interactions of colloids with the K+ channels we intended to study. 
However, lack of colloid oncotic agents in the perfusate is known to cause organ edema 349. To avoid 
renal edema as a confounder that by increasing intracapsular renal pressure might interfere with 
arterial perfusion pressure measurements, the capsula fibrosa was removed during microscopic 
preparation (see: Chapter 2.5.3) so that the kidneys were able to expand their interstitial volume. 
Additionally, we show that the baseline perfusion pressure actually decreased slightly over the course 
of the experiment, whereas the contractile response to Methoxamine before and after wash-in or resp. 
wash-out of the Kv7 modulators was similar (see: Figure 14). We may thus conclude that our usage of 
colloid-free perfusate did not produce organ edema to an extent large enough to interfere with our 
experiments during the time course explored.  
4.1.6 Limitations 
Besides these majorly important factors that were all accounted for, we in the following provide a list 
of limitations to our technique that might potentially influence our results: 
Venous pressure was not monitored. Venous thrombosis may have occurred during no-flow time in 
 preparation, causing backpressure within the capillary system and producing false-high 
 perfusion pressure readouts. 
Venous pO2 / O2 saturation was not monitored. The renal parenchyma may have been hypoxic and 
 therefore secreting paracrine vasoactive substances modifying vascular tone. 
Cell-free perfusate was used. The low viscosity of cell-free PSS may have altered endothelial function 
 and influenced NO production. 
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Perfusate temperature was not monitored. Lower perfusate temperatures due to a faster passage of 
 the heating chamber at higher flow rates during pressure-flow relationships may have caused 
 temperature-induced vasoconstriction instead of a myogenic response. 
Perfusion rate was not adjusted to kidney weight. Since kidneys were not weighed before starting 
 perfusion, all kidneys were perfused with equal flow rates, which may produce varying 
 responses in differently sized kidneys.  
In summary, our isolated perfused kidney technique provides a simple and inexpensive approach of 
studying renovascular reactivity in response to pharmacological modulators in a setting adequately 
resembling the in vivo situation with flow-induced perfusion pressure initiating a myogenic response 
and circulating vasoactive substances stimulating agonist-induced vasoconstriction.  
 
4.2 Contribution of Kv7.2-5 to agonist-induced renal vasoconstriction 
Kv7 are a group of K+ channels more recently discovered to participate in vascular smooth muscle 
contractility 166. The current state of knowledge is that activation of Kv7, i.e. via pharmacological 
activators like Retigabine or R-L3, enhances K+ currents, produces membrane hyperpolarization and 
reduces the probability of voltage-dependent Ca2+ channel opening, thus diminishing vasoconstrictor 
responses. Blockade of Kv7 on the other hand, i.e. via pan-Kv7 blockers like XE991, suppresses K+ 
currents and produces membrane depolarization, thus either contracting arteries at rest or enhancing 
agonist-induced vasoconstriction 123, 183, 300. Up to date, only a small number of studies have 
investigated the role of Kv7 in renal arteries 77, 96, 107, 243, 245, 246, 255, 262, 280. In this thesis, we provide new 
evidence for a strong anticontractile effect on agonist-induced renal resistance artery vasoconstriction 
caused by Kv7.2-5 activation. 
Retigabine is an antiepileptic drug that has been demonstrated to activate K+ currents conducted by 
Kv7.2-5 249, 252, 253, 273, 274, 350, but not Kv7.1, which lacks an essential tryptophan residue required for 
activation 272, 273, 277. It causes concentration-dependent relaxations in various rat arteries, including 
aorta and mesenteric artery 243, 256, 261, coronary artery 194, 228, 232 cerebral artery 196 and skeletal muscle 
artery 229. In humans, Retigabine has been shown to implement vasorelaxation of agonist-induced 
vasoconstriction in mesenteric and visceral adipose tissue arteries 239 and placental chorionic plate 
arteries 241. Specifically in the rat renal vasculature, so far only one study has examined Retigabine, 
conducting isometric tension myography experiments on the main renal artery and reporting 
concentration-dependent relaxations in precontraction induced by 3 µM Methoxamine 243. Several 
other studies have produced similar results using alternative Kv7.2-5 activators like flupirtine, S-1, 
ML213 or BMS204352 77, 96, 243, 246, 262. Thus, this thesis is the first report to confirm an anticontractile 
effect of Retigabine in rat renal resistance arteries, as we demonstrate similar concentration-
dependent vasorelaxation in Methoxamine precontractions (Figure 19 + Figure 20).  
In renal VSMCs, relative expression analyses of the pore-forming KCNQ mRNA in qPCR experiments 
have found predominance of KCNQ1, with KCNQ4 and KCNQ5 being readily, KCNQ3 more sporadically 
and KCNQ2 not at all expressed 96, 243, 244. Immunodetection has confirmed protein expression for Kv7.1, 
Kv7.4 and Kv7.5 channels 96 in the main renal artery. Pharmacologically, EC50 values of Retigabine for 
Kv7 activation in heterologous expression systems have been reported to be around ~1.4 µM 249, ~5.2 
µM 273 or ~5.9 µM 274 for Kv7.4 and around ~3.45 µM 274 or ~6.4 µM 252 for Kv7.5. Therefore, we conclude 
that the concentration-dependent (0.3-30 µM) Retigabine-induced relaxations of renal interlobar 
arteries we observed (Figure 19 – Figure 25) are mainly due to opening of Kv7.4 and Kv7.5, although an 
involvement of Kv7.3 cannot be entirely ruled out. More exact functional differentiation of which 
specific channel contributes most to Retigabine-induced relaxations is currently difficult, as single 
subunits-specific activators or blockers for Kv7.2-5 are not available. Instead, it is possible to inhibit 
expression of individual KCNQ subtypes, which has been achieved in main renal arteries, where a role 
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for Kv7.4 in agonist-induced contractions has been supported by demonstrating enhancement of the 
contractile effect of Methoxamine after Kv7.4 knockout with either morpholinos 262 or siRNA 96. 
Alternatively, the combination of Retigabine with specific Kv7.1 or unspecific pan-Kv7 blockers is an 
approach allowing further insight in Kv7 function. 
By doing so, we were able to demonstrate that an involvement of Kv7.1 in the anticontractile effect of 
Retigabine is unlikely, as we found the Kv7.1-specific blocker HMR1556 (10 µM) unable to diminish 
Retigabine-induced concentration-dependent relaxations, while the pan-Kv7 blocker XE991 was 
effective in doing so (Figure 23). This is in agreement with findings in mesenteric arteries of KCNQ1 
knockout mice, where Retigabine produced regular concentration-dependent relaxations in 
phenylephrine-preconstricted vessels 263. The only literature we found in opposition to our results, 
which was a study finding the alternative Kv7.1-specific blocker chromanol 293B (10 µM) to be effective 
in diminishing retigabine-induced relaxations in rat coronary arteries 194 does not profoundly 
undermine our findings, because chromanol 293B has been reported to have an IC50 for inhibition of 
Kv7.1 of 27 µM 269, 41 µM 270 or even 67 µM 271 and to also inhibit other K+ channels at similar 
concentrations 266-268, which in conclusion does not allow the effect of chromanol 293 to be attributed 
to Kv7.1 inhibition with enough certainty 300. 
XE991 is a cognitive enhancer that has been shown to block K+ currents through all Kv7.1-5, though 
with differential sensitivity 217, 219, 224, 249-253 and to cause vasoconstriction in various rat arteries, 
including aorta and mesenteric artery 256, 261, coronary artery 228, 232, intrapulmonary artery 226, cerebral 
artery 257, 258, and skeletal muscle artery 229, 234. In humans, XE991 has been demonstrated to increase 
both basal arterial tone and agonist-induced contraction in placental chorionic plate arteries 241 and to 
cause a tonic increase in isometric tension superimposed by phasic contractions in visceral adipose 
tissue arteries 239. Specifically in the rat renal vasculature, so far only two studies have tested XE991, 
reporting it to cause slight contractions (~17 ± 10% of KCl-induced contraction) of the main renal artery 
at 1 µM 255 or to induce dose-dependent vasoconstriction of interlobar arteries at 1-50 µM and dose-
dependent reductions in RBF in vivo at 0.1-5 µM 246. Thus, we are the first to confirm a contractile 
effect of XE991 in isolated perfused rat kidneys by demonstrating a sustained increase in perfusion 
pressure during Methoxamine-induced vasoconstriction (Figure 59 + Figure 60). 
 
Table 12: Effects of coadministration of the Kv7 blocker XE991 and the Kv7.2-5 activator Retigabine 
Source Vessel Precontraction 
Conc. 
XE991 
Conc. 
Reti 
Stronger 
effect 
Effect when 
combined 
239 
human mesenteric 
adipose tissue artery 
Phenylephrine 10 µM 10 µM XE991 contraction 
239 
human visceral 
adipose tissue artery 
Phenylephrine 10 µM 10 µM equal no dilation 
193 murine aorta Phenylephrine 10 µM 20 µM XE991 contraction 
193 murine aorta Phenylephrine 10 µM 20 µM equal no dilation 
256 rat mesenteric artery Methoxamine 10 µM 10 µM equal no dilation 
261 rat mesenteric artery U44619 30 µM 10 µM Reti dilation 
255 rat pulmonary artery 
none 
(XE991 only) 
1 µM 10 µM Reti dilation 
229 
rat gracilis muscle 
artery 
5-HT 30 µM 10 µM Reti dilation 
Conc. = concentration; Reti = Retigabine 
 
Existing data on the effect of combining pan-Kv7 blocker XE991 and Kv7.2-5 activator Retigabine is 
controversial. Intuitively, one would expect the effect of the Kv7.2-5 activator Retigabine to be 
overridden by the pan-Kv7 blocker XE991, which also blocks Kv7.1 channels. However, experiments in 
human mesenteric and visceral adipose tissue arteries 239, murine aorta 193, and rat mesenteric 256, 261, 
intrapulmonary, and skeletal muscle artery 229 using different Gq/11 coupled agonists for precontraction 
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(methoxamine, phenylephrine, serotonin, U44619 or none) have sometimes found the contractile 
effect of XE991, sometimes the anticontractile effect Retigabine to predominate or surpass the other, 
although mostly using similar concentrations of XE991 (1-30 µM) or Retigabine (10-20 µM) (see: Table 
12).  
In our experiments on Methoxamine-preconstricted renal interlobar arteries, (i) preincubation with 
XE991 (3 µM) did diminish, but not completely prevent, Retigabine-induced (0.3-30 µM) 
concentration-dependent relaxations (Figure 21 + Figure 23), while (ii) relaxations to Retigabine (30 
µM) were completely antagonized, but not surpassed by XE991 (3 or 10 µM) (Figure 25). These are the 
first findings on antagonization of XE991 and Retigabine in renal arterial vessels. Three previous reports 
have studied antagonization of other Kv7 blockers and activators in renal arteries, which also produce 
seemingly contradictory results: Two studies, both conducted on main renal arteries, report 
concentration-dependent relaxations of methoxamine-preconstricted arteries in response to Kv7.2-5 
activators Retigabine (no dosage given) or S-1 (up to 10 µM) to be completely prevented by prior pan-
Kv7 block via Linopirdine (10 µM) 96, 243. Opposingly, a study conducted on renal interlobar arteries 
reported Kv7.2-5 activator Flupirtine (1-100 µM) to cause slight relaxations even in arteries 
preconstricted with XE991 (5 µM) in the absence of other vasoconstrictors 246. Several explanations 
appear plausible for such observations: 
First, the degree of precontraction and/or the type of vasoconstrictor used may be of relevance, as 
certain data suggest modulation of Kv7 channel influence on VSM contractility by Gq/11 mediated 
activation of PKC 195, 225, 230, 257, 293, which is also a pathway involved in Ca2+ sensitization 16. According to 
our results, this is not the case in renal interlobar arteries, since we found different levels of 
Methoxamine-induced precontraction to have no differential effect on the degree of concentration-
dependent relaxations to Retigabine after preincubation with XE991 (Figure 24). In support of our 
findings is the fact that evidence for PKC involvement in Kv7 influence is either insufficient or 
contradictory when focusing on the renal vasculature: 
On the (i) cellular level, it has been suggested that Gq/11 coupled vasoconstrictors mediate VSMC 
activation by PKC-dependent inhibition of Kv7 channels. This is based mainly on two studies reporting 
Gq/11 coupled vasoconstrictor arginine vasopressin (AVP) to reduce retigabine- or flupirtine-sensitive 
K+ currents and thus cause depolarization, which could be reduced by PKC-inhibitors in VSMCs of rat 
aorta 230 and rat mesenteric artery 225. Additionally to AVP, other Gq/11 coupled vasoconstrictors 
including serotonin (5-HT) and endothelin-1 (ET-1) have been shown to suppress Retigabine-sensitive 
Kv7 currents in a manner similar to a direct PKC-inhibitor in rat cerebral artery, though without testing 
for PKC-dependency 257. Furthermore, indirect arguments in favor of an involvement of PKC have been 
made based on the inhibition of AVP-sensitive Kv currents by XE991 or linopirdine in rat aorta SMCs 230, 
the lacking additivity of AVP- and linopirdine- induced depolarization in rat mesenteric artery SMCs 225, 
the PKC-dependent inhibition of Kv7.5 currents induced by a DAG-analog in rat A7r5 aortic cells and 
the reduced extent of AVP-induced depolarization in KCNQ5 knockdown A7r5 cells 293. More direct 
proof has been provided by PKCα activation suppressing native Kv7 currents in mesenteric artery 
SMCs 195. 
On the (ii) whole-vessel level, to our knowledge no direct evidence has been presented for PKC-
dependency of Kv7-mediated regulation of vascular tone. One study examined the effect of PKC 
inhibitor calphostin in rat mesenteric arteries, finding it to be inefficient in preventing linopirdine-
induced contractions in both absence and presence of AVP (n=5), while L-type Ca2+ channel blocker 
verapamil (n=3) was effective in doing so 225. Another study did find PKC activator PMA to mimic the 
effect of XE991 in producing contractions in rat basilar arteries, but did not investigate whether XE991-
induced contractions were PKC-dependent 257. Nonetheless, indirect support for PKC involvement in 
vascular reactivity exists in the form of hypotheses based on the above described findings in VSMCs 
combined with reports of XE991 enhancing AVP-, ET-1- or phenylephrine-induced contractions in 
murine aorta 193 or rat cerebral arteries 257 as well as reports of retigabine or flupirtine diminishing 
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AVP-, ET-1, 5-HT- or phenylephrine-induced contractions in murine aorta 193 or rat cerebral arteries 258. 
Interestingly, recent evidence suggests a new mechanism of Gq/11-mediated regulation of Kv7 by 
demonstrating that long-term (> 1h) incubation of angiotensin II can decrease Kv7.4 protein expression 
without reducing KCNQ4 transcript levels via interaction with HSP90 247. 
In the (iii) renal vessels specifically, PKC-dependency of Kv7-mediated vascular reactivity has not been 
demonstrated directly. Nonetheless, various reports of methoxamine- or norepinephrine-induced 
vasoconstrictions in renal arteries being diminished by Retigabine, Flupirtine, S-1, ML213 or 
BMS204352 96, 243, 246, 262 or being enhanced by XE991 or linopirdine 77, 96, 246 as well as KCNQ4 
knockdown 96, 262 leave open the possibility of a functional relevance of this pathway. Contrarily though, 
in vivo measurements in rats found angiotensin II- and norepinephrine-induced decreases in RBF to be 
unaffected by pretreatment with flupirtine (10 µM) or XE991 (5 µM), giving no implication for a role of 
Kv7 in Gq/11 mediated renal arterial vasoconstriction 246. Concludingly, our results add to the complexity 
of the question of Gq/11 and PKC activation modulating Kv7 in renal vasoconstriction, in our case rather 
making an argument against a functional relevance of such a mechanism. Further research is needed, 
preferably directly testing the effect of PKC inhibitors in context with Kv7 modulators in renal vessels. 
Second, the size of the vessels studied may be of relevance, as different vasoconstrictive and 
vasodilative pathways tend to predominate in differently sized arteries 351, 352. In context with Ca2+ 
sensitization, PKC-mediated inhibition of myosin phosphatase (via phosphorylation of CPI-17) is the 
predominant pathway in small resistance arteries, whereas in large arteries like the aorta, it is ROCK-
mediated inhibition of myosin phosphatase (via phosphorylation of MYPT1) 351. This could help to 
explain why, in disagreement with our findings on small intrarenal resistance arteries, the 
anticontractile effect of Kv7.2-5 activators Retigabine (no concentration given) 243 or S-1 (1-10 µM) 96 
on Methoxamine precontractions was entirely abolished by preincubation with Kv7 blocker linopirdine 
(10 µM) in the main renal artery, which is a first order branch of the aorta conducting ~25% of cardiac 
output and thus one of the largest arteries in the body 6. It could be hypothesized that contractile 
pathways involving ROCK, but not PKC, may enhance the contractile effect of Kv7 blockers like XE991. 
Having elaborated above that a modulating effect of PKC on Kv7 remains yet to be established in renal 
vessels, this hypothesis could give impetus for further research on interactions of ROCK with Kv7 
channels in large vessels. 
Third, the chronological order in which Kv7 blockers or activators are applied may be important, as 
XE991 and linopirdine have been found to be state-dependent inhibitors favoring the activated subunit 
of Kv7 353 and that therefore their effect on vascular contractility depends upon VSMC Vm at the time 
of their application. A study on neuronal Kv7 demonstrated that XE991 (10 µM) had a half-inhibition 
potential for Kv7.2 of -51.6 ± 0.0 mV, producing near-complete inhibition when applied at potentials 
more positive than -30 mV, but having no effect in cells held at -70 mV (Greene et al., 2017). Similar 
results were found for linopirdine. Thus, XE991 and linopirdine preferentially inhibit Kv7.2 at Vm more 
depolarized than their activation threshold. This goes in line with the observation in blood vessels that 
for Kv7 blockers to develop a vasoconstrictive potential, there seems to be a need for a depolarizing 
stimulus like low concentrations of vasoconstrictors or perfusion pressure, as has been suggested 166 
based on data showing variable effects of pan-Kv7 blockers in mesenteric arteries 193, 225, 226. Retigabine 
(10 µM) on the other hand, in the same study on neurons, left-shifted the half-activation voltage of 
Kv7.2 by -24 mV (from ~-23 mV to -47 mV). Furthermore, Retigabine likewise left-shifted the half 
inhibition potential of XE991 for Kv7.2 by also -24 mV (from -51.6 ± 0.0 mV to -75 ± 0.6 mV) 353. 
Measurements of Vm in renal interlobar and afferent arteriolar VSMC at normal blood pressure have 
been made in hydronephrotic kidneys, reporting potentials ranging from -55 to -40 mV 118-120, 122, 129. 
Half maximum activation thresholds (V50) are somewhat different between the Kv7.x subunits, ranging 
from -20 mV (Kv7.1 and Kv7.4) over -30 mV (Kv7.2) down to -40 mV (Kv7.3 and Kv7.5) 183. Thus, based on 
the assumption that results for Retigabine and XE991 on Kv7.2 activation dynamics 353 can be 
extrapolated for other Kv7 channels, we might draw three conclusions: that (i) after preincubation with 
Retigabine, XE991 already inhibits Kv7 at more hyperpolarized potentials (ergo, Retigabine enhances 
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the inhibitory potential of XE991 at less depolarized Vm), explaining why in our findings, application of 
Retigabine prior to XE991 allows XE991 to reverse Retigabine-induced interlobar artery relaxations, 
returning the force level back to Methoxamine-only control (Figure 25), while vice versa preincubation 
with XE991 is unable to fully prevent relaxations to Retigabine (Figure 21 + Figure 23); that (ii) in the 
absence of agonist-induced contraction (ergo, at a not-depolarized Vm), XE991 is unable to unfold its 
full inhibitory potential, explaining why subsequent application of Flupirtine is still able to cause 
interlobar artery vasodilation 246; and that (iii) in the presence of agonist-induced contraction (ergo, at 
more depolarized Vm), the inhibitory potential of linopirdine is greater, explaining why subsequent 
application of Retigabine is not able to cause renal artery vasodilation 96, 243. The functional relevance 
of this on a systemic level has yet to be established, as so far, the only existing in vivo data showed no 
significant reduction in RBF when XE991 was administered after flupirtine-pretreatment 246. 
Furthermore, in order to make a valid statement on this matter, further research is required on Kv7 
activator and inhibitor dynamics with regards to specific Kv7.x subunits.  
Finally, differential sensitivity to XE991 among different KCNQ subunits could play a role in its 
incomplete antagonization of Retigabine. For example, the proposed existence of homomeric Kv7.5, 
which would require much higher doses of XE991 to be blocked, could be of help explaining this 
phenomenon: For homomeric Kv7.5 channels, the half maximal inhibitory concentration (IC50) of XE991 
has been reported to range from 61 µM 253 or ~65 μM 251 up to ~ 75 µM 252. Meanwhile, the half 
maximal effective concentration (EC50) for Kv7.5 activation by Retigabine is reported to be one order 
of magnitude lower, ranging from 2.0 µM 253 or 3.45 µM 274 to 6.4 µM 252. Studies testing antagonization 
of XE991 and Retigabine always used concentrations of Retigabine sufficiently high for Kv7.5 activation, 
as did we (0.3-30 µM), but XE991 is mostly used at only 1-10 µM 193, 226, 239, 256 or seldomly 30 µM 229, 
245, which is not enough to extensively block homomeric Kv7.5 channels. Thus, coapplication of XE991 
and Retigabine at such concentrations may result in Retigabine activating all Kv7.2-5, but XE991 only 
blocking Kv7.1-4, which would sum up to a net Kv7.5 activation and thus explain a net anticontractile 
effect, as we found it in renal resistance arteries (Figure 21 + Figure 23) and as previous studies have 
done in various other vessels 229, 255, 261. What might make this argumentation prone to error though, 
is the circumstance that drug potency may be underestimated, depending on the expression systems 
they are studied in 248, 354. Still, as this applies to not only Kv7.5, but all Kv7 equally, the fact that for the 
remaining Kv7.1-4, IC50 values are reported to be at least one order of magnitude lower while being 
studied in the same expression systems 217, 219, 249, 250, does validate the above hypothesis. Provided that 
homomeric Kv7.5 do exist in the vasculature, this hypothesis may further be supported by the 
observation that XE991 at 50 µM produced 3.5 times larger increases in isometric tension of rat renal 
interlobar arteries than at 5 µM 246. Opposingly though, studies on the functional assembly of KCNQ 
subunits as ion channel complexes have tended to find Kv7.4/ Kv7.5 heteromers rather than Kv7.4 or 
Kv7.5 homomers, at least in cerebral  196 and mesenteric 195, 242 artery myocytes. However, this does not 
rule out the existence of homomeric Kv7.5 channels in renal arteries, though possibly making it less 
likely. Besides homomeric Kv7.5 channels, another possibility would be a functional role for 
heteromeric Kv7.1/Kv7.5 channels. Their existence in VSMCs has early been suggested based on 
bimodal effects of Retigabine in murine portal vein myocytes 238. More recently, colocalization of Kv7.1 
and Kv7.5 subunits has been confirmed morphologically via coimmunoprecipitation in rat aortic 
myocytes and further indirect support has been provided for functional Kv7.1/Kv7.5 heteromeric 
channels by demonstrating that when expressed in Xenopus oocytes, these were found to be similarly 
activated by Retigabine as Kv7.5 homomers 194. The possibility of functionally relevant Kv7.1/Kv7.5 
heteromers has also been suggested as an explanation for relaxations induced by both Retigabine and 
R-L3 being more marked in myocytes isolated from the left coronary artery (LCA) than from the right 
coronary artery (RCA) with expression of Kv7.1 and Kv7.5, but not Kv7.4, being higher in LCA than in RCA 
myocytes 232. Unfortunately, no data is available on the sensitivity of Kv7.1/Kv7.5 heteromers to XE991. 
In case Kv7.1/Kv7.5 heteromers were to require an IC50 of XE991 close to that for Kv7.5 homomers (61-
70 µM, see above), their existence in renal arteries would be similarly able to explain the 
predominating effect of Retigabine over XE991. Concludingly, further research is needed on the 
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pharmacology of Kv7.1/Kv7.5 heteromeric channels in vascular smooth muscle. Also, morphological 
studies on Kv7 expression and distribution in renal arteries is required, specifically including testing for 
the existence of both homomeric Kv7.5 and heteromeric Kv7.1/Kv7.5 channels. 
For the sake of completeness, it must be noted that data exists suggesting unspecific effects of 
Retigabine at higher concentrations, leading to relaxations mediated by mechanisms other than K+ 
channel activation. This has been documented in form of an anticontractile effect of Retigabine on KCl-
induced precontractions in rat pulmonary arteries 255 and rat skeletal muscle arteries 229. However, this 
phenomenon was observed at concentration of 100 µM Retigabine 229, 255 and js therefore unlikely to 
be of relevance in our experiments, in which the maximum concentration of Retigabine used was 10-
fold lower. 
Concludingly, the evidence we found in renal resistance arteries for a strong anticontractile effect of 
Kv7.2-5 activation in agonist-induced vasoconstriction may well be attributed to Kv7.5-containing 
homo- or heteromeric channels, like the already known heteromeric Kv7.4/Kv7.5, while additionally, 
we thus provide an argument for a so far unappreciated functional relevance of homomeric Kv7.5 
channels or heteromeric Kv7.1/Kv7.5 channels. Furthermore, we argue that (i) our results provide no 
confirmation for a functional role of Kv7 modulation via a Gq/11 mediated, PKC-dependent mechanism 
and that differential responses to Kv7 modulators in our as well as in existing reports on renal vessels 
(ii) may be attributed to vessel size or (iii) may hint towards a role for the chronological order or the 
VSMC Vm at the point of time at which Kv7 modulators are applied. 
 
4.3 Contribution of Kv7.1 to agonist-induced renal vasoconstriction 
The role of Kv7.1 in vascular reactivity is so far incompletely understood and currently being discussed 
controversially 263, 300. Although vast evidence exists for the expression of KCNQ1 in various rodent 
blood vessels 96, 166, 193, 208, 223, 225-234, 236-238, 243-245, 255, 256, 258-260, 279 and also for Kv7.1 channel protein 
presence in VSMC membranes 96, 193, 208, 235, 238, 240, only few reports make an argument in favor of a 
functional relevance of these channels 232, 243, 260. In this thesis, our results in both interlobar artery 
isometric tension recordings as well as isolated perfused kidney experiments may not suggest a role 
for Kv7.1 channels in maintaining resting tone of renal resistance arteries, but provide evidence for 
their functional presence and pharmacological responsiveness in agonist-induced vascular 
contractility. 
R-L3 is a benzodiazepine acting as a partial agonist of Kv7.1 that is reported to either enhance K+ 
currents with an EC50 of <1 μM 213 or to have an only small effect at 1 µM, but to cause a ~100% increase 
in Kv7.1 currents at 10 µM 260 in Xenopus oocytes. A functional role in arterial contractility has been 
demonstrated in form of concentration-dependent relaxations of agonist-induced precontraction in 
murine renal and mesenteric artery 263 as well as in rat aorta, renal, mesenteric, coronary, and 
intrapulmonary artery 232, 260, 263, 280, while other studies found R-L3 ineffective in producing relaxations 
i.e. in rat coronary or cerebral arteries 196, 228, 279. In the rat renal vasculature specifically, to date only 
one study has examined the effect of R-L3, finding concentration-dependent (0.1, 0.3 and 1.0 µM) 
relaxations in Methoxamine preconstrictions of the main renal artery 280. Additionally, a suggestion for 
a functional role of Kv7.1 has been made based on the reduced potency of Kv7.2-5 activator Retigabine 
in the main renal artery compared to mesenteric artery, where Kv7.1 abundance is comparatively 
low 243. Thus, our report is the first to confirm an anticontractile effect of R-L3 in rat renal resistance 
arteries by demonstrating concentration-dependent relaxations in Methoxamine precontractions 
(Figure 26). 
These results require careful consideration, as R-L3 has been argued to be an inappropriate tool for 
the study of Kv7.1 in mice. This was based on findings of R-L3 producing normal endothelium-
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independent relaxations in KCNQ1-knockout mice, producing relaxations in both XE991- and KCl-
induced precontractions, and the inability of either HMR1556 or XE991 to reverse R-L3 relaxations 193, 
263. On the other hand, no such results have been published in rat arteries. Nonetheless, doubts have 
been raised in rat mesenteric arteries that R-L3 indeed primarily acts via Kv7.1 opening, based on the 
observation that its anticontractile effect in phenylephrine precontractions was reduced by HMR1556 
(10 µM) in only 3 out of 6, and with a sustained effect in only in 1 out of 6 artery rings, while chromanol 
293B (10 µM) completely failed to prevent R-L3 relaxations 263. Our results may help settle such doubts 
at least for the rat renal vasculature, as we provide profound evidence for a Kv7.1-specific effect of R-
L3: adding to previous unpublished results from our laboratory having found HMR1556 (10 µM) to 
completely abolish and considerably reduce the anticontractile effect of R-L3 (at 1 or 3 µM, 
respectively) on concentration-dependent contractions to Methoxamine which are incidentally 
confirmed in our experiments on ANP and Urocortin (Figure 32 – Figure 34 and Figure 47 + Figure 48) 
do we present not only data on renal resistance arteries but also on isolated perfused rat kidneys, 
demonstrating that R-L3 in Methoxamine precontractions causes marked relaxations of renal 
resistance arteries as well as decreases in renal perfusion pressure, all of which respond to 
antagonization by both HMR1556 at 10 µM and XE991 at 3 µM (Figure 26 – Figure 29 and Figure 62 – 
Figure 67). Our data support previous reports having found HMR1556 effective in reversing R-L3 
induced relaxations in rat thoracic aorta, mesenteric and intrapulmonary arteries 260. Interestingly 
though, that study also showed considerable variations in the percentage of reversal, depending on 
the concentration of R-L3 used. HMR1556 was only able to reduce relaxations to R-L3 at 10 µM by 47.3 
± 20.6 % or 66.7 ± 33.3 %, but by 104.2 ± 5.9 % when only 3 µM R-L3 were applied. This was interpreted 
to indicate that in rat aorta and pulmonary arteries, some effects of R-L3 at concentrations above 3 
µM are not due to stimulation of Kv7.1 260. Our results are somewhat similar, although R-L3 was only 
used at concentrations no higher than 1 µM. We found the percentage by which HMR1556 reduced 
the decrease in perfusion pressure caused by R-L3 at maximum (1 µM) or minimum effective 
concentrations (~0.6 µM) to change from 42.6 ± 9.1 % to 11.7 ± 3.6 % (Figure 64). Furthermore, we 
found that HMR1556 and XE991 were equally potent in reversing R-L3 induced decreases in perfusion 
pressure after 10 minutes (Figure 66). Combining these findings with our observation that in renal 
interlobar arteries, HMR1556 and XE991 were able to entirely prevent relaxations to R-L3 at 
concentrations up to 0,1 µM, but only diminish relaxations at 0,3 µM and 1 µM (Figure 29), one may 
be drawn towards suspecting a mechanism additional to Kv7.1 activation as part of the effect of R-L3. 
However, we were able to demonstrate that prolonged application of XE991 for 20 minutes resulted 
in a complete reversal of the pressure-decreasing effect of R-L3, though failing to witness an 
overshooting contraction as should be expected due to the blockade of the remaining Kv7 subunits by 
XE991 (Figure 67). Additionally, we showed that different levels of precontraction induced by 
Methoxamine do not affect the dimension of R-L3-induced relaxations after preincubation with XE991 
(Figure 30), providing an argument against an involvement of agonist-induced Gq/11-mediated PKC 
activation modulating Kv7.1 channels (for a more elaborate discussion, see Chapter 4.2). Thus, to 
conclude with, although we cannot with absolute certainty rule out an anticontractile mechanism 
other than Kv7.1 activation contributing to the effect of R-L3, a definite conclusion to be drawn from 
our results is that R-L3 does exert at least a considerable part of its anticontractile effect via Kv7.1 
channels. We may therefore confidently state that Kv7.1 channels do play a functional role in the renal 
vasculature insofar as when they are pharmacologically activated, they are effective in counteracting 
agonist-induced renal resistance arterial vasoconstriction. 
The next question to be addressed with regards to Kv7.1 function is whether they contribute to resting 
tension or to agonist-induced vascular tone. To examine this, the effect of specific Kv7.1 blockers on 
unstimulated or stimulated vessels is of particular interest, as in the case of Kv7.1 contributing to 
resting or stimulated VSMC Vm, this blockade would result in an increase in vessel tone. 
HMR1556 is a synthetic organic experimental drug initially used for the study of the cardiac IKs 
(KCNQ1/KCNE1) current 264. HMR1556 has been reported to block native or human cloned Kv7.1 
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expressed in Xenopus oocytes at an IC50 of 0.54 µM 216 or 0.42 µM 215 respectively and that at 10 µM it 
reduces K+ currents in Kv7.1-, but not in Kv7.4- or Kv7.5-injected oocytes 96. Studies testing its effect on 
resting vessel tone, thus without vasoconstrictive agents added, have uniformly found no effect of 
HMR1556 in rat coronary 228, cerebral 196, mesenteric, intrapulmonary artery and thoracic aorta 260. 
Studies testing its effect during active contraction have similarly denied an effect of HMR1556 on either 
pressurized 245 or methoxamine- and phenylephrine-contracted mesenteric arteries 210, 263. 
Furthermore, systemic application of HMR1556 in vivo did not induce vasoconstriction in dogs 264 or 
affect heart rate, blood pressure or GFR in rats 265. An even larger number of studies have examined 
the alternative Kv7.1 blocker chromanol 293B, which in various rodent blood vessels as well as human 
mesenteric and visceral adipose tissue arteries 239 likewise failed to show any effect on either resting 
tone or agonist-induced contraction, despite oftentimes within the same study effectively inhibiting 
Kv7.1 currents 193, 224, 232, 245, 259, 263. However, no study has done so in renal vessels yet. Our report is 
therefore the first to confirm the absence of an effect of HMR1556 (10 µM) on agonist-induced 
vasoconstriction in the renal vasculature by recording unaltered perfusion pressures in isolated rat 
kidneys during application of HMR1556 applied for over 40 minutes of observation (Figure 61) 
whereas, for reference, XE991 distinctly elevated perfusion pressure under the same conditions 
(Figure 59 + Figure 60). More data in support of this argument is given by previous unpublished 
experiments from our laboratory, where no contractile effect of HMR1556 (10 µM) on concentration-
dependent contraction to Methoxamine was found, as well as by the results presented in this report, 
where the pan-Kv7 blocker XE991 was coapplied with Kv7.2-5 activator Retigabine, thus leaving only 
Kv7.1 blocked and not activated. Since we observed persistence of only slightly diminished Retigabine-
induced relaxations after preincubation with XE991 (Figure 21 + Figure 23), and found complete 
antagonization, but no surpassing of the level of pre-Retigabine precontraction when XE991 was 
applied subsequently to counteract Retigabine-induced relaxations (Figure 25), there is no sign of Kv7.1 
blockade enhancing agonist-induced contraction in renal resistance arteries. 
As to the question why Kv7.1 apparently do not contribute to setting Vm or maintain resting vessel tone 
despite being present in the VSMC membrane, an involvement of the regulatory KCNE subunits has 
been suggested. Chadha et al. 260 proposed the pore-forming Kv7.1 subunit to associate with the 
regulatory subunit KCNE4, the gene product of which has been shown to be expressed in various blood 
vessels including renal arteries 193, 208, 210 and the presence of which is known to effectively silence Kv7.1 
activity at physiological Vm 209, 355, 356. However, this theory was opposed by Jepps et al. 210, who found 
HMR1556 to have no effect on Methoxamine contractions in either KCNE4 knockdown or control 
mesenteric arteries, although this is what would be expected if Kv7.1 were the predominant binding 
partner of KCNE4. Instead, the assumption was made that KCNE4 instead interacts with Kv7.4, as these 
two proteins co-localized in mesenteric artery myocytes, and KCNE4 knockout both abolished the 
contractile effect of linopirdine on Methoxamine contractions and reduced Kv7.4 expression in the cell 
membrane 210. However, interaction of Kv7.1 with other KCNE subunits seems plausible, since KCNQ1 
may assemble with all five KCNE members 182, 184 and all five KCNE genes have been identified in either 
aorta, renal, mesenteric, femoral, carotid, basilar or cerebral arteries, with no consistent pattern 
emerging except for KCNE4 being detectable in all vessels 193, 208, 210. Such interaction of Kv7.1 with KCNE 
can have numerous consequences on both K+ currents and pharmacological sensitivity to Kv7.1 
modulators. For example, interaction with KCNE1, which corresponds to the slow delayed rectifier 
current IKs in cardiac myocytes 197, 198, may cause a right-shift of the activation threshold, enhance 
current amplitudes, slow activation and deactivation 355, decrease sensitivity to XE991 ~14-fold (Wang 
et al., 2000), decrease sensitivity to R-L3 213, 214 or increase sensitivity to HMR1556 215, 216. Oppositely, 
interaction with KCNE2 can decrease current amplitude and transform Kv7.1 into a voltage-
independent channel 205, while KCNE3 is similarly able to nearly abolish Kv7.1 gating with nearly instant 
activation, leading to constitutively open channels 207. KCNE5 again has a similar effect on Kv7.1 as 
KCNE1, right-shifting the activation threshold by 140 mV towards +40 mV and allowing currents to be 
conducted only upon strong and continued depolarization 212. Eventually, while our data may not 
directly contribute in elucidating the question of KCNE involvement in Kv7 mediated regulation of 
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vascular tone, we can still provide an argument opposing the previously made suggestion that Kv7.1 
tetramers would be expressed, but rendered non-functional by the expression of inhibitory KCNE 
auxiliary subunits, as has been stated by Haick and Byron 300 as we clearly demonstrate a functional 
role for Kv7.1 channels in renal resistance arterial contractility. Furthermore, we may point out that 
since no pharmacological modulators of KCNE are available to date, studying the effect of KCNE subunit 
knockout in context with the above mentioned Kv7 modulators displaying differential effects in 
dependence of the presence of KCNE subunits may be a promising direction for future renovascular 
research. 
In summary, we argue that although K+ currents through Kv7.1 do not appear to be contributing to 
resting vessel tone and their complex interdependence with the KCNE auxiliary subunits leaves many 
questions unanswered, Kv7.1 channels represent an interesting therapeutic target as their 
pharmacological activation by substances like R-L3 is effective and mostly tissue-specific in its 
relaxation of renal resistance arteries and in its lowering of renal perfusion pressure in a flow-
controlled perfusion setup, possibly corresponding to an in vivo effect of selectively increasing renal 
blood flow that could be beneficial in certain forms of renovascular pathology. 
 
4.4 Contribution of Kv7 to the anticontractile effect of ANP in agonist-induced renal vasoconstriction 
With Kv7.1 being functionally present in renal resistance arteries, but not contributing to resting vessel 
tone, one assumption to be drawn with regards to their physiological role is that they may be involved 
in naturally existing vasodilation pathways. Although this has been suggested for Kv7.1 in context with 
rat arterial vessels a few years back already 260, only few studies have examined the effect of cyclic 
nucleotides on Kv7.1 in vascular smooth muscle 77, 107, 196. This seems surprising, considering that the 
name for KCNQ channels is originally derived from their characteristic of being K+ channels gated by 
cyclic nucleotides. A number of studies in VSMCs have by employing non-specific Kv7 modulators 
discovered hints towards an involvement of Kv7.4 and/or Kv7.5 channels rather than Kv7.1 channels in 
various endogenous vasodilator actions that exert their effect via the cyclic nucleotides cGMP, i.e. 
natriuretic peptides 77, or cAMP, i.e. β adrenoceptor agonists, adenosine or calcitonin gene-related 
peptide 96, 97, 107, 196, 228, 259, 262, 280. In this thesis, we undertook a thorough examination of both cGMP- 
and cAMP-dependent vasodilator actions in renal resistance arteries in context with all Kv7 channels, 
specifically including Kv7.1.    
The atrial natriuretic peptide (ANP) is a hormone or paracrine factor that binds to the natriuretic 
peptide receptor A (NPR-A, also known as NPR1 or GC-A) expressed in VSMCs 319. In its activated state, 
it acts as a guanylyl cyclase (GC), generating cGMP from GTP, which in turn may either directly interact 
with Kv7 channels or exert a variety of effects via stimulation of cGMP-dependent protein kinases 
(PKG), counteracting Ca2+-dependent and/or Ca2+-sensitizing mechanisms of contraction, but not 
directly phosphorylating MLCK itself 16, 55, 319. ANP has long been known to cause renal vasodilation, 
increase RBF, glomerular filtration rate and diuresis and thus reduce arterial pressure 357, 358, but has 
only more recently been linked to cardiovascular pathology, as ANP-induced relaxations were shown 
to be impaired in animal models of diabetes 359 and arterial hypertension 77. Simultaneously, Kv7 
channels have been suggested to be involved in natriuretic peptide vasodilations 77, which to date is 
the only published data describing such a phenomenon. Therefore, this thesis is one of the first 
profound examinations of a possible interdependence of ANP and Kv7 channels with regards to their 
contribution to vascular reactivity. 
Opposite to the above-mentioned study on the main renal artery 77, our extensive analysis found no 
evidence of Kv7 channel involvement in ANP-induced vasorelaxation of renal resistance arteries. We 
report that the anticontractile effect of ANP in renal resistance arteries, as indicated by decreases in 
Methoxamine sensitivity, does not affect and vice versa is itself unimpaired by the anticontractile 
effect of both Kv7.1 activation (Figure 32) or Kv7.2-5 activation (Figure 31) as well as by the contractile 
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effect of both Kv7.1 blockade after previous Kv7.1 activation (Figure 33 + Figure 34) and of pan-Kv7 
blockade (unpublished data). Furthermore, our results demonstrating that ANP-induced 
vasorelaxation of precontracted renal interlobar arteries (i) is more marked in α1-adrenoceptor 
agonist-induced than in depolarization-induced precontraction (Figure 35 – Figure 37), (ii) does not 
depend upon Kv7 channels in depolarization-induced precontraction (Figure 38 – Figure 40), and (iii) is 
similarly marked in α1-adrenoceptor agonist-induced precontraction during blockade of either all Kv7 
or only Kv7.1 channels (Figure 41 – Figure 44) all point towards the anticontractile mechanisms of ANP 
involving either Ca2+ sensitization in a manner independent of Kv7 channels or a Ca2+ dependent 
mechanism involving K+ channels other than Kv7.  
Stott et al. 77 have proposed that ANP-evoked relaxation is driven mainly through the activation of 
vascular Kv7.4 or Kv7.5 channels based on their findings in the main renal artery that ANP-induced 
relaxations of Methoxamine precontractions were impaired by the pan-Kv7 blocker linopirdine 
(10 µM), but not by the Kv7.1-specific blocker HMR1556 (10 µM), and were likewise impaired in arteries 
from SHRs, in which Kv7.4 protein is reduced 96. However, no results were presented for confirmation 
on whether the impairment caused by linopirdine was similarly present or absent in SHR arteries. 
Neither was there any evaluation done on the signal transduction mechanisms underlying the 
phenomenologically observed interaction of ANP and the Kv7 blocker. The question remains 
unanswered whether a direct interaction between the cyclic nucleotide cAMP and the cyclic-
nucleotide gated K+ channels was in fact causing the impairment of ANP-induced relaxations or 
whether both substances might merely be independently acting upon a common intermediate 
contractile mechanism, possibly Ca2+ sensitization. Furthermore, it was not shown whether conversely, 
pharmacological Kv7 activation would enhance, or at all affect the anticontractile effect of ANP. 
Shedding some more light on these questions, a thorough pharmacological dissection of ANP in 
context with Kv7 modulators was undertaken as part of this thesis. 
By demonstrating that the decrease in Methoxamine sensitivity caused by ANP was reciprocally 
unaffected by all Kv7 modulators we used (Retigabine at 30 µM, R-L3 at 1 µM, XE991 at 3 µM and 
HMR1556 at 10 µM) (Figure 31 – Figure 34 + unpublished data) we provide strong evidence that a 
direct interaction is unlikely in renal resistance arteries. It is established that cGMP can activate PKG, 
which in turn may induce vasorelaxations by decreasing cytosolic Ca2+, by decreasing Ca2+ sensitivity, 
or by causing hyperpolarization via activation of Kv-, BKCa- or KATP-mediated outward K+ currents 55 (see: 
Chapter 1.5.2.1). Several studies have in different arteries also implicated involvement of K+ channels 
specifically in ANP-induced vasorelaxations, including Kv, KATP, or BKCa channels 74, 84, 359-361. Based on 
our findings however, we conclude that Kv7 in renal resistance arteries are not among the K+ channels 
modified by mechanisms downstream of cGMP, since neither the contractile nor the anticontractile 
effect caused by either activation of Kv7.1 or Kv7.2-5 or blockade of Kv7.1 or all Kv7 was by any means 
affected by the presence of ANP in agonist-induced contraction (Figure 31 – Figure 34).  
Instead, our results suggest that ANP further downstream acts upon Ca2+ sensitization through 
pathways independent of Kv7 channels. This hypothesis is based on three observations: First (i), ANP-
induced vasorelaxation are more marked in Methoxamine- than in KCl-induced precontractions (Figure 
35 – Figure 37). By replacing extracellular NaCl with equimolar KCl and thus changing the K+ equilibrium 
potential, all K+ currents are effectively blocked and Vm is clamped at a depolarized level, allowing to 
study contraction in an artificial setting characterized by the absence of vasoconstrictive agonist 
influence 342. An important first conclusion to be drawn here is that since ANP is effective in producing 
relaxations in the presence of KCl, at least part of its anticontractile effect must result from 
mechanisms not involving K+ channels. KCl causes contraction via MLC phosphorylation in a strictly 
Ca2+-dependent manner 362. This happens initially through a phasic contractile response due to 
depolarization-induced gating of voltage-operated Ca2+ channels 363 and calmodulin-dependent MLCK 
activation 364 and subsequently through a tonic contractile response due to phosphorylation of CPI-17 
and MYPT1 via activation of the PI3K/Rho/Rho-associated kinase (ROCK) pathway (Ca2+-induced Ca2+ 
sensitization) 365. However, KCl-induced contraction does not involve activation of PKC 92 (for review, 
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see 366). Specifically in the renal preglomerular vasculature, Rho kinase inhibition has been 
demonstrated to reduce depolarization-induced vasoconstriction, though not as effectively as agonist-
induced or pressure-induced vasoconstriction 367. By contrast, α1-adrenoceptor agonists like 
Methoxamine, besides through Rho/ROCK inhibiting MLCP and through Gq/11 activating PLC to 
generate IP3, to release Ca2+ and to activate MLCK, also exert a contractile effect via PLC/DAG-mediated 
activation of PKC 19, 368. In small resistance arteries altogether, PKC is deemed to play a predominant 
role in both the initial rising and the late tonic phase of contraction of agonist-induced contraction, 
whereas the ROCK-MYPT1-mediated Ca2+-sensitizing pathway is of a lesser significance 351, 369. 
However, specifically in the renal preglomerular vasculature, Rho kinase inhibition has been 
demonstrated to completely abolish agonist-induced vasoconstriction 367. Thus, in renal resistance 
arteries, both ROCK and PKC must be considered relevant for agonist-induced vasoconstriction and 
recognized as central components of Ca2+ sensitization, whereas depolarization-induced 
vasoconstriction only involves Rho-mediated Ca2+ sensitization (for review, see 6). Therefore, upon 
observing more marked small renal resistance artery vasorelaxations in Methoxamine precontractions 
than in KCl precontractions, we argue that ANP may exert some of its effect via PKC-dependent 
mechanisms. 
Second (ii), the more marked relaxations in Methoxamine precontractions could be explained by the 
anticontractile effect of ANP relying upon hyperpolarization, possibly as ANP enhances K+ channel 
conductance, which is suppressed in KCl-induced contractions. This hypothesis goes in line with the 
above hypothesis of ANP-induced relaxations being PKC-dependent, since PKC-mediated blockade of 
K+ channels (specifically: 4-AP sensitive delayed rectifier K+ channels  channels) has been proposed as 
a mechanism contributing to rat preglomerular artery vasoconstriction 370. If this were the case, and if 
Kv7 were among these channels enhanced by ANP, one would expect a differential effect of ANP on 
contractions induced by blockade of all K+ channels compared to blockade of all except Kv7. However, 
as we examined this in our experiments we found no such difference (Figure 38 – Figure 40), 
implicating that ANP does not cause relaxations via enhancement of K+ currents through Kv7. 
Nonetheless, other K+ channels may well be involved in ANP-induced relaxations, which may be an 
interesting question for further research. 
Finally (iii), in case the PKC-dependent Ca2+ sensitizing mechanisms activated by Methoxamine were to 
enable specifically Kv7.4 or Kv7.5, but not Kv7.1 to counteract ANP-induced relaxations (as indicated by 
the results of Stott et al. 77 for the main renal artery), one would expect to find a differential effect of 
ANP in Methoxamine-precontractions after preincubation with Kv7.1 specific blocker HMR1556 as 
compared to preincubation with pan-Kv7 blocker XE991. Opposingly, our results fail to provide 
evidence for such circumstances (Figure 41 – Figure 44). We therefore argue that Kv7 do not participate 
in cGMP-mediated anticontractile mechanisms initiated by ANP, independently of whether agonist -
induced mechanisms of Ca2+ sensitization involving PKC or depolarization-induced mechanisms of Ca2+-
induced Ca2+ sensitization involving Rho/ROCK are active and contributing to tonic contraction. The 
discrepancy between our findings and Stott et al. 77 may be explained by differences in Ca2+ sensitizing 
mechanisms in differently sized vessels 351. However, as too little is known about the mechanisms by 
which ANP exerts its anticontractile effect downstream of cGMP, more research is required to 
elucidate this matter. 
In conclusion, we show that the contribution of Kv7 to renal resistance artery reactivity in response to 
vasoconstrictive α1-adrenoceptor agonists is independent of the anticontractile effect of the cGMP-
coupled vasodilator ANP. ANP may exert its effect in these vessels through modification of Ca2+ 
sensitization, which likewise does not appear to depend upon Kv7 channels. Notably, with the 
anticontractile effect of the Kv7.1 activator R-L3 and of the Kv7.2-5 activator Retigabine being 
unaffected by the presence of ANP, these two substances may be interesting candidates for future 
pharmacological studies, as they could represent a way to increase renal perfusion independently and 
additively to the endogenous vasodilator ANP. 
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4.5 Contribution of Kv7 to the anticontractile effect of Urocortin in agonist-induced renal 
vasoconstriction 
Urocortin 1 is an endogenous peptide belonging to the corticotropin-releasing factor (CRF) family that 
may act in a paracrine or autocrine fashion by binding to the CRF-R2 receptor 87, 371 expressed in 
VSMCs 372, which via coupling to different G-proteins may activate various intracellular signaling 
pathways 373 including activation of adenylyl cyclase (AC) and accumulation of cAMP 88, 322, 374 (for 
reviews, see 44, 323). In vivo application of Urocortin in rats dose-dependently reduces mean arterial 
blood pressure 322, 375-377. In humans, Urocortin has been found to produce vasodilation in both 
arteries 372, 378, 379 and veins 380. Besides vasodilation, recent studies have revealed various biological 
effects in the cardiovascular system like positive inotropy and lusitropy, cardioprotection against 
ischemia-reperfusion injury, suppression of the renin-angiotensin system or secretion of ANP, which is 
why Urocortins and CRF-R2 may be potential therapeutic effectors and targets in coronary heart 
disease, heart failure or hypertension 323, 381. No link has been made between the effect of Urocortin 
and vascular Kv7, but cAMP signaling has been recently appreciated as regulatory to Kv7 in various 
vessels 97, 196, 228, 259, 262, 280 including renal arteries 96, 107. Therefore, we as part of this thesis thoroughly 
examined Urocortin for a functional interaction with Kv7 in renal resistance arteries. 
Overall, the mechanisms of Urocortin-induced relaxations are very complex to understand, which is 
why a brief outline of its actions and interdependences in context with Kv7 shall be presented prior to 
the discussion of our results. The Urocortin-induced anticontractile effect may vary between different 
species, genders, age groups and vascular regions and may differentially involve AC or PKA activation 
as well as various signaling proteins like PKC, exchange factor directly activated by cAMP (EPAC), A-
kinase anchoring proteins (AKAPs) and several more 323. Further complicating the matter, Urocortin 
exerts its vasodilative effect not only directly through VSMCs, but also indirectly through endothelial 
cells. The endothelium-dependent dilations appear to be mediated by NO activating Ca2+-dependent 
or Ba2+-sensitive K+ channels in a cGMP-dependent manner, as was shown in rat coronary arteries 382 
and human internal mammary arteries 379. For this reason, endothelium removal (in our case achieved 
chemically with nitric oxide synthase inhibitor L-NNA) is essential to ensure validity of results in 
myography experiments. It may furthermore be noted that Urocortin-induced endothelium-
dependent NO-mediated relaxations are a phenomenon observed in female, but not in male rats 383. 
Mediators of the endothelium-independent anticontractile effect of Urocortin that have been 
identified in rat renal arteries include cAMP, cyclic adenosine diphosphate ribose (cADPR), BKCa and 
RyR in female rats, though not in male rats 383, 384. In other vessels, the structures and mechanisms 
employed in Urocortin-induced relaxations include K+ channels like BKCa 88, 379, 385 or Kir 386 and most 
notably, the decreasing of Ca2+ sensitivity in a cAMP/PKA-dependent manner 44, 49, 50, 387. More 
specifically, it has been shown that in tail arteries, Urocortin causes relaxations (i) with higher potency 
in KCl- than in agonist-induced precontraction purely through Ca2+ desensitization and not by 
decreasing Ca2+ itself 387, (ii) by cAMP-dependently increasing MLCP activity 50 and (iii) without affecting 
agonist-induced Ca2+ sensitization, possibly due to α-adrenoceptor mediated inhibition of cAMP 
generation 44. Clearly, the situation appears to be different in the renal vasculature, since in our 
findings, the potency of Urocortin was higher in relaxing agonist-induced than KCl-induced 
precontractions (Figure 49 – Figure 51). This is in line with the majority of reports made for other 
vascular beds 88, 385, 386, 388, 389, in all of which a connection between Urocortin-induced relaxations and 
cAMP and/or PKA has been demonstrated. However, we were unaware of specific data confirming 
Urocortin-induced cAMP elevation and PKA activation in renal resistance arteries, which represents a 
limitation to the interpretation of our findings.  
Substantial evidence exists for cAMP involvement in the regulation of vascular Kv7. Chadha et al. 96 first 
observed that cAMP elevation induced by β-adrenoceptor agonist isoproterenol (i) enhanced a robust 
Kv current sensitive to pan-Kv7 blocker linopirdine in renal artery VSMCs, (ii) induced relaxation of 
methoxamine-preconstricted renal arteries that were attenuated by linopirdine (but not by KATP 
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blocker glibenclamide or Kv1-4 blocker 4-AP), (iii) caused a smaller degree of renal artery 
vasorelaxation in KCNQ4 knockdown vessels compared to control vessels and (iv) did not produce 
relaxations at all in renal arteries from SHR, in which Kv7.4 abundance was reduced, altogether 
providing consistent evidence for Kv7.4 involvement in β-adrenoceptor responses and an impairment 
of this mechanism in hypertension. Later, the mechanisms of isoproterenol vasodilations in renal 
arteries were further defined as being (i) sensitive to PKA inhibition 107 and (ii) capable of increasing 
Kv7.4 colocalization with A-kinase anchoring protein (AKAP) 107 in a manner dependent on G-protein 
βγ subunits (Gβγ) 262.  
Interestingly, cAMP-activated pathways appear to differ between vascular beds, since in mesenteric 
arteries, cAMP-induced vasodilations (i) were sensitive not to inhibition of PKA, but of exchange 
protein directly activated by cAMP (EPAC) 107 and (ii) were unaffected by inhibition of Gβγ when 
isoproterenol was used, but were markedly attenuated when CGRP was used to cause cAMP 
elevation 262. In other vascular beds, various studies have identified vasodilators acting through Gs -
protein coupled elevation of intracellular cAMP or direct AC activators to cause vasorelaxations that 
are dependent on Kv7 97, 196, 227, 228, 232, 259, 262. Some of them have further specified the pore-forming 
subunits to be involved, either favoring Kv7.4 196, 262 or Kv7.5 97, 232, but thus far failed to produce 
evidence for an involvement of Kv7.1 107, 196.  
Putting this complex lot of data in context with our findings, it appears that the situation in renal 
resistance arteries may be different from what has been described for the main renal artery insofar as 
Urocortin relaxations do not appear to involve Kv7 . In our experiments, the anticontractile effect of 
Urocortin, represented by a decrease in Methoxamine sensitivity, does not affect and vice versa is 
itself unimpaired by the anticontractile effect of Kv7.2-5 activation (Figure 46) as well as by the 
contractile effect of pan-Kv7 blockade (Figure 45). Provided that Urocortin acts via cAMP, this is in 
opposition to the findings in the main renal artery, where cAMP-induced relaxations were attenuated 
by pan-Kv7 blocker linopirdine 96, 107. This points towards the existence of alternative signaling pathways 
downstream of cAMP, for which a myriad of possibilities exist, considering that cAMP may activate 
both PKA and PKG, and furthermore that PKA alone, which is supposed to be involved in the renal 
artery 107, offers a wide range of possible targets or mechanisms involved in agonist-induced 
contraction including the lowering of intracellular Ca2+and Ca2+desensitization as well as activation of 
either type of K+ channel expressed in VSM (Kv, BKCa, KATP or Kir) 55 (see: Chapter 1.5.2.2).  
Instead of Kv7 channel involvement in Urocortin-induced decreases of Methoxamine sensitivity, we 
provide evidence for Urocortin inducing Ca2+ desensitization. We demonstrated that the 
anticontractile effect of Urocortin is more marked in α1-adrenoceptor agonist- than in depolarization-
induced precontraction (Figure 49 – Figure 51). Parallel to our argumentation for ANP (see: Chapter 
4.4) the conclusions to be drawn from this are that Urocortin (i) induces relaxations at least in part via 
mechanisms independent of K+ channels, since it is effective in relaxing KCl-induced contractions; (ii) 
may exert some of its effect by counteracting PKC-dependent mechanisms of Ca2+ sensitization, since 
these are involved in Methoxamine- but not in KCl-induced contractions; and (iii) may require 
hyperpolarization by enhancing K+ current as another mechanism of relaxation, since it is less effective 
against KCl-induced contractions, in which all K+ channels are blocked. Furthermore, we show that in 
case K+ channels are responsible for the impairment of Urocortin relaxations in KCl contractions, it is 
unlikely that these channels are Kv7, as we found no difference in Urocortin relaxing renal vessels 
contracted with individual blockade of all vascular K+ channels compared to when blocking all except 
Kv7 (Figure 52 – Figure 54). Again, it must be noted that this does specifically not rule out, but rather 
suggests an involvement of K+ channels other than Kv7 to contribute in the anticontractile effect of 
Urocortin. For example, blockade of BKCa has been shown to impair Urocortin-induced 88, 379, 385 or 
cAMP-induced 106, 107 relaxations in non-renal vessels. Eventually, we demonstrate that a role for Kv7.4 
or Kv7.5, but specifically not Kv7.1 channels in cAMP-induced relaxations, as has been proposed for the 
main renal artery 107, 196, is unlikely to be functionally relevant in renal resistance arteries, since 
Urocortin-induced relaxations are similarly marked in α1-adrenoceptor agonist-induced precontraction 
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during blockade of either all Kv7 or only Kv7.1(Figure 55 – Figure 58). At this point, it must be noted as 
a minor limitation that the comparison of the effect of Urocortin in the presence or absence of Kv7 
blockade with XE991 (Figure 57) was done on vessels taken from different rats and that therefore 
ruling out the possible existence of a small effect would require confirmation of this data using a 
different protocol. Since no effect of Kv7 blockade was found in Urocortin relaxations of either agonist-
induced (PKC- and ROCK-involving) or depolarization-induced (only ROCK-involving) contractions, we 
further conclude that the activity or inactivity of PKC-dependent mechanisms of Ca2+ sensitization does 
not appear relevant to the lacking effect of Kv7. Nonetheless, it must be noted that with the 
innumerable effects Urocortin may have on VSMC signaling pathways, it is possible that some minor 
interaction with Kv7 takes place further downstream which is just too small and not functionally 
relevant enough to be detected in myography experiments. 
To conclude with, in our experiments examining Urocortin as a known cAMP elevating vasodilator, we 
demonstrate that this agent exerts its anticontractile effect in renal interlobar arteries without 
functionally employing Kv7 channels. Ca2+ desensitization may play a predominant role in Urocortin 
relaxations, specifically in counteracting PKC-dependent Ca2+ sensitization. Our results underline the 
complexity of intracellular and ion channel-dependent signaling mechanisms contributing to vascular 
reactivity even within closely related arterial beds. Remarkably, our observation that Kv7.1 activator R-
L3 and Kv7.2-5 activator Retigabine may exert their anticontractile effect on renal resistance arteries 
in a manner unaffected by the presence of Urocortin gives further impetus to the potential of these 
two drugs representing potential therapeutics able to increase renal perfusion independently and 
additively to the endogenous vasodilator Urocortin. 
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5 SUMMARY 
Vascular smooth muscle cell membranes contain potassium channels that by influencing membrane 
potential importantly contribute to the regulation of arterial tone. The KCNQ gene encodes for 5 
different K+ channel subunits forming homo- or heteromeric Kv7, which are a family of voltage-
dependent K+ channels functionally expressed in various vascular beds that can be activated by 
depolarizing stimuli and inactivated upon prolonged depolarization. 
In this thesis, the contribution of Kv7 to the regulation of renal arterial tone was studied, testing the 
hypotheses that (i) the Kv7.1-specific activator R-L3 is effective in causing reversible vasodilation of the 
entire renal arterial vasculature and that (ii) the endogenous vasodilators atrial natriuretic peptide 
(ANP) and Urocortin either attenuate or enhance the therapeutically intended vasodilatory effect of 
subunit-specific activation of Kv7.1 or Kv7.2-5 in small renal resistance arteries. Isometric wire 
myography was used to examine the contractile responses of short preglomerular resistance artery 
segments. A novel isolated perfused rat kidneys setup was introduced to investigate renal perfusion 
pressure as an indicator of arterial contractility on a whole-organ level. 
It was shown that pharmacological activation of Kv7.2-5 channels produces a strong anticontractile 
effect in agonist-induced vasoconstriction of renal resistance arteries. Specific activation of Kv7.1 was 
found to decrease sensitivity to vasoconstrictive agonists in small interlobar artery segments as well 
as to decrease perfusion pressure of intact perfused rat kidneys in a manner reversible by specific 
pharmacological Kv7.1 channel blockade. Unspecific blockade of all Kv7 was demonstrated to enhance 
arterial contractility in both isolated vessels and isolated perfused kidneys, whereas specific blockade 
of Kv7.1 was without either of these effects, indicating a contribution of homo- or heteromeric Kv7.4 
and Kv7.5, but not homomeric Kv7.1, to resting tone of the renal arterial vasculature.  
Experiments on isolated interlobar vessels displayed dose-dependent vasorelaxations in response to 
the cGMP-coupled hormone ANP and the cAMP-dependent autocrine and paracrine vasodilator 
Urocortin in both agonist-induced and depolarization-induced vasoconstriction. Further experiments 
revealed that Kv7 contribute to vascular reactivity independently of the anticontractile effect induced 
by both ANP and Urocortin.  
The results presented here confirm our first hypothesis that R-L3 is effective in causing reversible 
vasorelaxation of the entire renal arterial bed, undermining a previously unappreciated role for Kv7.1 
in regulating renal arterial contractility and renal perfusion pressure. By demonstrating the possibility 
to influence vascular tone through specific Kv7 modulators independently of both cGMP- and cAMP-
dependent endogenous vasodilators and thus negating our second hypothesis, this thesis stresses the 
importance of Kv7 as potential therapeutic targets in the treatment of renovascular pathology. 
Bibliography 
 
97 
 
6 BIBLIOGRAPHY 
1. Nelson, MT, Quayle, JM: Physiological roles and properties of potassium channels in arterial smooth 
muscle. Am J Physiol, 268: C799-822, 1995. 
2. Christensen, KL, Mulvany, MJ: Location of resistance arteries. J Vasc Res, 38: 1-12, 2001. 
3. Guyton, AC, Coleman, TG, Granger, HJ: Circulation: overall regulation. Annu Rev Physiol, 34: 13-46, 
1972. 
4. Guyton, AC, Cowley, AW, Jr., Young, DB, Coleman, TG, Hall, JE, DeClue, JW: Integration and control 
of circulatory function. Int Rev Physiol, 9: 341-385, 1976. 
5. Hall, JE: Control of blood pressure by the renin-angiotensin-aldosterone system. Clin Cardiol, 14: IV6-
21; discussion IV51-25, 1991. 
6. Carlstrom, M, Wilcox, CS, Arendshorst, WJ: Renal autoregulation in health and disease. Physiol Rev, 
95: 405-511, 2015. 
7. Gilmore, JP, Cornish, KG, Rogers, SD, Joyner, WL: Direct evidence for myogenic autoregulation of the 
renal microcirculation in the hamster. Circ Res, 47: 226-230, 1980. 
8. Navar, LG: Renal autoregulation: perspectives from whole kidney and single nephron studies. Am J 
Physiol, 234: F357-370, 1978. 
9. Moore, LC, Casellas, D: Tubuloglomerular feedback dependence of autoregulation in rat 
juxtamedullary afferent arterioles. Kidney Int, 37: 1402-1408, 1990. 
10. Pugsley, MK, Tabrizchi, R: The vascular system. An overview of structure and function. J Pharmacol 
Toxicol Methods, 44: 333-340, 2000. 
11. Khaddaj Mallat, R, Mathew John, C, Kendrick, DJ, Braun, AP: The vascular endothelium: A regulator 
of arterial tone and interface for the immune system. Crit Rev Clin Lab Sci, 54: 458-470, 2017. 
12. Majesky, MW: Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol, 36: e82-86, 2016. 
13. Sweeney, HL, Houdusse, A: Structural and functional insights into the Myosin motor mechanism. 
Annu Rev Biophys, 39: 539-557, 2010. 
14. Brozovich, FV, Nicholson, CJ, Degen, CV, Gao, YZ, Aggarwal, M, Morgan, KG: Mechanisms of 
Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth 
Muscle Disorders. Pharmacol Rev, 68: 476-532, 2016. 
15. Kordowska, J, Huang, R, Wang, CL: Phosphorylation of caldesmon during smooth muscle 
contraction and cell migration or proliferation. J Biomed Sci, 13: 159-172, 2006. 
16. Somlyo, AP, Somlyo, AV: Ca 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated 
by G proteins, kinases, and myosin phosphatase. Physiol Rev, 83: 1325-1358, 2003. 
17. Somlyo, AV, Somlyo, AP: Electromechanical and pharmacomechanical coupling in vascular smooth 
muscle. J Pharmacol Exp Ther, 159: 129-145, 1968. 
18. Schubert, R, Mulvany, MJ: The myogenic response: established facts and attractive hypotheses. 
Clin Sci (Lond), 96: 313-326, 1999. 
19. Somlyo, AP, Somlyo, AV: Signal transduction and regulation in smooth muscle. Nature, 372: 231-
236, 1994. 
20. Khalil, R, Lodge, N, Saida, K, van Breemen, C: Mechanism of calcium activation in vascular smooth 
muscle. J Hypertens Suppl, 5: S5-15, 1987. 
Bibliography 
 
98 
 
21. Adelstein, RS, Sellers, JR: Effects of calcium on vascular smooth muscle contraction. Am J Cardiol, 
59: 4b-10b, 1987. 
22. Amberg, GC, Navedo, MF: Calcium dynamics in vascular smooth muscle. Microcirculation, 20: 281-
289, 2013. 
23. Berridge, MJ: Inositol trisphosphate and calcium signalling. Nature, 361: 315-325, 1993. 
24. Wirth, A, Benyo, Z, Lukasova, M, Leutgeb, B, Wettschureck, N, Gorbey, S, Orsy, P, Horvath, B, 
Maser-Gluth, C, Greiner, E, Lemmer, B, Schutz, G, Gutkind, JS, Offermanns, S: G12-G13-LARG-
mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat 
Med, 14: 64-68, 2008. 
25. Webb, RC: Smooth muscle contraction and relaxation. Adv Physiol Educ, 27: 201-206, 2003. 
26. Cole, WC, Clement-Chomienne, O, Aiello, EA: Regulation of 4-aminopyridine-sensitive, delayed 
rectifier K+ channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol, 74: 439-
447, 1996. 
27. Brueggemann, LI, Haick, JM, Cribbs, LL, Byron, KL: Differential activation of vascular smooth muscle 
Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673. Mol Pharmacol, 86: 330-341, 
2014. 
28. Minami, K, Fukuzawa, K, Nakaya, Y: Protein kinase C inhibits the Ca(2+)-activated K+ channel of 
cultured porcine coronary artery smooth muscle cells. Biochem Biophys Res Commun, 190: 
263-269, 1993. 
29. Leo, MD, Bulley, S, Bannister, JP, Kuruvilla, KP, Narayanan, D, Jaggar, JH: Angiotensin II stimulates 
internalization and degradation of arterial myocyte plasma membrane BK channels to induce 
vasoconstriction. Am J Physiol Cell Physiol, 309: C392-402, 2015. 
30. Schubert, R, Noack, T, Serebryakov, VN: Protein kinase C reduces the KCa current of rat tail artery 
smooth muscle cells. Am J Physiol, 276: C648-658, 1999. 
31. Taguchi, K, Kaneko, K, Kubo, T: Protein kinase C modulates Ca2+-activated K+ channels in cultured 
rat mesenteric artery smooth muscle cells. Biol Pharm Bull, 23: 1450-1454, 2000. 
32. Crozatier, B: Central role of PKCs in vascular smooth muscle cell ion channel regulation. J Mol Cell 
Cardiol, 41: 952-955, 2006. 
33. Ledoux, J, Werner, ME, Brayden, JE, Nelson, MT: Calcium-activated potassium channels and the 
regulation of vascular tone. Physiology, 21: 69-78, 2006. 
34. Park, WS, Han, J, Kim, N, Youm, JB, Joo, H, Kim, HK, Ko, JH, Earm, YE: Endothelin-1 inhibits inward 
rectifier K+ channels in rabbit coronary arterial smooth muscle cells through protein kinase C. 
J Cardiovasc Pharmacol, 46: 681-689, 2005. 
35. Park, WS, Kim, N, Youm, JB, Warda, M, Ko, JH, Kim, SJ, Earm, YE, Han, J: Angiotensin II inhibits 
inward rectifier K+ channels in rabbit coronary arterial smooth muscle cells through protein 
kinase Calpha. Biochem Biophys Res Commun, 341: 728-735, 2006. 
36. Chrissobolis, S, Sobey, CG: Inhibitory effects of protein kinase C on inwardly rectifying K+- and ATP-
sensitive K+ channel-mediated responses of the basilar artery. Stroke, 33: 1692-1697, 2002. 
37. Bonev, AD, Nelson, MT: Vasoconstrictors inhibit ATP-sensitive K+ channels in arterial smooth 
muscle through protein kinase C. J Gen Physiol, 108: 315-323, 1996. 
38. Cole, WC, Malcolm, T, Walsh, MP, Light, PE: Inhibition by protein kinase C of the K(NDP) subtype 
of vascular smooth muscle ATP-sensitive potassium channel. Circ Res, 87: 112-117, 2000. 
Bibliography 
 
99 
 
39. Hayabuchi, Y, Davies, NW, Standen, NB: Angiotensin II inhibits rat arterial KATP channels by 
inhibiting steady-state protein kinase A activity and activating protein kinase Ce. J Physiol, 530: 
193-205, 2001. 
40. Quinn, KV, Cui, Y, Giblin, JP, Clapp, LH, Tinker, A: Do anionic phospholipids serve as cofactors or 
second messengers for the regulation of activity of cloned ATP-sensitive K+ channels? Circ Res, 
93: 646-655, 2003. 
41. Sampson, LJ, Davies, LM, Barrett-Jolley, R, Standen, NB, Dart, C: Angiotensin II-activated protein 
kinase C targets caveolae to inhibit aortic ATP-sensitive potassium channels. Cardiovasc Res, 
76: 61-70, 2007. 
42. Vanhoutte, PM, Verbeuren, TJ, Webb, RC: Local modulation of adrenergic neuroeffector 
interaction in the blood vessel well. Physiol Rev, 61: 151-247, 1981. 
43. Schubert, R, Lidington, D, Bolz, S: The emerging role of Ca2+ sensitivity regulation in promoting 
myogenic vasoconstriction. Cardiovasc Res, 77: 8-18, 2008. 
44. Pfitzer, G, Lubomirov, LT, Reimann, K, Gagov, H, Schubert, R: Regulation of the crossbridge cycle in 
vascular smooth muscle by cAMP signalling. J Muscle Res Cell Motil, 27: 445-454, 2006. 
45. Ringvold, HC, Khalil, RA: Protein Kinase C as Regulator of Vascular Smooth Muscle Function and 
Potential Target in Vascular Disorders. Adv Pharmacol, 78: 203-301, 2017. 
46. Puetz, S, Lubomirov, LT, Pfitzer, G: Regulation of smooth muscle contraction by small GTPases. 
Physiology, 24: 342-356, 2009. 
47. Wooldridge, AA, MacDonald, JA, Erdodi, F, Ma, C, Borman, MA, Hartshorne, DJ, Haystead, TA: 
Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 
696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J Biol Chem, 
279: 34496-34504, 2004. 
48. Nakamura, K, Koga, Y, Sakai, H, Homma, K, Ikebe, M: cGMP-dependent relaxation of smooth muscle 
is coupled with the change in the phosphorylation of myosin phosphatase. Circ Res, 101: 712-
722, 2007. 
49. Lubomirov, LT, Reimann, K, Metzler, D, Hasse, V, Stehle, R, Ito, M, Hartshorne, DJ, Gagov, H, Pfitzer, 
G, Schubert, R: Urocortin-induced decrease in Ca2+ sensitivity of contraction in mouse tail 
arteries is attributable to cAMP-dependent dephosphorylation of MYPT1 and activation of 
myosin light chain phosphatase. Circ Res, 98: 1159-1167, 2006. 
50. Lubomirov, LT, Schubert, R, Gagov, HS, Duridanova, DB, Pfitzer, G: Urocortin decreases 
phosphorylation of MYPT1 and increases the myosin phosphatase activity via elevation of the 
intracellular level of cAMP. Biofizika, 51: 773-780, 2006. 
51. Carvajal, JA, Germain, AM, Huidobro-Toro, JP, Weiner, CP: Molecular mechanism of cGMP-
mediated smooth muscle relaxation. J Cell Physiol, 184: 409-420, 2000. 
52. Moncada, S, Palmer, RM, Higgs, EA: Nitric oxide: physiology, pathophysiology, and pharmacology. 
Pharmacol Rev, 43: 109-142, 1991. 
53. Morita, T, Perrella, MA, Lee, ME, Kourembanas, S: Smooth muscle cell-derived carbon monoxide is 
a regulator of vascular cGMP. Proc Natl Acad Sci U S A, 92: 1475-1479, 1995. 
54. Maack, T: Receptors of atrial natriuretic factor. Annu Rev Physiol, 54: 11-27, 1992. 
55. Morgado, M, Cairrao, E, Santos-Silva, AJ, Verde, I: Cyclic nucleotide-dependent relaxation pathways 
in vascular smooth muscle. Cell Mol Life Sci, 69: 247-266, 2012. 
Bibliography 
 
100 
 
56. Tang, KM, Wang, GR, Lu, P, Karas, RH, Aronovitz, M, Heximer, SP, Kaltenbronn, KM, Blumer, KJ, 
Siderovski, DP, Zhu, Y, Mendelsohn, ME: Regulator of G-protein signaling-2 mediates vascular 
smooth muscle relaxation and blood pressure. Nat Med, 9: 1506-1512, 2003. 
57. Osei-Owusu, P, Sun, X, Drenan, RM, Steinberg, TH, Blumer, KJ: Regulation of RGS2 and second 
messenger signaling in vascular smooth muscle cells by cGMP-dependent protein kinase. J Biol 
Chem, 282: 31656-31665, 2007. 
58. Kobayashi, S, Kanaide, H, Nakamura, M: Cytosolic-free calcium transients in cultured vascular 
smooth muscle cells: microfluorometric measurements. Science, 229: 553-556, 1985. 
59. Rashatwar, SS, Cornwell, TL, Lincoln, TM: Effects of 8-bromo-cGMP on Ca2+ levels in vascular 
smooth muscle cells: possible regulation of Ca2+-ATPase by cGMP-dependent protein kinase. 
Proc Natl Acad Sci U S A, 84: 5685-5689, 1987. 
60. Cornwell, TL, Pryzwansky, KB, Wyatt, TA, Lincoln, TM: Regulation of sarcoplasmic reticulum protein 
phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle 
cells. Mol Pharmacol, 40: 923-931, 1991. 
61. Lincoln, TM, Cornwell, TL: Towards an understanding of the mechanism of action of cyclic AMP and 
cyclic GMP in smooth muscle relaxation. Blood vessels, 28: 129-137, 1991. 
62. Mundina-Weilenmann, C, Vittone, L, Rinaldi, G, Said, M, de Cingolani, GC, Mattiazzi, A: Endoplasmic 
reticulum contribution to the relaxant effect of cGMP- and cAMP-elevating agents in feline 
aorta. Am J Physiol Heart Circ Physiol, 278: H1856-1865, 2000. 
63. Furukawa, K, Ohshima, N, Tawada-Iwata, Y, Shigekawa, M: Cyclic GMP stimulates Na+/Ca2+ 
exchange in vascular smooth muscle cells in primary culture. J Biol Chem, 266: 12337-12341, 
1991. 
64. Furukawa, K, Tawada, Y, Shigekawa, M: Regulation of the plasma membrane Ca2+ pump by cyclic 
nucleotides in cultured vascular smooth muscle cells. J Biol Chem, 263: 8058-8065, 1988. 
65. Komalavilas, P, Lincoln, TM: Phosphorylation of the inositol 1,4,5-trisphosphate receptor. Cyclic 
GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the 
intact rat aorta. J Biol Chem, 271: 21933-21938, 1996. 
66. Komalavilas, P, Lincoln, TM: Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic 
GMP-dependent protein kinase. J Biol Chem, 269: 8701-8707, 1994. 
67. Schlossmann, J, Ammendola, A, Ashman, K, Zong, X, Huber, A, Neubauer, G, Wang, GX, Allescher, 
HD, Korth, M, Wilm, M, Hofmann, F, Ruth, P: Regulation of intracellular calcium by a signalling 
complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature, 404: 197-201, 2000. 
68. Schlossmann, J, Desch, M: IRAG and novel PKG targeting in the cardiovascular system. Am J Physiol 
Heart Circ Physiol, 301: H672-682, 2011. 
69. Keef, KD, Hume, JR, Zhong, J: Regulation of cardiac and smooth muscle Ca(2+) channels 
(Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol, 281: C1743-1756, 2001. 
70. Somlyo, AV: Cyclic GMP regulation of myosin phosphatase: a new piece for the puzzle? Circ Res, 
101: 645-647, 2007. 
71. Sauzeau, V, Le Jeune, H, Cario-Toumaniantz, C, Smolenski, A, Lohmann, SM, Bertoglio, J, Chardin, 
P, Pacaud, P, Loirand, G: Cyclic GMP-dependent protein kinase signaling pathway inhibits 
RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem, 275: 
21722-21729, 2000. 
Bibliography 
 
101 
 
72. Bonnevier, J, Arner, A: Actions downstream of cyclic GMP/protein kinase G can reverse protein 
kinase C-mediated phosphorylation of CPI-17 and Ca(2)(+) sensitization in smooth muscle. J 
Biol Chem, 279: 28998-29003, 2004. 
73. Bolz, SS, Vogel, L, Sollinger, D, Derwand, R, de Wit, C, Loirand, G, Pohl, U: Nitric oxide-induced 
decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin 
light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation, 107: 
3081-3087, 2003. 
74. Tanaka, Y, Tang, G, Takizawa, K, Otsuka, K, Eghbali, M, Song, M, Nishimaru, K, Shigenobu, K, Koike, 
K, Stefani, E: Kv channels contribute to nitric oxide- and atrial natriuretic peptide-induced 
relaxation of a rat conduit artery. J Pharmacol Exp Ther, 317: 341-354, 2006. 
75. Sathishkumar, K, Ross, RG, Bawankule, DU, Sardar, KK, Prakash, VR, Mishra, SK: Segmental 
heterogeneity in the mechanism of sodium nitroprusside-induced relaxation in ovine 
pulmonary artery. J Cardiovasc Pharmacol, 45: 491-498, 2005. 
76. Cairrao, E, Santos-Silva, AJ, Verde, I: PKG is involved in testosterone-induced vasorelaxation of 
human umbilical artery. Eur J Pharmacol, 640: 94-101, 2010. 
77. Stott, JB, Barrese, V, Jepps, TA, Leighton, EV, Greenwood, IA: Contribution of Kv7 channels to 
natriuretic peptide mediated vasodilation in normal and hypertensive rats. Hypertension, 65: 
676-682, 2014. 
78. Kubo, M, Nakaya, Y, Matsuoka, S, Saito, K, Kuroda, Y: Atrial natriuretic factor and isosorbide 
dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle 
cells. Circ Res, 74: 471-476, 1994. 
79. Miyoshi, H, Nakaya, Y, Moritoki, H: Nonendothelial-derived nitric oxide activates the ATP-sensitive 
K+ channel of vascular smooth muscle cells. FEBS Lett, 345: 47-49, 1994. 
80. Murphy, ME, Brayden, JE: Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive 
potassium channels. J Physiol, 486 ( Pt 1): 47-58, 1995. 
81. Wu, CC, Chen, SJ, Garland, CJ: NO and KATP channels underlie endotoxin-induced smooth muscle 
hyperpolarization in rat mesenteric resistance arteries. Br J Pharmacol, 142: 479-484, 2004. 
82. Barman, SA, Zhu, S, White, RE: PKC activates BKCa channels in rat pulmonary arterial smooth 
muscle via cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol, 286: L1275-
1281, 2004. 
83. Prieto, D, Rivera, L, Benedito, S, Recio, P, Villalba, N, Hernandez, M, Garcia-Sacristan, A: Ca2+-
activated K+ (KCa) channels are involved in the relaxations elicited by sildenafil in penile 
resistance arteries. Eur J Pharmacol, 531: 232-237, 2006. 
84. Otsuka, K, Tanaka, H, Horinouchi, T, Koike, K, Shigenobu, K, Tanaka, Y: Functional contribution of 
voltage-dependent and Ca2+ activated K+ (BK(Ca)) channels to the relaxation of guinea-pig 
aorta in response to natriuretic peptides. J Smooth Muscle Res, 38: 117-129, 2002. 
85. Stockand, JD, Sansom, SC: Role of large Ca(2+)-activated K+ channels in regulation of mesangial 
contraction by nitroprusside and ANP. Am J Physiol, 270: C1773-1779, 1996. 
86. Althoff, TF, Offermanns, S: G-protein-mediated signaling in vascular smooth muscle cells - 
implications for vascular disease. J Mol Med, 93: 973-981, 2015. 
87. Lovenberg, TW, Chalmers, DT, Liu, C, De Souza, EB: CRF2 alpha and CRF2 beta receptor mRNAs are 
differentially distributed between the rat central nervous system and peripheral tissues. 
Endocrinology, 136: 4139-4142, 1995. 
Bibliography 
 
102 
 
88. Schilling, L, Kanzler, C, Schmiedek, P, Ehrenreich, H: Characterization of the relaxant action of 
urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar 
artery. Br J Pharmacol, 125: 1164-1171, 1998. 
89. Barman, SA, Zhu, S, Han, G, White, RE: cAMP activates BKCa channels in pulmonary arterial smooth 
muscle via cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol, 284: L1004-
1011, 2003. 
90. Conti, MA, Adelstein, RS: The relationship between calmodulin binding and phosphorylation of 
smooth muscle myosin kinase by the catalytic subunit of 3':5' cAMP-dependent protein kinase. 
J Biol Chem, 256: 3178-3181, 1981. 
91. Rembold, CM: Regulation of contraction and relaxation in arterial smooth muscle. Hypertension, 
20: 129-137, 1992. 
92. Azam, MA, Yoshioka, K, Ohkura, S, Takuwa, N, Sugimoto, N, Sato, K, Takuwa, Y: Ca2+-independent, 
inhibitory effects of cyclic adenosine 5'-monophosphate on Ca2+ regulation of 
phosphoinositide 3-kinase C2alpha, Rho, and myosin phosphatase in vascular smooth muscle. 
J Pharmacol Exp Ther, 320: 907-916, 2007. 
93. Zieba, BJ, Artamonov, MV, Jin, L, Momotani, K, Ho, R, Franke, AS, Neppl, RL, Stevenson, AS, 
Khromov, AS, Chrzanowska-Wodnicka, M, Somlyo, AV: The cAMP-responsive Rap1 guanine 
nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of 
RhoA activity. J Biol Chem, 286: 16681-16692, 2011. 
94. Aiello, EA, Malcolm, AT, Walsh, MP, Cole, WC: Beta-adrenoceptor activation and PKA regulate 
delayed rectifier K+ channels of vascular smooth muscle cells. Am J Physiol, 275: H448-459, 
1998. 
95. Dong, H, Waldron, GJ, Cole, WC, Triggle, CR: Roles of calcium-activated and voltage-gated delayed 
rectifier potassium channels in endothelium-dependent vasorelaxation of the rabbit middle 
cerebral artery. Br J Pharmacol, 123: 821-832, 1998. 
96. Chadha, PS, Zunke, F, Zhu, HL, Davis, AJ, Jepps, TA, Olesen, SP, Cole, WC, Moffatt, JD, Greenwood, 
IA: Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies 
impaired beta-adrenoceptor-mediated relaxation of renal arteries in hypertension. 
Hypertension, 59: 877-884, 2012. 
97. Mani, BK, Robakowski, C, Brueggemann, LI, Cribbs, LL, Tripathi, A, Majetschak, M, Byron, KL: Kv7.5 
Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of 
Vascular Smooth Muscle Kv7 Currents. Mol Pharmacol, 89: 323-334, 2016. 
98. Aiello, EA, Walsh, MP, Cole, WC: Phosphorylation by protein kinase A enhances delayed rectifier 
K+ current in rabbit vascular smooth muscle cells. Am J Physiol, 268: H926-934, 1995. 
99. Berwick, ZC, Payne, GA, Lynch, B, Dick, GM, Sturek, M, Tune, JD: Contribution of adenosine A(2A) 
and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels. 
Microcirculation, 17: 600-607, 2010. 
100. Dick, GM, Bratz, IN, Borbouse, L, Payne, GA, Dincer, UD, Knudson, JD, Rogers, PA, Tune, JD: 
Voltage-dependent K+ channels regulate the duration of reactive hyperemia in the canine 
coronary circulation. Am J Physiol Heart Circ Physiol, 294: H2371-2381, 2008. 
101. Heaps, CL, Bowles, DK: Gender-specific K(+)-channel contribution to adenosine-induced 
relaxation in coronary arterioles. J Appl Physiol, 92: 550-558, 2002. 
102. Heaps, CL, Tharp, DL, Bowles, DK: Hypercholesterolemia abolishes voltage-dependent K+ channel 
contribution to adenosine-mediated relaxation in porcine coronary arterioles. Am J Physiol 
Heart Circ Physiol, 288: H568-576, 2005. 
Bibliography 
 
103 
 
103. Li, H, Chai, Q, Gutterman, DD, Liu, Y: Elevated glucose impairs cAMP-mediated dilation by reducing 
Kv channel activity in rat small coronary smooth muscle cells. Am J Physiol Heart Circ Physiol, 
285: H1213-1219, 2003. 
104. Satake, N, Shibata, M, Shibata, S: The inhibitory effects of iberiotoxin and 4-aminopyridine on the 
relaxation induced by beta 1- and beta 2-adrenoceptor activation in rat aortic rings. Br J 
Pharmacol, 119: 505-510, 1996. 
105. Zhang, Y, Pertens, E, Janssen, LJ: 8-isoprostaglandin E(2) activates Ca(2+)-dependent K(+) current 
via cyclic AMP signaling pathway in murine renal artery. Eur J Pharmacol, 520: 22-28, 2005. 
106. Roberts, OL, Kamishima, T, Barrett-Jolley, R, Quayle, JM, Dart, C: Exchange protein activated by 
cAMP (Epac) induces vascular relaxation by activating Ca2+-sensitive K+ channels in rat 
mesenteric artery. J Physiol, 591: 5107-5123, 2013. 
107. Stott, JB, Barrese, V, Greenwood, IA: Kv7 Channel Activation Underpins EPAC-Dependent 
Relaxations of Rat Arteries. Arterioscler Thromb Vasc Biol, 36: 2404-2411, 2016. 
108. Friis, UG, Jorgensen, F, Andreasen, D, Jensen, BL, Skott, O: Molecular and functional identification 
of cyclic AMP-sensitive BKCa potassium channels (ZERO variant) and L-type voltage-dependent 
calcium channels in single rat juxtaglomerular cells. Circ Res, 93: 213-220, 2003. 
109. White, R, Bottrill, FE, Siau, D, Hiley, CR: Protein kinase A-dependent and -independent effects of 
isoproterenol in rat isolated mesenteric artery: interactions with levcromakalim. J Pharmacol 
Exp Ther, 298: 917-924, 2001. 
110. Orie, NN, Thomas, AM, Perrino, BA, Tinker, A, Clapp, LH: Ca2+/calcineurin regulation of cloned 
vascular K ATP channels: crosstalk with the protein kinase A pathway. Br J Pharmacol, 157: 
554-564, 2009. 
111. Wellman, GC, Quayle, JM, Standen, NB: ATP-sensitive K+ channel activation by calcitonin gene-
related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol, 507 ( Pt 
1): 117-129, 1998. 
112. Kleppisch, T, Nelson, MT: Adenosine activates ATP-sensitive potassium channels in arterial 
myocytes via A2 receptors and cAMP-dependent protein kinase. Proc Natl Acad Sci U S A, 92: 
12441-12445, 1995. 
113. Quayle, JM, Bonev, AD, Brayden, JE, Nelson, MT: Calcitonin gene-related peptide activated ATP-
sensitive K+ currents in rabbit arterial smooth muscle via protein kinase A. J Physiol, 475: 9-13, 
1994. 
114. Miyoshi, H, Nakaya, Y: Activation of ATP-sensitive K+ channels by cyclic AMP-dependent protein 
kinase in cultured smooth muscle cells of porcine coronary artery. Biochem Biophys Res 
Commun, 193: 240-247, 1993. 
115. Son, YK, Park, WS, Ko, JH, Han, J, Kim, N, Earm, YE: Protein kinase A-dependent activation of 
inward rectifier potassium channels by adenosine in rabbit coronary smooth muscle cells. 
Biochem Biophys Res Commun, 337: 1145-1152, 2005. 
116. Park, WS, Han, J, Kim, N, Ko, JH, Kim, SJ, Earm, YE: Activation of inward rectifier K+ channels by 
hypoxia in rabbit coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol, 289: 
H2461-2467, 2005. 
117. Hirst, GD, Edwards, FR: Sympathetic neuroeffector transmission in arteries and arterioles. Physiol 
Rev, 69: 546-604, 1989. 
118. Loutzenhiser, R, Chilton, L, Trottier, G: Membrane potential measurements in renal afferent and 
efferent arterioles: actions of angiotensin II. Am J Physiol, 273: F307-314, 1997. 
Bibliography 
 
104 
 
119. Buhrle, CP, Nobiling, R, Mannek, E, Schneider, D, Hackenthal, E, Taugner, R: The afferent 
glomerular arteriole: immunocytochemical and electrophysiological investigations. J 
Cardiovasc Pharmacol, 6 Suppl 2: S383-393, 1984. 
120. Nelson, MT, Patlak, JB, Worley, JF, Standen, NB: Calcium channels, potassium channels, and 
voltage dependence of arterial smooth muscle tone. Am J Physiol, 259: C3-18, 1990. 
121. Sorensen, CM, Braunstein, TH, Holstein-Rathlou, NH, Salomonsson, M: Role of vascular potassium 
channels in the regulation of renal hemodynamics. Am J Physiol Renal Physiol, 302: F505-518, 
2012. 
122. Salomonsson, M, Brasen, JC, Sorensen, CM: Role of renal vascular potassium channels in 
physiology and pathophysiology. Acta Physiol, 221: 14-31, 2017. 
123. Tykocki, NR, Boerman, EM, Jackson, WF: Smooth Muscle Ion Channels and Regulation of Vascular 
Tone in Resistance Arteries and Arterioles. Compr Physiol, 7: 485-581, 2017. 
124. Nichols, CG, Lopatin, AN: Inward rectifier potassium channels. Annu Rev Physiol, 59: 171-191, 
1997. 
125. Quayle, JM, McCarron, JG, Brayden, JE, Nelson, MT: Inward rectifier K+ currents in smooth muscle 
cells from rat resistance-sized cerebral arteries. Am J Physiol, 265: C1363-1370, 1993. 
126. Knot, HJ, Zimmermann, PA, Nelson, MT: Extracellular K(+)-induced hyperpolarizations and 
dilatations of rat coronary and cerebral arteries involve inward rectifier K(+) channels. J Physiol, 
492 ( Pt 2): 419-430, 1996. 
127. Chilton, L, Loutzenhiser, K, Morales, E, Breaks, J, Kargacin, GJ, Loutzenhiser, R: Inward rectifier K+ 
currents and Kir2. 1 expression in renal afferent and efferent arterioles. J Am Soc Nephrol, 19: 
69-76, 2008. 
128. Chilton, L, Smirnov, SV, Loutzenhiser, K, Wang, X, Loutzenhiser, R: Segment-specific differences in 
the inward rectifier K+ current along the renal interlobular artery. Cardiovasc Res, 92: 169-177, 
2011. 
129. Chilton, L, Loutzenhiser, R: Functional evidence for an inward rectifier potassium current in rat 
renal afferent arterioles. Circ Res, 88: 152-158, 2001. 
130. Troncoso Brindeiro, CM, Fallet, RW, Lane, PH, Carmines, PK: Potassium channel contributions to 
afferent arteriolar tone in normal and diabetic rat kidney. Am J Physiol Renal Physiol, 295: 
F171-178, 2008. 
131. Kurtz, A, Hamann, M, Gotz, K: Role of potassium channels in the control of renin secretion from 
isolated perfused rat kidneys. Pflugers Arch, 440: 889-895, 2000. 
132. Magnusson, L, Sorensen, CM, Braunstein, TH, Holstein-Rathlou, NH, Salomonsson, M: 
Mechanisms of K(+) induced renal vasodilation in normo- and hypertensive rats in vivo. Acta 
Physiol, 202: 703-712, 2011. 
133. Noma, A: ATP-regulated K+ channels in cardiac muscle. Nature, 305: 147-148, 1983. 
134. Ashcroft, SJ, Ashcroft, FM: Properties and functions of ATP-sensitive K-channels. Cell Signal, 2: 
197-214, 1990. 
135. Li, L, Wu, J, Jiang, C: Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of 
various tissues in rats. J Membr Biol, 196: 61-69, 2003. 
136. Bonev, AD, Nelson, MT: ATP-sensitive potassium channels in smooth muscle cells from guinea pig 
urinary bladder. Am J Physiol, 264: C1190-1200, 1993. 
Bibliography 
 
105 
 
137. Jensen, BL, Gambaryan, S, Scholz, H, Kurtz, A: KATP channels are not essential for pressure-
dependent control of renin secretion. Pflugers Arch, 435: 670-677, 1998. 
138. Yamashita, T, Masuda, Y, Kawamura, N, Fujikura, N, Tanaka, S: Comparative study of vasodilator 
effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats. Jpn J 
Pharmacol, 68: 145-152, 1995. 
139. Uchida, W, Masuda, N, Taguchi, T, Shibasaki, K, Shirai, Y, Asano, M, Matsumoto, Y, Tsuzuki, R, 
Fujikura, T, Takenaka, T: Pharmacologic profiles of YM934, a novel potassium channel opener. 
J Cardiovasc Pharmacol, 23: 180-187, 1994. 
140. Kawata, T, Mimuro, T, Onuki, T, Tsuchiya, K, Nihei, H, Koike, T: The K(ATP) channel opener 
nicorandil: effect on renal hemodynamics in spontaneously hypertensive and Wistar Kyoto 
rats. Kidney Int Suppl, 67: S231-233, 1998. 
141. Sorensen, CM, Giese, I, Braunstein, TH, Holstein-Rathlou, NH, Salomonsson, M: Closure of 
multiple types of K+ channels is necessary to induce changes in renal vascular resistance in 
vivo in rats. Pflugers Arch, 462: 655-667, 2011. 
142. Loutzenhiser, RD, Parker, MJ: Hypoxia inhibits myogenic reactivity of renal afferent arterioles by 
activating ATP-sensitive K+ channels. Circ Res, 74: 861-869, 1994. 
143. Reslerova, M, Loutzenhiser, R: Renal microvascular actions of calcitonin gene-related peptide. Am 
J Physiol, 274: F1078-1085, 1998. 
144. Tang, L, Parker, M, Fei, Q, Loutzenhiser, R: Afferent arteriolar adenosine A2a receptors are 
coupled to KATP in in vitro perfused hydronephrotic rat kidney. Am J Physiol Renal Physiol, 
277: F926-933, 1999. 
145. Brayden, JE, Nelson, MT: Regulation of arterial tone by activation of calcium-dependent 
potassium channels. Science, 256: 532-535, 1992. 
146. Nelson, MT, Cheng, H, Rubart, M, Santana, LF, Bonev, AD, Knot, HJ, Lederer, WJ: Relaxation of 
arterial smooth muscle by calcium sparks. Science, 270: 633-637, 1995. 
147. Horrigan, FT, Cui, J, Aldrich, RW: Allosteric voltage gating of potassium channels I. Mslo ionic 
currents in the absence of Ca(2+). J Gen Physiol, 114: 277-304, 1999. 
148. Cox, DH, Cui, J, Aldrich, RW: Allosteric gating of a large conductance Ca-activated K+ channel. J 
Gen Physiol, 110: 257-281, 1997. 
149. Perez, GJ, Bonev, AD, Patlak, JB, Nelson, MT: Functional coupling of ryanodine receptors to KCa 
channels in smooth muscle cells from rat cerebral arteries. J Gen Physiol, 113: 229-238, 1999. 
150. Harraz, OF, Abd El-Rahman, RR, Bigdely-Shamloo, K, Wilson, SM, Brett, SE, Romero, M, Gonzales, 
AL, Earley, S, Vigmond, EJ, Nygren, A, Menon, BK, Mufti, RE, Watson, T, Starreveld, Y, 
Furstenhaupt, T, Muellerleile, PR, Kurjiaka, DT, Kyle, BD, Braun, AP, Welsh, DG: Ca(V)3.2 
channels and the induction of negative feedback in cerebral arteries. Circ Res, 115: 650-661, 
2014. 
151. Harraz, OF, Brett, SE, Zechariah, A, Romero, M, Puglisi, JL, Wilson, SM, Welsh, DG: Genetic ablation 
of CaV3.2 channels enhances the arterial myogenic response by modulating the RyR-BKCa axis. 
Arterioscler Thromb Vasc Biol, 35: 1843-1851, 2015. 
152. Zhao, G, Neeb, ZP, Leo, MD, Pachuau, J, Adebiyi, A, Ouyang, K, Chen, J, Jaggar, JH: Type 1 IP3 
receptors activate BKCa channels via local molecular coupling in arterial smooth muscle cells. 
J Gen Physiol, 136: 283-291, 2010. 
Bibliography 
 
106 
 
153. Yang, Y, Li, PY, Cheng, J, Cai, F, Lei, M, Tan, XQ, Li, ML, Liu, ZF, Zeng, XR: IP3 decreases coronary 
artery tone via activating the BKCa channel of coronary artery smooth muscle cells in pigs. 
Biochem Biophys Res Commun, 439: 363-368, 2013. 
154. Magnusson, L, Sorensen, CM, Braunstein, TH, Holstein-Rathlou, NH, Salomonsson, M: 
Renovascular BK(Ca) channels are not activated in vivo under resting conditions and during 
agonist stimulation. Am J Physiol Regul Integr Comp Physiol, 292: R345-353, 2007. 
155. Gebremedhin, D, Kaldunski, M, Jacobs, ER, Harder, DR, Roman, RJ: Coexistence of two types of 
Ca(2+)-activated K+ channels in rat renal arterioles. Am J Physiol, 270: F69-81, 1996. 
156. Stockand, JD, Sansom, SC: Large Ca(2+)-activated K+ channels responsive to angiotensin II in 
cultured human mesangial cells. Am J Physiol, 267: C1080-1086, 1994. 
157. Galvez, A, Gimenez-Gallego, G, Reuben, JP, Roy-Contancin, L, Feigenbaum, P, Kaczorowski, GJ, 
Garcia, ML: Purification and characterization of a unique, potent, peptidyl probe for the high 
conductance calcium-activated potassium channel from venom of the scorpion Buthus 
tamulus. J Biol Chem, 265: 11083-11090, 1990. 
158. Prior, HM, Yates, MS, Beech, DJ: Functions of large conductance Ca2+-activated (BKCa), delayed 
rectifier (KV) and background K+ channels in the control of membrane potential in rabbit renal 
arcuate artery. J Physiol Pharmacol, 511: 159-169, 1998. 
159. Fallet, RW, Bast, JP, Fujiwara, K, Ishii, N, Sansom, SC, Carmines, PK: Influence of Ca(2+)-activated 
K(+) channels on rat renal arteriolar responses to depolarizing agonists. Am J Physiol Renal 
Physiol, 280: F583-591, 2001. 
160. Sheldon, JH, Norton, NW, Argentieri, TM: Inhibition of guinea pig detrusor contraction by NS-1619 
is associated with activation of BKCa and inhibition of calcium currents. J Pharmacol Exp Ther, 
283: 1193-1200, 1997. 
161. Schubert, R, Nelson, MT: Protein kinases: tuners of the BKCa channel in smooth muscle. Trends 
Pharmacol Sci, 22: 505-512, 2001. 
162. Gutman, GA, Chandy, KG, Grissmer, S, Lazdunski, M, McKinnon, D, Pardo, LA, Robertson, GA, 
Rudy, B, Sanguinetti, MC, Stuhmer, W, Wang, X: International Union of Pharmacology. LIII. 
Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol 
Rev, 57: 473-508, 2005. 
163. Gonzalez, C, Baez-Nieto, D, Valencia, I, Oyarzun, I, Rojas, P, Naranjo, D, Latorre, R: K(+) channels: 
function-structural overview. Compr Physiol, 2: 2087-2149, 2012. 
164. Kukuljan, M, Labarca, P, Latorre, R: Molecular determinants of ion conduction and inactivation in 
K+ channels. Am J Physiol, 268: C535-556, 1995. 
165. Cox, RH: Molecular determinants of voltage-gated potassium currents in vascular smooth muscle. 
Cell Biochem Biophys, 42: 167-195, 2005. 
166. Greenwood, IA, Ohya, S: New tricks for old dogs: KCNQ expression and role in smooth muscle. Br 
J Pharmacol, 156: 1196-1203, 2009. 
167. Jackson, WF: KV channels and the regulation of vascular smooth muscle tone. Microcirculation, 
25, 2018. 
168. Hara, Y, Kitamura, K, Kuriyama, H: Actions of 4-aminopyridine on vascular smooth muscle tissues 
of the guinea-pig. Br J Pharmacol, 68: 99-106, 1980. 
169. Uchida, Y, Nakamura, F, Tomaru, T, Sumino, S, Kato, A, Sugimoto, T: Phasic contractions of canine 
and human coronary arteries induced by potassium channel blockers. Jpn Heart J, 27: 727-740, 
1986. 
Bibliography 
 
107 
 
170. Leblanc, N, Wan, X, Leung, PM: Physiological role of Ca(2+)-activated and voltage-dependent K+ 
currents in rabbit coronary myocytes. Am J Physiol, 266: C1523-1537, 1994. 
171. Gelband, CH, Ishikawa, T, Post, JM, Keef, KD, Hume, JR: Intracellular divalent cations block smooth 
muscle K+ channels. Circ Res, 73: 24-34, 1993. 
172. Knot, HJ, Nelson, MT: Regulation of membrane potential and diameter by voltage-dependent K+ 
channels in rabbit myogenic cerebral arteries. Am J Physiol, 269: H348-355, 1995. 
173. Cox, RH, Fromme, S: Comparison of Voltage Gated K(+) Currents in Arterial Myocytes with 
Heterologously Expressed K v Subunits. Cell Biochem Biophys, 74: 499-511, 2016. 
174. Cox, RH, Fromme, S: Functional Expression Profile of Voltage-Gated K(+) Channel Subunits in Rat 
Small Mesenteric Arteries. Cell Biochem Biophys, 74: 263-276, 2016. 
175. Lagrutta, A, Wang, J, Fermini, B, Salata, JJ: Novel, potent inhibitors of human Kv1.5 K+ channels 
and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther, 317: 
1054-1063, 2006. 
176. Tsvetkov, D, Tano, JY, Kassmann, M, Wang, N, Schubert, R, Gollasch, M: The Role of DPO-1 and 
XE991-Sensitive Potassium Channels in Perivascular Adipose Tissue-Mediated Regulation of 
Vascular Tone. Front Physiol, 7: 335, 2016. 
177. Escoubas, P, Diochot, S, Celerier, ML, Nakajima, T, Lazdunski, M: Novel tarantula toxins for 
subtypes of voltage-dependent potassium channels in the Kv2 and Kv4 subfamilies. Mol 
Pharmacol, 62: 48-57, 2002. 
178. Fergus, DJ, Martens, JR, England, SK: Kv channel subunits that contribute to voltage-gated K+ 
current in renal vascular smooth muscle. Pflugers Arch, 445: 697-704, 2003. 
179. Betts, LC, Kozlowski, RZ: Electrophysiological effects of endothelin-1 and their relationship to 
contraction in rat renal arterial smooth muscle. Br J Pharmacol, 130: 787-796, 2000. 
180. Gordienko, DV, Clausen, C, Goligorsky, MS: Ionic currents and endothelin signaling in smooth 
muscle cells from rat renal resistance arteries. Am J Physiol, 266: F325-341, 1994. 
181. Zou, AP, Fleming, JT, Falck, JR, Jacobs, ER, Gebremedhin, D, Harder, DR, Roman, RJ: 20-HETE is an 
endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. 
Am J Physiol, 270: R228-237, 1996. 
182. Mackie, AR, Byron, KL: Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators 
and new targets for therapeutic intervention. Mol Pharmacol, 74: 1171-1179, 2008. 
183. Barrese, V, Stott, JB, Greenwood, IA: KCNQ-Encoded Potassium Channels as Therapeutic Targets. 
Annu Rev Pharmacol Toxicol, 58: 625-648, 2018. 
184. Cooper, EC: Made for "anchorin": Kv7.2/7.3 (KCNQ2/KCNQ3) channels and the modulation of 
neuronal excitability in vertebrate axons. Semin Cell Dev Biol, 22: 185-192, 2011. 
185. Delmas, P, Brown, DA: Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev 
Neurosci, 6: 850, 2005. 
186. Hernandez, CC, Zaika, O, Tolstykh, GP, Shapiro, MS: Regulation of neural KCNQ channels: signalling 
pathways, structural motifs and functional implications. J Physiol, 586: 1811-1821, 2008. 
187. Brown, DA, Hughes, SA, Marsh, SJ, Tinker, A: Regulation of M(Kv7.2/7.3) channels in neurons by 
PIP(2) and products of PIP(2) hydrolysis: significance for receptor-mediated inhibition. J 
Physiol, 582: 917-925, 2007. 
Bibliography 
 
108 
 
188. Xu, J, Yu, W, Jan, YN, Jan, LY, Li, M: Assembly of voltage-gated potassium channels. Conserved 
hydrophilic motifs determine subfamily-specific interactions between the alpha-subunits. J 
Biol Chem, 270: 24761-24768, 1995. 
189. Long, SB, Campbell, EB, Mackinnon, R: Crystal structure of a mammalian voltage-dependent 
Shaker family K+ channel. Science, 309: 897-903, 2005. 
190. Schwake, M, Athanasiadu, D, Beimgraben, C, Blanz, J, Beck, C, Jentsch, TJ, Saftig, P, Friedrich, T: 
Structural determinants of M-type KCNQ (Kv7) K+ channel assembly. J Neurosci, 26: 3757-
3766, 2006. 
191. Howard, RJ, Clark, KA, Holton, JM, Minor, DL, Jr.: Structural insight into KCNQ (Kv7) channel 
assembly and channelopathy. Neuron, 53: 663-675, 2007. 
192. Jentsch, TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci, 
1: 21-30, 2000. 
193. Yeung, SY, Pucovský, V, Moffatt, JD, Saldanha, L, Schwake, M, Ohya, S, Greenwood, IA: Molecular 
expression and pharmacological identification of a role for K(v)7 channels in murine vascular 
reactivity. Br J Pharmacol, 151: 758-770, 2007. 
194. Oliveras, A, Roura-Ferrer, M, Sole, L, de la Cruz, A, Prieto, A, Etxebarria, A, Manils, J, Morales-
Cano, D, Condom, E, Soler, C, Cogolludo, A, Valenzuela, C, Villarroel, A, Comes, N, Felipe, A: 
Functional assembly of Kv7.1/Kv7.5 channels with emerging properties on vascular muscle 
physiology. Arterioscler Thromb Vasc Biol, 34: 1522-1530, 2014. 
195. Brueggemann, LI, Mackie, AR, Cribbs, LL, Freda, J, Tripathi, A, Majetschak, M, Byron, KL: 
Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular 
Kv7 channels. J Biol Chem, 289: 2099-2111, 2014. 
196. Chadha, PS, Jepps, TA, Carr, G, Stott, JB, Zhu, HL, Cole, WC, Greenwood, IA: Contribution of 
kv7.4/kv7.5 heteromers to intrinsic and calcitonin gene-related peptide-induced cerebral 
reactivity. Arterioscler Thromb Vasc Biol, 34: 887-893, 2014. 
197. Barhanin, J, Lesage, F, Guillemare, E, Fink, M, Lazdunski, M, Romey, G: K(V)LQT1 and lsK (minK) 
proteins associate to form the I(Ks) cardiac potassium current. Nature, 384: 78, 1996. 
198. Sanguinetti, MC, Curran, ME, Zou, A, Shen, J, Spector, PS, Atkinson, DL, Keating, MT: Coassembly 
of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature, 384: 80-
83, 1996. 
199. Jespersen, T, Grunnet, M, Olesen, SP: The KCNQ1 potassium channel: from gene to physiological 
function. Physiology, 20: 408-416, 2005. 
200. Vetter, DE, Mann, JR, Wangemann, P, Liu, J, McLaughlin, KJ, Lesage, F, Marcus, DC, Lazdunski, M, 
Heinemann, SF, Barhanin, J: Inner ear defects induced by null mutation of the isk gene. Neuron, 
17: 1251-1264, 1996. 
201. Neyroud, N, Tesson, F, Denjoy, I, Leibovici, M, Donger, C, Barhanin, J, Faure, S, Gary, F, Coumel, P, 
Petit, C, Schwartz, K, Guicheney, P: A novel mutation in the potassium channel gene KVLQT1 
causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet, 15: 186-189, 1997. 
202. Vallon, V, Grahammer, F, Volkl, H, Sandu, CD, Richter, K, Rexhepaj, R, Gerlach, U, Rong, Q, Pfeifer, 
K, Lang, F: KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad 
Sci U S A, 102: 17864-17869, 2005. 
203. Dedek, K, Waldegger, S: Colocalization of KCNQ1/KCNE channel subunits in the mouse 
gastrointestinal tract. Pflugers Arch, 442: 896-902, 2001. 
Bibliography 
 
109 
 
204. Kunzelmann, K, Bleich, M, Warth, R, Levy-Holzman, R, Garty, H, Schreiber, R: Expression and 
function of colonic epithelial KvLQT1 K+ channels. Clin Exp Pharmacol Physiol, 28: 79-83, 2001. 
205. Tinel, N, Diochot, S, Borsotto, M, Lazdunski, M, Barhanin, J: KCNE2 confers background current 
characteristics to the cardiac KCNQ1 potassium channel. Embo j, 19: 6326-6330, 2000. 
206. Roepke, TK, King, EC, Reyna-Neyra, A, Paroder, M, Purtell, K, Koba, W, Fine, E, Lerner, DJ, Carrasco, 
N, Abbott, GW: Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis. Nat 
Med, 15: 1186-1194, 2009. 
207. Schroeder, BC, Waldegger, S, Fehr, S, Bleich, M, Warth, R, Greger, R, Jentsch, TJ: A constitutively 
open potassium channel formed by KCNQ1 and KCNE3. Nature, 403: 196-199, 2000. 
208. Zhong, XZ, Harhun, MI, Olesen, SP, Ohya, S, Moffatt, JD, Cole, WC, Greenwood, IA: Participation 
of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol, 
588: 3277-3293, 2010. 
209. Grunnet, M, Jespersen, T, Rasmussen, HB, Ljungstrom, T, Jorgensen, NK, Olesen, SP, Klaerke, DA: 
KCNE4 is an inhibitory subunit to the KCNQ1 channel. J Physiol, 542: 119-130, 2002. 
210. Jepps, TA, Carr, G, Lundegaard, PR, Olesen, SP, Greenwood, IA: Fundamental role for the KCNE4 
ancillary subunit in Kv7.4 regulation of arterial tone. J Physiol, 593: 5325-5340, 2015. 
211. Abbott, GW, Jepps, TA: Kcne4 Deletion Sex-Dependently Alters Vascular Reactivity. J Vasc Res, 53: 
138-148, 2016. 
212. Angelo, K, Jespersen, T, Grunnet, M, Nielsen, MS, Klaerke, DA, Olesen, SP: KCNE5 induces time- 
and voltage-dependent modulation of the KCNQ1 current. Biophys J, 83: 1997-2006, 2002. 
213. Salata, JJ, Jurkiewicz, NK, Wang, J, Evans, BE, Orme, HT, Sanguinetti, MC: A novel benzodiazepine 
that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol, 54: 220-230, 1998. 
214. Yu, H, Lin, Z, Mattmann, ME, Zou, B, Terrenoire, C, Zhang, H, Wu, M, McManus, OB, Kass, RS, 
Lindsley, CW, Hopkins, CR, Li, M: Dynamic subunit stoichiometry confers a progressive 
continuum of pharmacological sensitivity by KCNQ potassium channels. Proc Natl Acad Sci U S 
A, 110: 8732-8737, 2013. 
215. Lerche, C, Seebohm, G, Wagner, CI, Scherer, CR, Dehmelt, L, Abitbol, I, Gerlach, U, Brendel, J, 
Attali, B, Busch, AE: Molecular impact of MinK on the enantiospecific block of I(Ks) by 
chromanols. Br J Pharmacol, 131: 1503-1506, 2000. 
216. Gogelein, H, Bruggemann, A, Gerlach, U, Brendel, J, Busch, AE: Inhibition of IKs channels by HMR 
1556. Naunyn Schmiedebergs Arch Pharmacol, 362: 480-488, 2000. 
217. Wang, HS, Brown, BS, McKinnon, D, Cohen, IS: Molecular basis for differential sensitivity of KCNQ 
and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol, 57: 1218-1223, 2000. 
218. Brown, DA, Adams, PR: Muscarinic suppression of a novel voltage-sensitive K+ current in a 
vertebrate neurone. Nature, 283: 673-676, 1980. 
219. Wang, HS, Pan, Z, Shi, W, Brown, BS, Wymore, RS, Cohen, IS, Dixon, JE, McKinnon, D: KCNQ2 and 
KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science, 282: 
1890-1893, 1998. 
220. Brown, DA, Passmore, GM: Neural KCNQ (Kv7) channels. Br J Pharmacol, 156: 1185-1195, 2009. 
221. Kubisch, C, Schroeder, BC, Friedrich, T, Lutjohann, B, El-Amraoui, A, Marlin, S, Petit, C, Jentsch, TJ: 
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in 
dominant deafness. Cell, 96: 437-446, 1999. 
Bibliography 
 
110 
 
222. Kharkovets, T, Hardelin, JP, Safieddine, S, Schweizer, M, El-Amraoui, A, Petit, C, Jentsch, TJ: 
KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear 
and the central auditory pathway. Proc Natl Acad Sci U S A, 97: 4333-4338, 2000. 
223. Ohya, S, Sergeant, GP, Greenwood, IA, Horowitz, B: Molecular variants of KCNQ channels 
expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res, 92: 1016-
1023, 2003. 
224. Yeung, SY, Greenwood, IA: Electrophysiological and functional effects of the KCNQ channel 
blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol, 146: 585-595, 2005. 
225. Mackie, AR, Brueggemann, LI, Henderson, KK, Shiels, AJ, Cribbs, LL, Scrogin, KE, Byron, KL: Vascular 
KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by 
vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements 
of mesenteric vascular resistance. J Pharm Exp Ther, 325: 475-483, 2008. 
226. Joshi, S, Balan, P, Gurney, AM: Pulmonary vasoconstrictor action of KCNQ potassium channel 
blockers. Respir Res, 7: 31, 2006. 
227. Lee, S, Yang, Y, Tanner, MA, Li, M, Hill, MA: Heterogeneity in Kv7 channel function in the cerebral 
and coronary circulation. Microcirculation, 22: 109-121, 2015. 
228. Khanamiri, S, Soltysinska, E, Jepps, TA, Bentzen, BH, Chadha, PS, Schmitt, N, Greenwood, IA, 
Olesen, SP: Contribution of Kv7 channels to basal coronary flow and active response to 
ischemia. Hypertension, 62: 1090-1097, 2013. 
229. Zavaritskaya, O, Zhuravleva, N, Schleifenbaum, J, Gloe, T, Devermann, L, Kluge, R, Mladenov, M, 
Frey, M, Gagov, H, Fesus, G, Gollasch, M, Schubert, R: Role of KCNQ channels in skeletal muscle 
arteries and periadventitial vascular dysfunction. Hypertension, 61: 151-159, 2013. 
230. Brueggemann, LI, Moran, CJ, Barakat, JA, Yeh, JZ, Cribbs, LL, Byron, KL: Vasopressin stimulates 
action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic 
smooth muscle cells. Am J Physiol Heart Circ Physiol, 292: H1352-1363, 2007. 
231. Sedivy, V, Joshi, S, Ghaly, Y, Mizera, R, Zaloudikova, M, Brennan, S, Novotna, J, Herget, J, Gurney, 
AM: Role of Kv7 channels in responses of the pulmonary circulation to hypoxia. Am J Physiol 
Lung Cell Mol Physiol, 308: L48-L57, 2015. 
232. Morales-Cano, D, Moreno, L, Barreira, B, Pandolfi, R, Chamorro, V, Jimenez, R, Villamor, E, Duarte, 
J, Perez-Vizcaino, F, Cogolludo, A: Kv7 channels critically determine coronary artery reactivity: 
left-right differences and down-regulation by hyperglycaemia. Cardiovasc Res, 106: 98-108, 
2015. 
233. Hedegaard, ER, Johnsen, J, Povlsen, JA, Jespersen, NR, Shanmuganathan, JA, Laursen, MR, 
Kristiansen, SB, Simonsen, U, Botker, HE: Inhibition of KV7 Channels Protects the Rat Heart 
against Myocardial Ischemia and Reperfusion Injury. J Pharmacol Exp Ther, 357: 94-102, 2016. 
234. Shvetsova, AA, Gaynullina, DK, Tarasova, OS, Schubert, R: Negative feedback regulation of 
vasocontraction by potassium channels in 10- to 15-day-old rats: Dominating role of Kv 7 
channels. Acta Physiol: e13176, 2018. 
235. Zimmer, J, Takahashi, T, Hofmann, AD, Puri, P: Downregulation of KCNQ5 expression in the rat 
pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia. J Pediatr Surg, 
52: 702-705, 2017. 
236. de Jong, IEM, Jepps, TA: Impaired Kv7 channel function in cerebral arteries of a tauopathy mouse 
model (rTg4510). Physiol Rep, 6: e13920, 2018. 
Bibliography 
 
111 
 
237. Jepps, TA, Olesen, SP, Greenwood, IA, Dalsgaard, T: Molecular and functional characterization of 
Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome 
rats. Br J Pharmacol, 173: 1478-1490, 2016. 
238. Yeung, SY, Schwake, M, Pucovsky, V, Greenwood, IA: Bimodal effects of the Kv7 channel activator 
retigabine on vascular K+ currents. Br J Pharmacol, 155: 62-72, 2008. 
239. Ng, FL, Davis, AJ, Jepps, TA, Harhun, MI, Yeung, SY, Wan, A, Reddy, M, Melville, D, Nardi, A, Khong, 
TK, Greenwood, IA: Expression and function of the K+ channel KCNQ genes in human arteries. 
Br J Pharmacol, 162: 42-53, 2011. 
240. Mills, TA, Greenwood, SL, Devlin, G, Shweikh, Y, Robinson, M, Cowley, E, Hayward, CE, Cottrell, 
EC, Tropea, T, Brereton, MF, Dalby-Brown, W, Wareing, M: Activation of KV7 channels 
stimulates vasodilatation of human placental chorionic plate arteries. Placenta, 36: 638-644, 
2015. 
241. Wei, X, Zhang, Y, Yin, B, Wen, J, Cheng, J, Fu, X: The expression and function of KCNQ potassium 
channels in human chorionic plate arteries from women with normal pregnancies and pre-
eclampsia. PLoS One, 13: e0192122, 2018. 
242. Brueggemann, LI, Mackie, AR, Martin, JL, Cribbs, LL, Byron, KL: Diclofenac distinguishes among 
homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. 
Mol Pharmacol, 79: 10-23, 2011. 
243. Jepps, TA, Bentzen, BH, Stott, JB, Povstyan, OV, Sivaloganathan, K, Dalby-Brown, W, Greenwood, 
IA: Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J 
Pharmacol, 171: 4413-4424, 2014. 
244. Ogiwara, K, Ohya, S, Suzuki, Y, Yamamura, H, Imaizumi, Y: Up-Regulation of the Voltage-Gated 
KV2.1 K(+) Channel in the Renal Arterial Myocytes of Dahl Salt-Sensitive Hypertensive Rats. 
Biol Pharm Bull, 40: 1468-1474, 2017. 
245. Schleifenbaum, J, Kassmann, M, Szijarto, IA, Hercule, HC, Tano, JY, Weinert, S, Heidenreich, M, 
Pathan, AR, Anistan, YM, Alenina, N, Rusch, NJ, Bader, M, Jentsch, TJ, Gollasch, M: Stretch-
activation of angiotensin II type 1a receptors contributes to the myogenic response of mouse 
mesenteric and renal arteries. Circ Res, 115: 263-272, 2014. 
246. Salomonsson, M, Brasen, JC, Braunstein, TH, Hagelqvist, P, Holstein-Rathlou, NH, Sorensen, CM: 
K(V)7.4 channels participate in the control of rodent renal vascular resting tone. Acta Physiol, 
214: 402-414, 2015. 
247. Barrese, V, Stott, JB, Figueiredo, HB, Aubdool, AA, Hobbs, AJ, Jepps, TA, McNeish, AJ, Greenwood, 
IA: Angiotensin II Promotes KV7.4 Channels Degradation Through Reduced Interaction With 
HSP90 (Heat Shock Protein 90). Hypertension, 71: 1091-1100, 2018. 
248. Gollasch, M, Welsh, DG, Schubert, R: Perivascular adipose tissue and the dynamic regulation of 
Kv 7 and Kir channels: Implications for resistant hypertension. Microcirculation, 25, 2018. 
249. Schroder, RL, Jespersen, T, Christophersen, P, Strobaek, D, Jensen, BS, Olesen, SP: KCNQ4 channel 
activation by BMS-204352 and retigabine. Neuropharmacology, 40: 888-898, 2001. 
250. Sogaard, R, Ljungstrom, T, Pedersen, KA, Olesen, SP, Jensen, BS: KCNQ4 channels expressed in 
mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol, 280: 
C859-866, 2001. 
251. Schroeder, BC, Hechenberger, M, Weinreich, F, Kubisch, C, Jentsch, TJ: KCNQ5, a novel potassium 
channel broadly expressed in brain, mediates M-type currents. J Biol Chem, 275: 24089-24095, 
2000. 
Bibliography 
 
112 
 
252. Yeung, SY, Lange, W, Schwake, M, Greenwood, IA: Expression profile and characterisation of a 
truncated KCNQ5 splice variant. Biochem Biophys Res Com, 371: 741-746, 2008. 
253. Jensen, HS, Callo, K, Jespersen, T, Jensen, BS, Olesen, SP: The KCNQ5 potassium channel from 
mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and 
volume changes. Brain Res Mol Brain Res, 139: 52-62, 2005. 
254. Lerche, C, Scherer, CR, Seebohm, G, Derst, C, Wei, AD, Busch, AE, Steinmeyer, K: Molecular cloning 
and functional expression of KCNQ5, a potassium channel subunit that may contribute to 
neuronal M-current diversity. J Biol Chem, 275: 22395-22400, 2000. 
255. Joshi, S, Sedivy, V, Hodyc, D, Herget, J, Gurney, AM: KCNQ Modulators Reveal a Key Role for KCNQ 
Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle. J 
Pharmacol Exp Ther, 329: 368-376, 2009. 
256. Jepps, TA, Chadha, PS, Davis, AJ, Harhun, MI, Cockerill, GW, Olesen, SP, Hansen, RS, Greenwood, 
IA: Downregulation of Kv7.4 channel activity in primary and secondary hypertension. 
Circulation, 124: 602-611, 2011. 
257. Mani, BK, O'Dowd, J, Kumar, L, Brueggemann, LI, Ross, M, Byron, KL: Vascular KCNQ (Kv7) 
potassium channels as common signaling intermediates and therapeutic targets in cerebral 
vasospasm. J Cardiovasc Pharmacol, 61: 51-62, 2013. 
258. Mani, BK, Brueggemann, LI, Cribbs, LL, Byron, KL: Activation of vascular KCNQ (Kv7) potassium 
channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J 
Pharmacol, 164: 237-249, 2011. 
259. Hedegaard, ER, Nielsen, BD, Kun, A, Hughes, AD, Kroigaard, C, Mogensen, S, Matchkov, VV, 
Frobert, O, Simonsen, U: KV 7 channels are involved in hypoxia-induced vasodilatation of 
porcine coronary arteries. Br J Pharmacol, 171: 69-82, 2014. 
260. Chadha, PS, Zunke, F, Davis, AJ, Jepps, TA, Linders, JT, Schwake, M, Towart, R, Greenwood, IA: 
Pharmacological dissection of K(v)7.1 channels in systemic and pulmonary arteries. Br J 
Pharmacol, 166: 1377-1387, 2012. 
261. Schleifenbaum, J, Köhn, C, Voblova, N, Dubrovska, G, Zavarirskaya, O, Gloe, T, Crean, CS, Luft, FC, 
Huang, Y, Schubert, R: Systemic peripheral artery relaxation by KCNQ channel openers and 
hydrogen sulfide. J Hypertens, 28: 1875-1882, 2010. 
262. Stott, JB, Barrese, V, Suresh, M, Masoodi, S, Greenwood, IA: Investigating the Role of G Protein 
betagamma in Kv7-Dependent Relaxations of the Rat Vasculature. Arterioscler Thromb Vasc 
Biol, 38: 2091-2102, 2018. 
263. Tsvetkov, D, Kassmann, M, Tano, JY, Chen, L, Schleifenbaum, J, Voelkl, J, Lang, F, Huang, Y, 
Gollasch, M: Do KV 7.1 channels contribute to control of arterial vascular tone? Br J Pharmacol, 
174: 150-162, 2017. 
264. Towart, R, Linders, JT, Hermans, AN, Rohrbacher, J, van der Linde, HJ, Ercken, M, Cik, M, Roevens, 
P, Teisman, A, Gallacher, DJ: Blockade of the I(Ks) potassium channel: an overlooked 
cardiovascular liability in drug safety screening? J Pharmacol Toxicol Methods, 60: 1-10, 2009. 
265. Pangidis, K: Wirkung des K+-Kanalblockers HMR 1556 auf die Nierenfunktion bei Ratten. Med. 
Dissertation. Institut für Pharmakologie und Toxikologie, Eberhard-Karls-Universität zu 
Tübingen, 2003. 
266. Bachmann, A, Quast, U, Russ, U: Chromanol 293B, a blocker of the slow delayed rectifier K+ 
current (IKs), inhibits the CFTR Cl- current. Naunyn Schmiedebergs Arch Pharmacol, 363: 590-
596, 2001. 
Bibliography 
 
113 
 
267. Karle, CA, Bauer, A, Weretka, S, Zitron, E, Abushi, A, Kreye, VA, Schoels, W: Vascular effects of 
class-III antiarrhythmic drugs: chromanol 293B, but not dofetilide blocks the smooth muscle 
delayed rectifier K+ channel. Basic Res Cardiol, 97: 17-25, 2002. 
268. Lo, YC, Yang, SR, Huang, MH, Liu, YC, Wu, SN: Characterization of chromanol 293B-induced block 
of the delayed-rectifier K+ current in heart-derived H9c2 cells. Life Sci, 76: 2275-2286, 2005. 
269. Lerche, C, Bruhova, I, Lerche, H, Steinmeyer, K, Wei, AD, Strutz-Seebohm, N, Lang, F, Busch, AE, 
Zhorov, BS, Seebohm, G: Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves 
electrostatic interactions with a potassium ion in the selectivity filter. Mol Pharmacol, 71: 
1503-1511, 2007. 
270. Busch, AE, Busch, GL, Ford, E, Suessbrich, H, Lang, HJ, Greger, R, Kunzelmann, K, Attali, B, Stuhmer, 
W: The role of the IsK protein in the specific pharmacological properties of the IKs channel 
complex. Br J Pharmacol, 122: 187-189, 1997. 
271. Bett, GC, Morales, MJ, Beahm, DL, Duffey, ME, Rasmusson, RL: Ancillary subunits and stimulation 
frequency determine the potency of chromanol 293B block of the KCNQ1 potassium channel. 
J Physiol, 576: 755-767, 2006. 
272. Main, MJ, Cryan, JE, Dupere, JR, Cox, B, Clare, JJ, Burbidge, SA: Modulation of KCNQ2/3 potassium 
channels by the novel anticonvulsant retigabine. Mol Pharmacol, 58: 253-262, 2000. 
273. Tatulian, L, Delmas, P, Abogadie, FC, Brown, DA: Activation of expressed KCNQ potassium currents 
and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J 
Neurosci, 21: 5535-5545, 2001. 
274. Wang, L, Qiao, GH, Hu, HN, Gao, ZB, Nan, FJ: Discovery of Novel Retigabine Derivatives as Potent 
KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity. ACS Med Chem Lett, 10: 27-
33, 2018. 
275. Wuttke, TV, Seebohm, G, Bail, S, Maljevic, S, Lerche, H: The new anticonvulsant retigabine favors 
voltage-dependent opening of the Kv7. 2 (KCNQ2) channel by binding to its activation gate. 
Mol Pharmacol, 67: 1009-1017, 2005. 
276. Lange, W, Geißendörfer, J, Schenzer, A, Grötzinger, J, Seebohm, G, Friedrich, T, Schwake, M: 
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ 
K+ channels. Mol Pharmacol, 75: 272-280, 2009. 
277. Schenzer, A, Friedrich, T, Pusch, M, Saftig, P, Jentsch, TJ, Grötzinger, J, Schwake, M: Molecular 
determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci, 
25: 5051-5060, 2005. 
278. Seebohm, G, Pusch, M, Chen, J, Sanguinetti, MC: Pharmacological activation of normal and 
arrhythmia-associated mutant KCNQ1 potassium channels. Circ Res, 93: 941-947, 2003. 
279. Goodwill, AG, Fu, L, Noblet, JN, Casalini, ED, Sassoon, D, Berwick, ZC, Kassab, GS, Tune, JD, Dick, 
GM: KV7 channels contribute to paracrine, but not metabolic or ischemic, regulation of 
coronary vascular reactivity in swine. Am J Physiol Heart Circ Physiol, 310: H693-704, 2016. 
280. Lindman, J, Khammy, MM, Lundegaard, PR, Aalkjaer, C, Jepps, TA: Microtubule Regulation of Kv7 
Channels Orchestrates cAMP-Mediated Vasorelaxations in Rat Arterial Smooth Muscle. 
Hypertension, 71: 336-345, 2018. 
281. Elmedyb, P, Calloe, K, Schmitt, N, Hansen, RS, Grunnet, M, Olesen, SP: Modulation of ERG channels 
by XE991. Basic Clin Pharmacol Toxicol, 100: 316-322, 2007. 
282. Byron, KL, Brueggemann, LI: Kv7 potassium channels as signal transduction intermediates in the 
control of microvascular tone. Microcirculation, 25, 2018. 
Bibliography 
 
114 
 
283. Wiener, R, Haitin, Y, Shamgar, L, Fernandez-Alonso, MC, Martos, A, Chomsky-Hecht, O, Rivas, G, 
Attali, B, Hirsch, JA: The KCNQ1 (Kv7.1) COOH terminus, a multitiered scaffold for subunit 
assembly and protein interaction. J Biol Chem, 283: 5815-5830, 2008. 
284. Haitin, Y, Attali, B: The C-terminus of Kv7 channels: a multifunctional module. J Physiol, 586: 1803-
1810, 2008. 
285. Zaydman, MA, Cui, J: PIP2 regulation of KCNQ channels: biophysical and molecular mechanisms 
for lipid modulation of voltage-dependent gating. Front Physiol, 5: 195, 2014. 
286. Zhang, H, Craciun, LC, Mirshahi, T, Rohacs, T, Lopes, CM, Jin, T, Logothetis, DE: PIP(2) activates 
KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. 
Neuron, 37: 963-975, 2003. 
287. Li, Y, Gamper, N, Hilgemann, DW, Shapiro, MS: Regulation of Kv7 (KCNQ) K+ channel open 
probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci, 25: 9825-9835, 2005. 
288. Taylor, KC, Sanders, CR: Regulation of KCNQ/Kv7 family voltage-gated K(+) channels by lipids. 
Biochim Biophys Acta Biomembr, 1859: 586-597, 2017. 
289. Zaydman, MA, Silva, JR, Delaloye, K, Li, Y, Liang, H, Larsson, HP, Shi, J, Cui, J: Kv7.1 ion channels 
require a lipid to couple voltage sensing to pore opening. Proc Natl Acad Sci U S A, 110: 13180-
13185, 2013. 
290. Loussouarn, G, Park, KH, Bellocq, C, Baro, I, Charpentier, F, Escande, D: Phosphatidylinositol-4,5-
bisphosphate, PIP2, controls KCNQ1/KCNE1 voltage-gated potassium channels: a functional 
homology between voltage-gated and inward rectifier K+ channels. Embo j, 22: 5412-5421, 
2003. 
291. Povstyan, OV, Barrese, V, Stott, JB, Greenwood, IA: Synergistic interplay of Gbetagamma and 
phosphatidylinositol 4,5-bisphosphate dictates Kv7.4 channel activity. Pflugers Arch, 469: 213-
223, 2017. 
292. Matavel, A, Medei, E, Lopes, CM: PKA and PKC partially rescue long QT type 1 phenotype by 
restoring channel-PIP2 interactions. Channels (Austin), 4: 3-11, 2010. 
293. Mani, BK, Brueggemann, LI, Cribbs, LL, Byron, KL: Opposite regulation of KCNQ5 and TRPC6 
channels contributes to vasopressin-stimulated calcium spiking responses in A7r5 vascular 
smooth muscle cells. Cell Calcium, 45: 400-411, 2009. 
294. Marx, SO, Kurokawa, J, Reiken, S, Motoike, H, D'Armiento, J, Marks, AR, Kass, RS: Requirement of 
a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-
KCNE1 potassium channel. Science, 295: 496-499, 2002. 
295. Potet, F, Scott, JD, Mohammad-Panah, R, Escande, D, Baro, I: AKAP proteins anchor cAMP-
dependent protein kinase to KvLQT1/IsK channel complex. Am J Physiol Heart Circ Physiol, 280: 
H2038-2045, 2001. 
296. Martelli, A, Testai, L, Breschi, MC, Lawson, K, McKay, NG, Miceli, F, Taglialatela, M, Calderone, V: 
Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. 
Pharmacol Res, 70: 27-34, 2013. 
297. Kansui, Y, Goto, K, Ohtsubo, T, Murakami, N, Ichishima, K, Matsumura, K, Kitazono, T: Facilitation 
of sympathetic neurotransmission by phosphatidylinositol-4,5-bisphosphate-dependent 
regulation of KCNQ channels in rat mesenteric arteries. Hypertens Res, 35: 909-916, 2012. 
298. Bellocq, C, van Ginneken, AC, Bezzina, CR, Alders, M, Escande, D, Mannens, MM, Baró, I, Wilde, 
AA: Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation, 109: 
2394-2397, 2004. 
Bibliography 
 
115 
 
299. Chen, YH, Xu, SJ, Bendahhou, S, Wang, XL, Wang, Y, Xu, WY, Jin, HW, Sun, H, Su, XY, Zhuang, QN, 
Yang, YQ, Li, YB, Liu, Y, Xu, HJ, Li, XF, Ma, N, Mou, CP, Chen, Z, Barhanin, J, Huang, W: KCNQ1 
gain-of-function mutation in familial atrial fibrillation. Science, 299: 251-254, 2003. 
300. Haick, JM, Byron, KL: Novel treatment strategies for smooth muscle disorders: Targeting Kv7 
potassium channels. Pharmacol Ther, 165: 14-25, 2016. 
301. Gollasch, M: Vasodilator signals from perivascular adipose tissue. Br J Pharmacol, 165: 633-642, 
2012. 
302. Carr, G, Barrese, V, Stott, JB, Povstyan, OV, Jepps, TA, Figueiredo, HB, Zheng, D, Jamshidi, Y, 
Greenwood, IA: MicroRNA-153 targeting of KCNQ4 contributes to vascular dysfunction in 
hypertension. Cardiovasc Res, 112: 581-589, 2016. 
303. Tano, JY, Schleifenbaum, J, Gollasch, M: Perivascular adipose tissue, potassium channels, and 
vascular dysfunction. Arterioscler Thromb Vasc Biol, 34: 1827-1830, 2014. 
304. Kimmelstiel, P, Wilson, C: Inflammatory Lesions in the Glomeruli in Pyelonephritis in Relation to 
Hypertension and Renal Insufficiency. Am J Pathol, 12: 99-106.103, 1936. 
305. Moritz, AR, Oldt, MR: Arteriolar Sclerosis in Hypertensive and Non-Hypertensive Individuals. Am 
J Pathol, 13: 679-728.677, 1937. 
306. Goldblatt, H, Lynch, J, Hanzal, RF, Summerville, WW: Studies on Experimental Hypertension: I. The 
Production of Persistent Elevation of Systolic Blood Pressure by Means of Renal Ischemia. J Exp 
Med, 59: 347-379, 1934. 
307. Textor, SC, Wilcox, CS: Renal artery stenosis: a common, treatable cause of renal failure? Annu 
Rev Med, 52: 421-442, 2001. 
308. Sakakibara, K, Feng, GG, Li, J, Akahori, T, Yasuda, Y, Nakamura, E, Hatakeyama, N, Fujiwara, Y, 
Kinoshita, H: Kynurenine causes vasodilation and hypotension induced by activation of KCNQ-
encoded voltage-dependent K(+) channels. J Pharmacol Sci, 129: 31-37, 2015. 
309. Morecroft, I, Murray, A, Nilsen, M, Gurney, AM, MacLean, MR: Treatment with the Kv7 potassium 
channel activator flupirtine is beneficial in two independent mouse models of pulmonary 
hypertension. Br J Pharmacol, 157: 1241-1249, 2009. 
310. Mulvany, MJ, Halpern, W: Mechanical properties of vascular smooth muscle cells in situ. Nature, 
260: 617-619, 1976. 
311. Mulvany, MJ, Halpern, W: Contractile properties of small arterial resistance vessels in 
spontaneously hypertensive and normotensive rats. Circ Res, 41: 19-26, 1977. 
312. Mulvany, M: Procedures for investigation of small vessels using small vessel myograph. Aarhus, 
Denmark: Danish Myo Technology, 2004. 
313. Angus, JA, Wright, CE: Techniques to study the pharmacodynamics of isolated large and small 
blood vessels. J Pharmacol Toxicol Methods, 44: 395-407, 2000. 
314. International Committee on Veterinary Gross Anatomical Nomenclature: Nomina anatomica 
veterinaria. Sixth edition. 2017. Online: www.wava-amav.org/downloads/nav_6_2017.zip, 
Stand: 09.11.2019. 
315. Stott, JB, Barrese, V, Jepps, TA, Leighton, EV, Greenwood, IA: Contribution of Kv7 channels to 
natriuretic peptide mediated vasodilation in normal and hypertensive rats. Hypertension, 65: 
676-682, 2015. 
316. Ross, BD: The isolated perfused rat kidney. Clin Sci Mol Med Suppl, 55: 513-521, 1978. 
Bibliography 
 
116 
 
317. Yoldas, A, Dayan, MO: Morphological characteristics of renal artery and kidney in rats. Sci World 
J, 2014: 468982, 2014. 
318. Seebohm, G, Pusch, M, Chen, J, Sanguinetti, MC: Pharmacological activation of normal and 
arrhythmia-associated mutant KCNQ1 potassium channels. Circ Res, 93: 941-947, 2003. 
319. Potter, LR, Abbey-Hosch, S, Dickey, DM: Natriuretic peptides, their receptors, and cyclic guanosine 
monophosphate-dependent signaling functions. Endocr Rev, 27: 47-72, 2005. 
320. Gribble, FM, Reimann, F: Pharmacological modulation of K(ATP) channels. Biochem Soc Trans, 30: 
333-339, 2002. 
321. Schubert, R, Krien, U, Wulfsen, I, Schiemann, D, Lehmann, G, Ulfig, N, Veh, RW, Schwarz, JR, Gago, 
H: Nitric oxide donor sodium nitroprusside dilates rat small arteries by activation of inward 
rectifier potassium channels. Hypertension, 43: 891-896, 2004. 
322. Vaughan, J, Donaldson, C, Bittencourt, J, Perrin, MH, Lewis, K, Sutton, S, Chan, R, Turnbull, AV, 
Lovejoy, D, Rivier, C, et al.: Urocortin, a mammalian neuropeptide related to fish urotensin I 
and to corticotropin-releasing factor. Nature, 378: 287-292, 1995. 
323. Rademaker, MT, Richards, AM: Urocortins: Actions in health and heart failure. Clin Chim Acta, 
474: 76-87, 2017. 
324. Weiss, C, Passow, H, Rothstein, A: Autoregulation of flow in isolated rat kidney in the absence of 
red cells. Am J Physiol, 196: 1115-1118, 1959. 
325. Vandongen, R, Peart, WS, Boyd, GW: Adrenergic stimulation of renin secretion in the isolated 
perfused rat kidney. Circ Res, 32: 290-296, 1973. 
326. Bowman, RH: Gluconeogenesis in the isolated perfused rat kidney. J Biol Chem, 245: 1604-1612, 
1970. 
327. Scholz, H, Kaissling, B, Inagami, T, Kurtz, A: Differential response of renin secretion to 
vasoconstrictors in the isolated perfused rat kidney. J Physiol, 441: 453-468, 1991. 
328. Scholz, H, Gotz, KH, Hamann, M, Kurtz, A: Differential effects of extracellular anions on renin 
secretion from isolated perfused rat kidneys. Am J Physiol, 267: F1076-1081, 1994. 
329. Wang, J, Nation, RL, Evans, AM, Cox, S: Isolated rat kidney perfused with dextran and bovine 
serum albumin: a stable model for investigating renal drug handling. J Pharmacol Toxicol 
Methods, 49: 105-113, 2004. 
330. Georgiev, T, Iliev, R, Mihailova, S, Hadzhibozheva, P, Ilieva, G, Kamburova, M, Tolekova, A: The 
isolated perfused kidney models-certain aspects. Trakia J Sci, 9: 82-87, 2011. 
331. Chang, HH, Choong, B, Phillips, A, Loomes, KM: Isolated perfused rat kidney: a technical update. 
Exp Anim, 62: 19-23, 2013. 
332. Lee, HB, Blaufox, MD: Blood volume in the rat. J Nucl Med, 26: 72-76, 1985. 
333. Coleman, TG: Cardiac output by dye dilution in the conscious rat. J Appl Physiol, 37: 452-455, 
1974. 
334. Maack, T: Physiological evaluation of the isolated perfused rat kidney. Am J Physiol, 238: F71-78, 
1980. 
335. Hsu, CH, Slavicek, JM: The effect of renal perfusion pressure on renal vascular resistance in the 
spontaneously hypertensive rat. Pflugers Arch, 393: 340-343, 1982. 
336. Flemming, B, Arenz, N, Seeliger, E, Wronski, T, Steer, K, Persson, PB: Time-dependent 
autoregulation of renal blood flow in conscious rats. J Am Soc Nephrol, 12: 2253-2262, 2001. 
Bibliography 
 
117 
 
337. Loutzenhiser, R, Horton, C, Epstein, M: Flow-induced errors in estimating perfusion pressure of 
the isolated rat kidney. Kidney Int, 22: 693-696, 1982. 
338. Just, A: Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol 
Regul Integr Comp Physiol, 292: R1-17, 2007. 
339. Loutzenhiser, RD: In situ studies of renal arteriolar function using the in vitro-perfused 
hydronephrotic rat kidney. Int Rev Exp Pathol, 36: 145-160, 1996. 
340. Cupples, WA, Loutzenhiser, RD: Dynamic autoregulation in the in vitro perfused hydronephrotic 
rat kidney. Am J Physiol Renal Physiol, 275: F126-130, 1998. 
341. Arendshorst, WJ, Finn, WF, Gottschalk, CW: Autoregulation of blood flow in the rat kidney. Am J 
Physiol, 228: 127-133, 1975. 
342. Bolton, TB: Mechanisms of action of transmitters and other substances on smooth muscle. Physiol 
Rev, 59: 606-718, 1979. 
343. Fésüs, G, Dubrovska, G, Gorzelniak, K, Kluge, R, Huang, Y, Luft, FC, Gollasch, M: Adiponectin is a 
novel humoral vasodilator. Cardiovasc Res, 75: 719-727, 2007. 
344. Trendelenburg, U, Maxwell, RA, Pluchino, S: Methoxamine as a tool to assess the importance of 
intraneuronal uptake of l-norepinephrine in the cat's nictitating membrane. J Pharmacol Exp 
Ther, 172: 91-99, 1970. 
345. Hashimoto, K, Kumakura, S: The pharmacological features of the coronary, renal, mesenteric and 
femoral arteries. Jpn J Physiol, 15: 540-551, 1965. 
346. Grant, R: Physiological effects of heat and cold. Annu Rev Physiol, 13: 75-98, 1951. 
347. McIntyre, CA, Williams, BC, Lindsay, RM, McKnight, JA, Hadoke, PW: Preservation of vascular 
function in rat mesenteric resistance arteries following cold storage, studied by small vessel 
myography. Br J Pharmacol, 123: 1555-1560, 1998. 
348. Jia, L, Li, X, Shao, C, Wei, L, Li, M, Guo, Z, Liu, Z, Gao, Y: Using an isolated rat kidney model to 
identify kidney origin proteins in urine. PLoS One, 8: e66911, 2013. 
349. Guyton, AC, Granger, HJ, Taylor, AE: Interstitial fluid pressure. Physiol Rev, 51: 527-563, 1971. 
350. Dupuis, DS, Schroder, RL, Jespersen, T, Christensen, JK, Christophersen, P, Jensen, BS, Olesen, SP: 
Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J 
Pharmacol, 437: 129-137, 2002. 
351. Kitazawa, T, Kitazawa, K: Size-dependent heterogeneity of contractile Ca2+ sensitization in rat 
arterial smooth muscle. J Physiol, 590: 5401-5423, 2012. 
352. Dippold, RP, Fisher, SA: Myosin phosphatase isoforms as determinants of smooth muscle 
contractile function and calcium sensitivity of force production. Microcirculation, 21: 239-248, 
2014. 
353. Greene, DL, Kang, S, Hoshi, N: XE991 and Linopirdine Are State-Dependent Inhibitors for 
Kv7/KCNQ Channels that Favor Activated Single Subunits. J Pharmacol Exp Ther, 362: 177-185, 
2017. 
354. Grissmer, S, Nguyen, AN, Aiyar, J, Hanson, DC, Mather, RJ, Gutman, GA, Karmilowicz, MJ, Auperin, 
DD, Chandy, KG: Pharmacological characterization of five cloned voltage-gated K+ channels, 
types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol, 
45: 1227-1234, 1994. 
355. Jespersen, T, Grunnet, M, Olesen, S-P: The KCNQ1 potassium channel: from gene to physiological 
function. Physiology, 20: 408-416, 2005. 
Bibliography 
 
118 
 
356. McCrossan, ZA, Abbott, GW: The MinK-related peptides. Neuropharmacology, 47: 787-821, 2004. 
357. Burnett, JC, Jr., Granger, JP, Opgenorth, TJ: Effects of synthetic atrial natriuretic factor on renal 
function and renin release. Am J Physiol, 247: F863-866, 1984. 
358. Aalkjaer, C, Mulvany, MJ, Nyborg, NC: Atrial natriuretic factor causes specific relaxation of rat 
renal arcuate arteries. Br J Pharmacol, 86: 447-453, 1985. 
359. Marrachelli, VG, Centeno, JM, Miranda, I, Castello-Ruiz, M, Burguete, MC, Jover-Mengual, T, 
Salom, JB, Torregrosa, G, Miranda, FJ, Alborch, E: Diabetes impairs the atrial natriuretic peptide 
relaxant action mediated by potassium channels and prostacyclin in the rabbit renal artery. 
Pharmacol Res, 66: 392-400, 2012. 
360. Matsumoto, T, Watanabe, S, Yamada, K, Ando, M, Iguchi, M, Taguchi, K, Kobayashi, T: Relaxation 
Induced by Atrial Natriuretic Peptide Is Impaired in Carotid but Not Renal Arteries from 
Spontaneously Hypertensive Rats Due to Reduced BKCa Channel Activity. Biol Pharm Bull, 38: 
1801-1808, 2015. 
361. Zhang, S, Geng, X, Zhao, L, Li, J, Tian, F, Wang, Y, Fan, R, Feng, N, Liu, J, Cheng, L, Pei, J: 
Cardiovascular and renal effect of CNAAC: An innovatively designed natriuretic peptide. Eur J 
Pharmacol, 761: 180-188, 2015. 
362. Sakurada, S, Takuwa, N, Sugimoto, N, Wang, Y, Seto, M, Sasaki, Y, Takuwa, Y: Ca2+-dependent 
activation of Rho and Rho kinase in membrane depolarization-induced and receptor 
stimulation-induced vascular smooth muscle contraction. Circ Res, 93: 548-556, 2003. 
363. Sato, K, Ozaki, H, Karaki, H: Changes in cytosolic calcium level in vascular smooth muscle strip 
measured simultaneously with contraction using fluorescent calcium indicator fura 2. J 
Pharmacol Exp Ther, 246: 294-300, 1988. 
364. Wilson, DP, Sutherland, C, Walsh, MP: Ca2+ activation of smooth muscle contraction: evidence 
for the involvement of calmodulin that is bound to the triton insoluble fraction even in the 
absence of Ca2+. J Biol Chem, 277: 2186-2192, 2002. 
365. Mita, M, Tanaka, H, Yanagihara, H, Nakagawa, J, Hishinuma, S, Sutherland, C, Walsh, MP, Shoji, 
M: Membrane depolarization-induced RhoA/Rho-associated kinase activation and sustained 
contraction of rat caudal arterial smooth muscle involves genistein-sensitive tyrosine 
phosphorylation. J Smooth Muscle Res, 49: 26-45, 2013. 
366. Mills, RD, Mita, M, Walsh, MP: A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic 
depolarization-induced vascular smooth muscle contraction. J Muscle Res Cell Motil, 36: 479-
489, 2015. 
367. Nakamura, A, Hayashi, K, Ozawa, Y, Fujiwara, K, Okubo, K, Kanda, T, Wakino, S, Saruta, T: Vessel- 
and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res, 
40: 244-251, 2003. 
368. Davis, MJ, Hill, MA: Signaling mechanisms underlying the vascular myogenic response. Physiol 
Rev, 79: 387-423, 1999. 
369. Minneman, KP: Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell 
Ca2+. Pharmacol Rev, 40: 87-119, 1988. 
370. Kirton, CA, Loutzenhiser, R: Alterations in basal protein kinase C activity modulate renal afferent 
arteriolar myogenic reactivity. Am J Physiol, 275: H467-475, 1998. 
371. Hillhouse, EW, Grammatopoulos, DK: The molecular mechanisms underlying the regulation of the 
biological activity of corticotropin-releasing hormone receptors: implications for physiology 
and pathophysiology. Endocr Rev, 27: 260-286, 2006. 
Bibliography 
 
119 
 
372. Wiley, KE, Davenport, AP: CRF2 receptors are highly expressed in the human cardiovascular 
system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol, 
143: 508-514, 2004. 
373. Adao, R, Santos-Ribeiro, D, Rademaker, MT, Leite-Moreira, AF, Bras-Silva, C: Urocortin 2 in 
cardiovascular health and disease. Drug Discov Today, 20: 906-914, 2015. 
374. Kageyama, K, Furukawa, K, Miki, I, Terui, K, Motomura, S, Suda, T: Vasodilative effects of urocortin 
II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc 
Pharmacol, 42: 561-565, 2003. 
375. Parkes, DG, Weisinger, RS, May, CN: Cardiovascular actions of CRH and urocortin: an update. 
Peptides, 22: 821-827, 2001. 
376. Abdelrahman, AM, Syyong, HT, Tjahjadi, AA, Pang, CC: Analysis of the mechanism of the 
vasodepressor effect of urocortin in anesthetized rats. Pharmacology, 73: 175-179, 2005. 
377. Chen, J, Tao, J, Zhang, R, Xu, Y, Soong, T, Li, S: Urocortin inhibits mesenteric arterial remodeling in 
spontaneously hypertensive rats. Peptides, 30: 1117-1123, 2009. 
378. Leitch, IM, Boura, AL, Botti, C, Read, MA, Walters, WA, Smith, R: Vasodilator actions of urocortin 
and related peptides in the human perfused placenta in vitro. J Clin Endocrinol Metab, 83: 
4510-4513, 1998. 
379. Chen, Z-W, Huang, Y, Yang, Q, Li, X, Wei, W, He, G-W: Urocortin-induced relaxation in the human 
internal mammary artery. Cardiovasc Res, 65: 913-920, 2005. 
380. Sanz, E, Monge, L, Fernandez, N, Martinez, MA, Martinez-Leon, JB, Dieguez, G, Garcia-Villalon, AL: 
Relaxation by urocortin of human saphenous veins. Br J Pharmacol, 136: 90-94, 2002. 
381. Walczewska, J, Dzieza-Grudnik, A, Siga, O, Grodzicki, T: The role of urocortins in the cardiovascular 
system. J Physiol Pharmacol, 65: 753-766, 2014. 
382. Yao, X, He, GW, Chan, FL, Lau, CW, Tsang, SY, Chen, ZY, Huang, Y: Endothelium-dependent and -
independent coronary relaxation induced by urocortin. J Card Surg, 17: 347-349, 2001. 
383. Sanz, E, Fernández, N, Monge, L, Climent, B, Diéguez, G, García-Villalón, AL: Relaxation by 
urocortin of rat renal arteries: effects of diabetes in males and females. Cardiovasc Res, 58: 
706-711, 2003. 
384. Sanz, E, Monge, L, Fernández, N, Climent, B, Diéguez, G, Garcia‐Villalón, AL: Mechanisms of 
relaxation by urocortin in renal arteries from male and female rats. Br J Pharmacol, 140: 1003-
1007, 2003. 
385. Huang, Y, Chan, FL, Lau, CW, Tsang, SY, Chen, ZY, He, GW, Yao, X: Roles of cyclic AMP and Ca2+-
activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary 
artery. Cardiovasc Res, 57: 824-833, 2003. 
386. Chan, Y, Yao, X, Lau, C, Chan, F, He, G, Bourreau, J-P, Huang, Y: The relaxant effect of urocortin in 
rat pulmonary arteries. Regul Pept, 121: 11-18, 2004. 
387. Lubomirov, L, Gagov, H, Petkova-Kirova, P, Duridanova, D, Kalentchuk, VU, Schubert, R: Urocortin 
relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile 
apparatus for calcium. Br J Pharmacol, 134: 1564-1570, 2001. 
388. Seçilmis, MA, Özü, ÖY, Emre, M, Büyükafsar, K, Kiroglu, OE, Ertug, P, Karatas, Y, Önder, S, Singirik, 
E: Urocortin induces endothelium-dependent vasodilatation and hyperpolarization of rat 
mesenteric arteries by activating Ca2+-activated K+ channels. Tohoku J Exp Med, 213: 89-98, 
2007. 
Bibliography 
 
120 
 
389. Smani, T, Domínguez-Rodríguez, A, Hmadcha, A, Calderón-Sánchez, E, Horrillo-Ledesma, A, 
Ordóñez, A: Role of Ca2+-independent phospholipase A2 and store-operated pathway in 
urocortin-induced vasodilatation of rat coronary artery. Circ Res, 101: 1194-1203, 2007. 
Appendix 
 
121 
 
7 APPENDIX 
Table 13: Statistics for myography experiments following concentration-response relationship protocols (see: Table 3) 
Figure: Experiment description: n  Drug added:     
31 CON vs. RETI/ANP vs. MIX 6   CON/RETI CON/ANP RETI/MIX ANP/MIX 
   1. CRR none  >0,9999 0,4491 0,4491 >0,9999 
   2. CRR solvent 0,6492 0,8726 0,5567 >0,9999 
   3./4. CRR RETI/ANP/MIX 0,0008 0,0134 0,0088 0,0329 
32 CON vs. R-L3/ANP vs. MIX 6   CON/R-L3 CON/ANP R-L3/MIX ANP/MIX 
   1. CRR none  >0,9999 0,8305 0,8305 >0,9999 
   2. CRR solvent >0,9999 0,4212 0,3453 0,7582 
   3./4. CRR R-L3/ANP/MIX 0,0001 <0,0001 0,0016 <0,0001 
33 CON vs. HMR/ANP(-7) vs. MIX 6   CON/HMR CON/ANP HMR/MIX ANP/MIX 
 (in the presence of R-L3)  1.CRR none 0,4937 0,8551 0,6333 0,6063 
   2.CRR HMR 0,468 0,7239 0,5044 0,2544 
   3.CRR R-L3 (all), ANP (-7) 0,0008 <0,0001 <0,0001 0,0027 
34 CON vs. HMR/ANP(3-8) vs. MIX 6   CON/HMR CON/ANP HMR/MIX ANP/MIX 
 (in the presence of R-L3)  1.CRR none 0,4937 0,8551 0,6333 0,6063 
   2.CRR HMR 0,468 0,8512 0,7622 0,2109 
   3.CRR R-L3 (all), ANP (3-8) 0,0004 0,0147 0,0003 0,0155 
44 CON vs. XE/URO vs. MIX 10   CON/XE CON/URO XE/MIX URO/MIX 
   1. CRR none 0,7756 0,633 0,8721 0,7674 
   2. CRR XE 0,0081 0,7726 0,7981 0,0465 
   3. CRR URO 0,0022 <0,0001 <0,0001 0,0207 
45 CON vs. RETI/URO vs. MIX 9   CON/RETI CON/URO RETI/MIX URO/MIX 
   1. CRR none  >0,9999 0,7109 0,7109 >0,9999 
   2. CRR solvent 0,8267 0,8188 0,5943 0,9005 
   3./4. CRR RETI/URO/MIX <0,0001 0,0001 0,0003 0,0022 
46 CON vs. R-L3/Uro vs. MIX 9   CON/R-L3 CON/URO R-L3/MIX URO/MIX 
   1. CRR none  >0,9999 0,6884 0,6884 >0,9999 
   2. CRR solvent >0,9999 0,6674 0,6674 >0,9999 
   3./4. CRR R-L3/URO/MIX <0,0001 0,0041 0,0258 0,0014 
47 CON vs. HMR/URO(-7) vs. MIX 9   CON/HMR CON/URO HMR/MIX URO/MIX 
 (in the presence of R-L3)  1. CRR none 0,7474 0,6884 0,99 0,5155 
   2. CRR HMR 0,3285 0,2816 0,8359 0,8287 
   3. CRR URO (-7) 0,6468 0,0001 0,0005 0,7392 
   4. CRR R-L3 (all) 0,0055 0,002 0,0014 0,0263 
Two-way repeated-measures ANOVA was used for statistical analysis.   ANP = atrial natriuretic peptide; CON = control; CRR = 
concentration-response relationship; HMR = HMR1556; MIX = application of both drugs; RETI = Retigabine; URO = Urocortin; 
XE = XE991; 
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Table 14: Statistics for myography experiments following precontraction protocols (see: Table 4 and Table 5) 
Figure: Experiment description:   Drug added:     
20 – 25 Retigabine precontraction    CON/XE CON/HMR LO/HI  
     (n = 9) (n = 9) (n = 9)  
   1. CRR none  0,7764 0,6431 0,3889  
   1. PRC solvent 0,8335 0,0337 0,4458  
   2. PRC Retigabine 0,0018 0,8484 0,4895  
26 – 30 R-L3 precontraction    CON/XE CON/HMR LO/HI  
     (n = 10) (n = 10) (n = 10)  
   1. CRR none  0,6597 0,6182 0,7188  
   1. PRC solvent 0,4920 0,0812 0,6268  
   2. PRC R-L3 <0,0001 0,0001 0,6536  
35 – 43 ANP precontraction    KCl/Mx ALL/no XE HMR/XE  
     (n = 13) (n = 14) (n = 8)  
   1. CRR none 0,7303 0,1559 0,8377  
   1. PRC solvent 0,7471 0,0826 0,6240  
   2. PRC ANP 0,0075 0,3518 0,4612  
48 – 56 Urocortin precontraction    KCl/Mx ALL/no XE HMR/XE  
     (n = 12) (n = 10) (n = 8)  
   1. CRR none 0,1103 0,7383 0,9027  
   1. PRC solvent 0,2962 0,3119 0,2363  
   2. PRC Urocortin 0,0010 0,2586 0,1637  
Two-way repeated-measures ANOVA was used for statistical analysis.   ALL = precontraction induced by all K+ channel blockers; 
ANP = atrial natriuretic peptide; CON = control; CRR = concentration-response relationship; HI = high level of Methoxamine-
induced precontraction; HMR = HMR1556; no XE = precontraction induced by all K+ channel blockers without XE991; KCl = KCl-
induced precontraction; LO = low level of Methoxamine-induced precontraction; MIX = application of both drugs; Mx = 
Methoxamine-induced precontraction; PRC = precontraction curve; URO = Urocortin; XE = XE991; 
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